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Localization of endothelin-1 receptor subtypes in normal and remnant
rat kidney. J. Zhuo, R. Dean, L. Wu, D. Alcom, D. Casley, and F.A. 0.
Mendelsohn, Department of Medicine, University of Melbourne, Austin
Hospita4 Heidelberg, Victoria, Australia. Endothelin-1 (ET-1) has been
implicated in the pathogenesis of acute renal failure after ischemia and in
the early development of glomeruloscierosis in remnant kidney. However,
the subtype of ET-1 receptors involved in these processes remains
unknown. The aim of this study was to localize ET-1 receptor subtypes in
sham-operated and remnant rat kidney using in vitro macro- and electron
microscopic autoradiography and subtype-selective ligands. Two groups of
male Sprague-Dawley rats (200 g) were anesthetized with sodium pento-
barbital and were either sham-operated (N = 6) or underwent a 5/6
nephrectomy (5/6-NPX) (N = 6). Five days after surgery the rats were
sacrificed and the kidneys removed for ET-1 receptor localization. Frozen
sections of both groups of kidneys were incubated with '251-ET-1 (—-0.3
Ci/ml) in 20 m HEPES buffer, pH 7.4, in the absence or presence of 1
si unlabelled ET-1, the ETA receptor antagonist, BQ123, or the ET
receptor analogue, sarafotoxin 6C (S6C). The densities of ET-1 receptor
subtypes were quantified by a computerized densitometry. The 5/6 NPX
rats had higher serum levels of creatininc (0.12 0.01 mmol/liter vs.
0.05 0.01 mmo!/liter) and urea (18.2 0.01 mmol/litcr vs. 4.5 0.2
mmol/liter), and tail-cuff systolic blood pressure (187 9mm Hg vs. 109
7 mm Hg) than the sham-operated rats. A high density of ET-l receptors
occurred in the glomerulus and the inner medulla, and a moderate density
of ET-1 receptors was localized in the outer cortex between glomeruli and
in the inner stripe of the outer medulla. There was no significant difference
in renal ET-1 receptor binding between sham-operated and 5/6 NPX rats.
In both groups of rats, SbC potently inhibited up to 95% of ET-1 receptor
binding in a!! anatomical sites, whereas BQ123 had little effect. In normal
rat kidney, electron microscopic autoradiography revealed that ETu
receptor binding (silver grains) was localized almost exclusively in the
fenestrated endothelial cells of glomerular capillaries in the cortex and in
the endothelial cells of peritubular capillaries in the medulla. Interestingly,
both ETA and ET receptor binding occurred in the renomedullary
interstitial cells in the inner medulla, whereas no binding was observed
overlying the renal tubular cells. These results indicate that the endothelial
cells of glomerular and peritubular capillaries are the primary target of
ET-1, which may act mainly on ET receptors to exert its actions on renal
hemodynamics and tubular function in both physiological and pathological
states.
Action of epidermal growth factor on circulatory homeostasis in the rat.
S.L. Grant, C.B. Gow, and PA. Phillips, Department of Medicine, University
of Melbourne, Austin Hospital, Heidelberg, Victoria, and Department of
Agriculture, La Trobe University, Bundoora, Australia. Epidermal growth
factor (EGF) is best known as a mitogen; however, recent studies have
demonstrated a diuresis and natriuresis when administered intravenously
to sheep. The aim of this study was to determine if the observed
diuresis/natriuresis seen in sheep occurred in other species, and whether
EGF produced any hemodynamic changes in a genetic model of hyper-
tension. After a three day baseline period, Sprague-Dawley (SD) (—250
g), Wistar-Kyoto (WKY) and Spontaneously Hypertensive (SI-IR) rats (17
weeks) received continuous intravenous infusion of either isotonic saline
or EGF (2.0 .rg/kg hr) via osmotic minipumps and jugular cannulas
implanted on day 4 for a further 6 days with daily measurement of urine
flow rate, osmolality, sodium and potassium excretion, water and food
intake, body weight and systolic blood pressure. Mean arterial blood
pressure on conscious free moving rats and glomerular filtration rate
(TcDTPA method) were measured on day 5, 48 hours after infusion
began. Rats were killed on day 10 and trunk blood collected. After the
commencement of infusions those rats receiving EGF significantly in-
creased their water intake (P < 0.05) and urine output (P < 0.05) and
reduced osmolality compared to the controls. Mean arterial blood pres-
sure was lower in those SHR that received EGF (154 10 mm Hg)
compared to control SHR (204 3 mm Hg), while there was no change
in those normotensive rats, SD control (102 7 mm Hg), EGF (107 8
mm Ug), WKY control (123 5 mm Hg), and EGF (114 5 mm Hg).
Food intake over the EGF infusion period was not affected, while body
weight increased in all groups. Both sodium and potassium excretion/24 hr
were unaffected in normotensive rats while in the SHR both sodium and
potassium excretion/24 hr were elevated in those rats receiving EGF.
Glomerular filtration rates did not differ between those rats receiving EGF
and those rats receiving saline while plasma arginine vasopressin and atrial
natriuretic factor also remained unchanged. These findings demonstrate
that chronic intravenous infusion of EGF caused diuresis in the SD, SHR
and WKY rat, while decreasing the mean arterial pressure only in the
SHR. These results raise the possibility that alterations in EGF may play
a functional role in renal water and salt homeostasis in the rat and blood
pressure control in the SHR.
High affinity amylin binding sites in the proximal tubule, sodium/water
resorption and hypertension. ME. Cooper, P.J. Harris, fL. Berka, S.
Hiranyachattada, and P.J. Wookey, Departments of Medicine, Physiology and
Anatomy, University of Melbourne, Heidelberg Repatriation Hospital, Hei-
delberg West, and Parkville, Australia. Amylin, a 37-amino acid peptide, is
cosecreted with insulin from the pancreatic p-cells. In the normal rat
kidney, we have shown that high affinity (<nM range) binding sites for
amylin are associated with the outer cortex (1), and that the binding of
[1251]-amylin was competitively inhibited by increasing concentrations of
analogues, including the peptide antagonist AC413. These characteristics
suggest that this binding site shared similar properties with the amylin or
C3 site in the rat brain. Previous studies by our group have also shown that
low concentrations of amylin injected into rats or human subjects increase
plasma renin by greater than two-fold, and that in the former experiments
AC413 administered prior to the amylin injection attenuated this stimu-
lation. The purpose of the studies described here is to pinpoint the exact
cellular location of amylin binding using the techniques of injection of
radioactive tracer into the renal artery of unconscious animals, removal of
the kidney, and analysis of the binding location using high resolution light
and electron microscopy, and emulsion autoradiography. As a result of the
finding that amylin binding was found almost exclusively in the proximal
tubules, we studied the function of low concentrations of amylin at this
site. Amylin (—10 M), introduced on the basolateral side of the proximal
tubules in micropuncture experiments, stimulated sodium and water
resorption by 29%, making it equipotent with angiotensin II or endothelin.
This stimulation was inhibited by the amylin antagonist AC187 and the
inhibitor of the Na4 /H exchanger, ethyl isopropyl amiloride, demonstrat-
ing the direct functional relationship between the amylin receptor on
proximal tubular epithelium and sodium/water resorption. From these
results we hypothesize that amylin plays a role in the genesis of hyperten-
sion, particularly in those pathophysiological conditions of hyperamyline-
mia, such as type II diabetes and obesity.
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Proteinuria in hypertensive pregnancy: Detection and clinical rele.
vance. MA. Brown, ML. Buddle, andf.A. Whitworth, Departments of Renal
Medicine and Medicine, St. George Hospital, Kogarah, NSW, Australia.
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Proteinuria (>300 mg/day) is considered a pre-requisite for the diagnosis
of pre-eclampsia and is thought to convey a worse outcome in hyperten-
sive pregnancy. This is often diagnosed by detection of >1+ (0.3 g/liter)
proteinuria by dipstick testing alone. We conducted studies to determine
the accuracy of ward urinalyses for detection of significant proteinuria in
hypertensive pregnant women, and to compare the maternal and fetal
outcomes of proteinuric and non-proteinuric hypertensive pregnancies. In
the first study, ward urinalyses recorded by midwives immediately before
and after 285 24 hour urine collections for protein excretion were
compared with both total protein excretion and dipstick urinalysis on the
mixed 24 hr urine sample by a single observer. Positive predictive values
(%) for dipstick testing reflecting true proteinuria are in the Table.
Nil Trace
0.3 g/litcr
(1+)
Pre 24 hour urinalysis
Post-24 hour urinalysis
Aliquot urinalysis
6
7
10
16
13
15
—
18
23
34
1 g/liter
(2+)
3 g/liter
(3+)
>20 glliter
(4+)
Pre 24 hour urinalysis
Post-24 hour urinalysis
Aliquot urinalysis
48
64
81
89
85
100
83
100
100
In the second (prospective) study, maternal and fetal complications were
compared between 126 third trimester hypertensive pregnant women with
de novo proteinuria and 614 without proteinuria, all managed by one
physician and a uniform departmental protocol. Maternal complications
were all higher in proteinuric pregnancies (neurological 34% vs. 7%; liver
disease 21% vs. 8%; thrombocytopenia 20% vs. 8%; renal insufficiency
24% vs. 4%; severe hypertension 57% vs. 13%; all P < 0.001). Perinatal
mortality was higher in proteinuric pregnancies (48/1 000 vs. 5/1 000, P <
0.001) but fetal growth retardation did not differ significantly (30% vs.
19%, NS). These studies demonstrate that although true proteinuria
conveys a worse maternal and fetal prognosis for hypertensive pregnant
women, substantial complications still arise without proteinuria, that is
non-proteinurie hypertensive pregnancy is not always a benign disorder.
Dipstick testing is not sufficiently accurate (both due to observer and
dipstick errors) to avoid the need for 24 hour urine collections in these
women.
Up-regulation of adhesion molecule expression on endothelial cells
(EC) by anti-DNA autoantibodies. K.N. Lai, K.B. Lai, J. Leung, Depart-
ment of Medicine, The Chinese University of Hong Kong, Hong Kong. We
examined the effect of polyclonal lgG anti-DNA autoantibodies (d5DNA)
purified from 17 patients with systemic lupus erythematosis (SLE) (mean
titer 2972 lU/mI) on the expression of intracellular adhesion molecule-I
(ICAM), vascular cell adhesion molecule-i (VCAM) and E-selectin
(ELAM) on human EC using flow eytometry. Compared with IgG from
healthy controls [(n = 9), mean dsDNA titer 39 IU/mIl, EC incubated with
dsDNA expressed a higher mean fluorescence intensity (MFI) in anti-
endothelial cell antibodies (AECA) (P = 0.0001), von Willebrand factor
(vWF) (P = 0.019), ICAM (P = 0.012), and VCAM (P = 0.037), hut not
in ELAM. dsDNA-depleted polyclonal IgG (d5DNA-dep-IgG) (mean
dsDNA titer 23 lU/mI) was prepared from sera of these patients with SLE
by affinity chromatography with DNA cellulose eolumn. The MFI of EC
incubated with dsDNA was higher than EC incubated with d5DNA-dep-
IgG with respect to AECA (P = 0.005) vWF (P = 0.0015), ICAM (P =
0.0024) or VCAM [P = 0.0021. Pretreating EC with DNA before
incubating with dsDNA did not increase the binding to AECA or
expression of vWF, ICAM, or VCAM. The supernatant level of ICAM
was significantly elevated in EC cultured with dsDNA as compared with
control lgG or dsDNA-dep-lgG. The mRNA encoding for ICAM was
similarly raised in EC incubated with dsDNA. Increased proinflammatory
activities induced by dsDNA on EC were shown by elevated supeinatant
levels of interleukin-if3 and interlcukin-6 in EC incubated with dsDNA.
Our findings strongly suggest that anti-DNA autoantibodies play an
important pathogenetic role in inducing inflammatory injury of vascular
endothelium in SLE.
Comparison of adhesion molecule expression on blood monocytes and
peritoneal macrophages from patients on CAFD. Ri. Fault, J. Wang, and
L. Peters, Department of Renal Medicine, and Flow ytometry Laboratory,
Southpath Laboratories, St. George Hospital, Kogarah, NSW Australia.
Peritoneal macrophages are generally regarded as the first cellular defense
against microorganisms invading the peritoneal space. Normally, at least
50% of leukocytes in the peritoneum are macrophages, and during
episodes of peritonitis their absolute number increases. The aim of this
project is to better understand how peripheral blood monocytes migrate
into the peritoneal space, and to study their changing adhesive properties
as they differentiate into macrophages. In this study we compared the
profiles of adhesion molecules expressed by peripheral blood monocytes
and peritoneal macrophages from patients on CAPD. Analysis was by flow
cytometry using 22 monoclonal antibodies against different adhesion
molecules. The monoeyte/macrophage population in blood or peritoneal
fluid was determined with a phyeoeiythrin-labelled anti-CD 14 monoelonal
antibody. So far we have studied 8 patients on 10 different occasions (1
patient during 2 episodes of peritonitis; another when infection-free after
a studied episode of peritonitis). Four episodes were during culture-
positive peritonitis (3 Staphylococcus epidermidis, 1 Pseudomonas fluores-
cens); 4 culture-negative, clinical peritonitis; I infection-free follow-up
study; and I patient was studied during a dialysis-free recovery period
from prolonged renal failure. Several clear patterns have emerged. The
following adhesion molecules are consistently down-regulated on perito-
neal maerophages compared to blood monocytes: integrins a41, a6l,
aL2 and av3, and CD31 (PECAM-i). Each of these has important
roles in monocyte extravasation and migration, but this down-regulation
implies that they are less important on tissue macrophages. Only one
molecule (av5) is consistently up-regulated on peritoneal macrophages.
The exact role of this vitronectin and fibronectin receptor is less well-
defined, but this finding suggests that it may be important in macrophage
tissue residence. The other adhesion molecules studied either had un-
changed expression or exhibited no consistent pattern. Peritonitis had no
clear effect on adhesion molecule expression on macrophages or mono-
cytes. These preliminary studies give insights into monocyte/macrophage
adhesive behavior and will guide future functional studies.
Up-regulated expression of fibrogenic growth factors is linked to
monocyte/macrophage infiltrate in patients with glomerulonephritis. AN.
Stein-Oakley, G. Perry, N.M. Thomson, Department of Medicine and Renal
Unit, Monash Medical School, Alfred Hospital, Melbourne, Australia.
Chronic injury in glomerulonephritis is characterized by glomeruloselero-
sis, interstitial fibrosis and vascular damage, features consistent with the
involvement of fibrogenic growth factors in the pathophysiology of this
disease. The expression and distribution of platelet-derived growth factor
(PDGF), transforming growth factor (TGFP), basic fibroblast growth
factor (bFGF), and their receptors, and the severity and nature of
interstitial and glomerular leukocyte infiltration were analyzed by immu-
nohistoehemistry in biopsy samples from 15 IgA ncphropathy (IgAN)
patients and 10 focal glomeruloselerosis (FGS) patients. Control renal
tissue (N = 3) was obtained from areas remote from tumor in nephree-
tomies performed for renal malignancy. Growth factor expression was
up-regulated in varying proportions of IgAN and FGS patients depending
on the severity of damage and on the degree of mononuclear cell infiltrate.
There were no significant differences in the relative numbers of IgAN vs.
FGS patients demonstrating altered growth factor expression. Specific
staining patterns were observed for each growth factor. Up-regulation of
PDGF AA and PDGF receptors was prevalent in the patient population
examined, with lower numbers of patients demonstrating up-regulation of
the other growth factors. TGF- receptors and FGF receptors were
ubiquitous in normal and diseased kidneys. The expression of PDGF
receptor p (PDGFRP) was evaluated using an image analysis system, and
the numbers of infiltrating leukocytes were counted using an ocular grid.
Mean expression of PDGFR was increased in IgAN [16 3% in
interstitium (1); 28 3% in glomeruli (G)j versus controls (9 3% I; 16
3% G), although differences were not significant due to low control
numbers and wide variation between individual patients. There was a
strong correlation between interstitial PDGFRP expression and numbers
of CDl4 infiltrating monoeytes/maerophages in all patients (P < 0.01).
Up-regulated glomerular PDGFAA was also accompanied by glomerular
CD14 leueocyte infiltration. The results presented in this study suggest a
major involvement of the fibrogenic growth factors in the chronic injury of
glomerulonephritis, and demonstrate a strong link between infiltrating
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monocytes/macrophages and altered growth factor expression in this
pathology.
CD44 expression in rat anti-GBM glomerulonephritis. J. Zhao, H. Y
Lan, R.C. Atkins, D.J. Nikolic-Paterson, Department of Nephrology, Monash
Medical Centre, Clayton, Victoria 3168, Australia. CD44 is the major cell
surface receptor for hyaluronan. Multiple forms of CD44 are expressed
through alternative mRNA splicing. The 90 kDa form of the CD44
molecule (termed CD44H) is expressed by cells of hemopoietic and
mesodermal origin. A number of functions have been ascribed to CD44H,
including lymphocyte homing and extracellular matrix adhesion. We have
examined CD44 expression in rat accelerated anti-GBM glomerulonephri-
tis (days 1, 7, 14, 21 and 28) by immunoperoxidase staining of PLP-fixed
cryostat sections using the OX-49 mAb which recognizes the 90 kDa form
of CD44 expressed by lymphoid cells. In normal kidney, CD44 is expressed
by Bowman's capsule parietal epithelium, occasional interstitial cells,
medullary tubules, thick ascending limb of Henle and distal tubules. CD44
expression was strongest on the basolateral surface of tubular epithelial
cells. In anti-GBM glomerulonephritis strong CD44 expression was seen
on infiltrating glomerular neutrophils and rnacrophages during the first 24
hours following antibody deposition on the GBM. However, at later time
points there was little CD44 expression by glomerular macrophages,
except that CD44+ cells were prominent in cellular crescents. From day
14 onwards there was a marked increase in the number of CD44+ tubules
which was evident in focal areas of tubular damage with prominent local
CD44+ leukocytic infiltration. In addition, areas of fibrosis (particularly
crescents and periglomerular) also exhibited anti-CD44 staining which did
not appear to be cell associated, but may reflect shed CD44 antigen. In
conclusion, CD44 expression in rat anti-GBM glomerulonephritis was
associated with the early glomerular leukocytic infiltrate, glomerular
crescent formation, localization of interstitial leukocytes in areas of focal
tubular damage and fibrosis.
Genetic predisposition to TH1 type T helper cell responses favors
crescent formation in glomerulonephritis. XR. Huang, SR. Holdsworth,
P. U. Tipping, Centre For Inflammatoiy Disease, Monash University Depart-
ment of Medicine, Monash Medical Centre, Clayton, 3186, Victoria, Austra-
lia. The Thi subset of T helper cells is identified by its capacity to produce
the cytokines interferon-y, tumor necrosis factor-n and interleukin-2. Thi
cells are involved in direct T cell-mediated immune responses, typified by
delayed type hypersensitivity (DTH). The Th2 subset of T helper cells
produces interleukin-4 and interleukin-lO and helps in antibody produc-
tion. Glomerular crescent formation shows features of classical DTH with
local T helper cell and macrophage accumulation and fibrin deposition,
suggesting a Thi type response. To assess the contribution of Thi and Th2
T cell subsets to the development of glomerular crescent formation,
glomerulonephritis (GN) induced by antigen representation in the gb-
merulus of sensitized mice was compared in strains known to produce
predominantly a Thi (C57BL/6) or Th2 (BALB/c) type immune response
to antigens. Anti-glomerular basement membrane (GBM) GN was in-
duced by the iv. injection of sheep anti-mouse GBM globulin to mice
presensitized ten days earlier with sheep globulin in Freund's complete
adjuvant. This produced a proliferative GN with proteinuria and renal
impairment (increased serum creatinine). Ten days after initiation of GN,
C57BL/6 mice showed a more cellular proliferative pattern of GN, with
significantly more crescent formation (41 3% of glomeruli with crescents
compared to 10 3% of glomeruli in BALB/c mice, P < 0.01). Glomerular
fibrin deposition assessed by immunofluorescence was more extensive in
C57BL/6 mice than that in BALB/c mice. Circulating mouse anti-sheep
antibody levels (assessed by ELISA) and deposition of mouse immuno-
globulin in gbomeruli (assessed by immunofluorescenee) were no different
in the two strains. Gbomerular C3 deposition was less prominent in
C57BL/6 mice. These studies demonstrate that a dominant Thi type T
helper cell response favors the development of crescents in ON indepen-
dent of the humoral immune response. This suggests that Thi T helper
cells contribute to glomerular crescent formation via DTH-like mecha-
nisms.
The proinflammatory and cytotoxic activities of TNF-a. .T.A.J. Barbara,
W.B. Smith, X VanOstade, W Fiers, MA. Vadas, and A.F. Lopez, Division
of Human Immunology, Hanson Centre ft.r Cancer Research, Frame Rd.,
Adelaide, South Australia 5000. Tumor necrosis factor-alpha (TNF-a) is a
pleiotropic cytokine which has been administered in viva as an antineo-
plastic agent and is implicated in the pathophysiology of SLE, transplant
rejection, CMV reactivation, hemolytie-uremie syndrome and nephrotic
syndrome. However, the molecular mechanisms through which TNF-a
expresses its biological activities are only now being unraveled. Using TNF
mutants with selective binding to the two TNF receptors (TNFR55 and
TNFR75), the receptor biology of TNF was examined in human neutro-
phils, endothelium and malignant cell lines. The TNFR55-selective mu-
tants resulted in neutrophil and endothelial proinflammatory activities
which were reduced up to 170- and 280-fold, respectively, when compared
to wild-type TNF. However, these mutants shared similar activity to
wild-type TNF in causing cytotoxicity of a human carcinoma-derived cell
line and eytostasis in a human leukemic cell line. The TNFR75-selective
mutant did not directly mediate any of the proinflammatory activities
examined giving an important insight into the mechanism of action of
TNF-n. In addition, the TNFR55-selective mutants resulted in neutrophil
apoptosis, as determined by microscopy (light and fluorescent) and DNA
fragmentation gels, which was significantly decreased compared to wild-
type TNF (ED5O wt 7.9 ng/ml, E146K 115.7, P < 0.05, R32W-S86T 97.6,
P < 0.005) and indicates that similar mechanisms may be involved in the
noninflammatory removal of these cells after functional activation. These
results have implications not only for the treatment of malignancies such
as renal cell carcinoma, but also for the design of other specific therapeutic
modalities.
Tamm-Horsfall protein (THP) in rat anti-GBM glomerulonephritis
(GN). II. Is it a leukocyte mitogen? S. Qing, Di. Nikolic-Paterson, R.C.
Atkins and H. Y Lan, Department of Nephrology, Monash Medical Centre,
Clayton, Victoria 3168, Australia. THP has been reported to be a leukocyte
mitogen in vitro. However, in the accompanying abstract we demonstrated
the development of an antigen-specific immune response to THP in rat
accelerated rat anti-GBM GN. This raised the question of whether THP
acts as a conventional antigen or as a mitogen in this disease. We
confirmed the mitogenie activity of highly purified rat THP in vitro.
Splenocytes isolated from normal rats or animals sensitised to THP were
cultured for 36 or 72 hrs with THP (50 to 400 jLg/ml) and the high level of
3H-thymidine incorporation was equivalent to that obtained with a
conventional mitogen, Concanavalin-A (5 Wml). Double immunohisto-
chemistry found that 10 to 20% of T cells, B cells and macrophages
expressed the proliferating cell nuclear antigen (PCNA). This was abro-
gated by the addition of anti-THP antibody. Next, we looked for evidence
of a mitogenic effect of THP upon leukocytes in rat anti-GBM ON.
Leukocytes, PCNA and THP were co-localized using triple immunohisto-
chemistry staining. In normal rat kidney, the resident interstitial leuko-
cytes (OX-1) showed no evidence of proliferation. During development
of rat anti-GBM ON there was significant accumulation of T cells and
macrophages around THP tubules (i.e. contacting the tubule), which was
3- to 4-fold greater than that present around THP tubules. Some 0.8
0.2 0X-1PCNA cells per T}TIP tubule (distal and thick ascending limb
of the loop of Henle) were seen on day 1. This number increased to 2.4 to
2.6 OX-I PCNA cells/THP tubule (distal and thick ascending limb of
the loop of Henle) were seen on day 1. This number increased to 2.4 to 2.6
OX-I PCNA cellsiTHP4 tubule from day 7 onwards. This accounted for
27 to 36% of OX-i cells around THP tubules and was comprised of
both R73 T cells and EDI macrophages. However, a very similar
percentage of OX-L cells around THP tubules (22 to 33%) was also
PCNA, and again this was comprised of both T cells and macrophages.
In conclusion, we have found that, while THP acts as a mitogen in vitro,
there is no evidence of such an activity in vivo. The differences in THP
behavior requires further investigation.
Lack of large deletions affecting 3' end of locus for autosomal dominant
polycystic kidney disease in 73 affected individuals. J. Ellis and J. Savige,
University Department of Medicine, Austin Hcopita4 Heidelberg, Victoria
3084, Australia. The abnormal gene in patients with autosomal dominant
polycystic kidney disease (ADPKD, PKDI) is located on the short arm of
chromosome 16 and encodes a novel protein, PBP (polycystic kidney
disease breakpoint protein). A large part of this gene is duplicated nearby
on the same chromosome, and this has made it difficult firstly to identify
the mutant gene, and secondly to screen the DNA for mutations. We used
PCR primers to amplify the unreduphicated 3' end of the PBP gene from
the DNA of 73 individuals with ADPKD. The amplified product is about
400 bp long, and in no individual was a shortened or absent product
observed. Initially it was thought that mutations probably took place more
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often within this region of the ADPKD gene, but our results suggest that
large deletions within the 3' end of the PBP are rare.
Aiphal-antitrypsin deficiency and anti-proteinase 3 antibodies in
ANCA-associated systemic vasculitis. J.A. Savige, L. Chang, M Daskalakis
and J. Doeiy, Molecular Medicine, University Department of Medicine,
Austin Hospital, Melbourne, Victoria, and Biochemist,y Department, Mo-
nash Medical Centre, Clayton, Victoria, Australia. Alphal-antitrypsin (Al-
AT) is a naturally-occurring inhibitor of proteinase 3 and elastase, two of
the target antigens of anti-neutrophil cytoplasmic antibodies (ANCA).
These antibodies are often associated with Wegener's granulomatosis and
microscopic polyarteritis. An increased incidence of Al-AT phenotypes
that result in dysfunctional protein or low levels has been reported in
patients with anti-proteinase 3 antibodies, and we have looked at this
association. Phenotypes associated with a moderate or severe deficiency of
Al-AT were found more often in individuals with anti-proteinase 3
antibodies than in the general population: 4 of 31 patients with anti-
proteinase 3 antibodies (13%) had the phenotypes MZ (N = 2), S (N =
1) or Z (N = 1), p < 0.01). However, overall levels of Al-AT were normal
(12/26, 46%) or elevated (14/26, 54%) in patients with anti-proteinase 3
antibodies, including the patients with deficient phenotypes. There were
no abnormal phenotypes demonstrated in any sera from patients with
anti-elastase, anti-myeloperoxidase or anti-glomerular basement mem-
brane antibodies. ANCA were not demonstrated by indirect immunoflu-
orescence in the serum from any of 73 patients with abnormal Al-AT
phenotypes, including 23 individuals with ZZ. We have confirmed an
association between abnormal Al-AT phenotypes and the demonstration
of anti-proteinase 3 antibodies, but there is no reduction in levels of
Al-AT in these individuals. The development of anti-proteinase 3 anti-
bodies may relate to the increased propensity of unbound and uninhibited
proteinase 3 to stimulate autoantibody production.
Antibodies to endothelial cells (AECA) and epithelial cells (AEpCA) in
IgA nephritis (IgAN) and lupus nephritis (LN). L.M. Johnstone, R.G.
Walker, G.J. Becker, Department of Nephrology, Royal Melbourne Hospital,
Parkville, Victoria, 3052, Australia. AECA have been described in several
diseases including LN, IgAN, vasculitis, diabetes, thrombomicroangiopa-
thies and renal transplantation. Their significance remain unclear. Previ-
ously, we have shown in LN and IgAN patients increased levels of AECA
compared to Controls (C) and that some AECA positive sera from IgAN
patients showed binding activity on fibroblasts suggesting that endothelial
cells (EC) and fibroblasts may share common antigens recognised by these
sera. In this study we have investigated the presence of AECA and
antibodies to kidney epithelial cells in sera from patients with IgAN and
LN. AECA and AEpCA were detected using a cellular ELISA. AECA
were tested against human unfixed umbilical vein EC. AEpCA were tested
against monkey kidney epithelial cells (CSL) in a commercial cell line.
Binding the cells were exposed with goat anti-human immunoglobulin G
(IgG) and goat anti-human total immunoglobulin (Ig) with an alkaline
phosphatase label. All sera were tested in triplicate. An ELISA ratio (ER)
was calculated for each set of sera, i.e., ER (%) = [(sample OD —
negative control OD)/(positive control OD — negative control OD)] X
100.
-
IgG % Total Ig %
AECA
No correlation was evident between AECA and AEpCA, IgG or Total Ig
level (Spearmans test, data not shown). We concluded that AECA and
AEpCA were present in IgAN but were not demonstrated in LN. Further
work is required to determine the nature of antigenic determinants
recognised by AECA and AEpCA.
Cyclosporine in renal transplantation: A nine-year experience. Z.F.
Yuan, R. R. Bailey and J. Gardner, Departments of Nephrology and Pathol-
ogy, Christchurch Hospital, Christchurch, New Zealand. Cyclosporine A
(C5A) has been used in a triple immunosuppressive regimen in our renal
transplant program since 1 October 1984. From that time until 30 June
1993, 117 patients had a total of 130 renal transplants. This review was
confined to 52 of these patients who had been on CsA for at least 12
months and had remained under regular surveillance in this clinic; 65 were
excluded for various reasons (transferred to home town, 27; graft failed
within 12 months, 22; follow-up <12 months, 11; miscellaneous, 5).
Patients were given 10 mg/kg of CsA prior to transplantation then 8
mg/kg/day in two divided doses after the onset of graft function. The
maintenance dose was tapered to a mean of 3.5 mg/kg/day (SD 1.4) within
9 months, and thereafter ranged from 3.0 to 3.4 mg/kg/day. Individual
patients differed significantly in the trough whole blood CsA concentra-
tions that they produced on a certain dose. Definite chronic CsA
nephrotoxicity occurred in three patients and equivocal changes in an-
other patient, while on a CsA dose of 3.0 to 4.0 mg/kg/day. CsA was an
effective drug as part of a triple immunosuppressive regimen for renal
transplantation. Chronic CsA nephrotoxicity was an unpredictable finding,
and occurred with doses as low as 3.0 to 4.0 mg/kg/day and with trough
drug concentrations within the recommended therapeutic range. All
patients on CsA should be under regular supervision and early graft biopsy
undertaken if graft dysfunction occurs.
Predicting GFR after renal transplantation. B.J. Nankivell, JR. Chap-
man, Department of Renal Medicine, Westmead Hospital, NSW 2145,
Australia. Serum creatinine is an important marker of the impairment of
glomerular filtration rate (GFR) after kidney transplantation. Predictive
formulae (such as Cockroft and Gault) derived from patients with chronic
renal failure using creatinine clearance are inaccurate when applied to
kidney transplant recipients. The purpose of this study was to investigate
causes of this inaccuracy and to derive specific predictive GFR formulae
appropriate to kidney transplant recipients. Predictive factors for isotopic
GFR, serum creatinine and muscle mass were evaluated in consecutive
kidney recipients (N = 146) using Tcs9m DTPA GFR measurements (N =
751) as a reference method. Factors which predicted GFR apart from
serum creatinine included sex, height, body weight, serum urea, years on
dialysis, number of rejection and infective episodes, and prednisolone
dose. The relationship between serum creatinine and GFR was highly
variable and dependent on factors that alter muscle mass and muscle
catabolic rate. Further variation was introduced by clinical situations
where tubular secretion of creatinine may be reduced such as ATN and
chronic rejection. Three GFR formulae (according to availability of
clinical data) were specifically derived and tested against six published
methods of GFR estimation: GFR (mI/mm) = 6.7/creatinine (mmol/liter)
+ body wt (kg)/4 — urea(mmol/liter)/2 — 100/height(m)2 + [35(3) or
25( ? )]. These derived formulae had the highest correlation, no overall
bias, least scatter of sum of squares, and least error at low levels of GFR.
They provide a better estimation of GFR in kidney transplantation and
their use is recommended when isotopic methods are not available or
inappropriate.
The mechanisms of cyclosporine toxicity induced by clarithromycin.
S. T. Spicer, C. Liddle, J. C'hapman, P. Barclay, B. Nanki veil, P. Thomas, P.
O'Connell, Department of Renal Medicine, Westmead Hospital, NSW
Australia. Recently a number of case reports have described the interac-
tion of clarithromycin with cyclosporine A, resulting in cyclosporine
toxicity. Following a case of cyclosporine toxicity with acute renal failure
in a clarithromycin-treated transplant patient, the effect of oral clarithro-
mycin on the hepatic P450 system was investigated in five healthy male
volunteers using the erythromycin breath test (EBT). Hepatic P450-3A
enzymes form the main mechanism for elimination of cyclosporine A, and
the EBT is a specific probe for the activity of these enzymes. Each subject
underwent an erythromycin breath test in which the amount of radioactive
CO2 exhaled was correlated with the activity of hepatic P450-3A in each
volunteer. One week later each volunteer received clarithromycin 500 mg,
q12 hourly for 48 hrs (i.e. 4 doses), and the EBT was repeated to
determine if hepatic P450-3A had been inhibited. There was a significant
reduction in the area under the curve (AUC) of exhaled C'4 erythromycin.
The mean reduction in the AUC was 26.2%. The degree of reduction
varied widely from 16.3% to as much as 35.9% (P = 0.0075). We conclude
C (N = 22)
IgAN (N = 69)
LN (N = 17)
AEpCA C (N = 22)
IgAN (N = 66)
LN(N= 16)
10.4 (1.4—37.0)
25.7 (3.9—172.9)
15.8 (3.0—157.6)
22.3 (0.0—88.8)
60.9 (0.0_i 19.9)c
30.5 (14. 1—81.0)
17.1 (5.3—48.2)
30.3 (3.4—118.4)"
13.3 (6.1—148.6)
29.0 (0.0—90.6)
56.3 (0.0—143.0)
32.4 (16.3—68.3)
Median (range). "P = 00004,bp=00017, "P = 0.0002, Wilcoxon
rank-sum test compared to C.
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that clarithromycin causes cyclosporine toxicity by inhibiting its metabo-
lism via the Hepatic P450 enzyme system. The wide intcrsubject variability
may explain the variable effect on cyclosporine levels noted clinically, and
suggests competitive inhibition rather than complexing of the P450 3A
enzymes as the mechanism of this interaction.
Use of acitretin for the skin complications in renal transplant recipi-
ents. Z.F. Yuan, A. Davis, K. Macdonald, and R.R. Bailey, Departments of
Nephrology and Dermatology, Christchurch Hospital, Christchurch, New
Zealand. Fifteen long-term Caucasian renal transplant recipients suffering
skin complications were treated with acitretin, a second generation
retinoid. Indications for its use were progressive actinic keratoses, wide-
spread warts or recurrent skin malignancies. The daily dose ranged from
10 to 50 mg. Therapeutic benefit was assessed by the general condition of
the skin and the number of skin malignancies excised. Side effects and
toxicity were monitored by regular enquiry, skin examination, liver func-
tion tests and lipid profiles. All patients experienced subjective improve-
ment with the skin becoming softer and smoother. Aetinic keratoses and
warts improved or disappeared. Six patients had been on acitretin for >12
months. The number of malignancies were decreased in 4 of these 6
patients. Nine of the 15 patients had skin side effects, including dry lips,
hair thinning, skin scaling, nail changes and photosensitivity. Acitretin had
to be reduced in dose in these 9 patients and stopped in 4. There were no
biochemical side effects. Seven patients were on cyclosporine and no
interaction was found with acitretin. In summary, most of the patients
experienced subjective improvement and actinic keratoses and warts were
improved or disappeared. The effect on the skin malignancy rate was
variable. The benefits of acitretin treatment are still anecdotal and there
is a need for a multicentre, prospective, randomized study.
Combined liver-kidney transplantation in the treatment of primary
type 1 hyperoxaluria. P. Branley, P. Angus, R. MeL. Jones, R.A. Sinclair,
and P.J. Miach, Renal & Liver Units, and Department Anatomical Pathology,
Austin Hospital, Heidelberg, Victoria, Australia. Type I hyperoxaluria
presents in children or young adults with bone disease or renal disease due
to oxalate accumulation from deficiency in the hepatic enzyme alanine,
glyoxylate aminotransferase. The clinical severity of disease varies with the
amount of residual enzyme. Liver transplantation corrects the enzyme
deficiency and combined liver-kidney transplantation is the treatment of
choice for patients with renal failure. We report th1ee cases of combined
liver-kidney transplantation in this condition. Renal transplantation alone
failed in two cases due to recurrent renal oxalosis and renal failure. All
patients survive with a functioning liver transplant after 2-1/2, 3-1/2 and
4-1/2 years. However high oxalate excretion has continued in all patients
despite good renal function (plasma creatinine 0.t2—0.15 mmol/liter)
causing loss of one kidney transplant after 3 years. A second kidney has
failed due to an undefined cause. Patients with primary oxaluria should be
considered for liver or liver kidney transplantation before heavy oxalate
deposition occurs in kidney and bone if subsequent loss of kidney function
due to oxalosis is to he avoided.
Hepatitis B virus (HBv) associated chronic liver disease in cyclospor-
me-treated renal allograft recipients. 1.). Roy, B. Ramakrishna, B.S.
Ramakrishna, C.K Jacob, J.C.M. Shastiy. Departments of Nephrology,
Pathology and Gastroenterology, Christian Medical College & Hospital,
Vellore, India. Hepatitis B virus associated chronic liver disease is an
important cause of long-term mortality and morbidity in renal allograft
recipients. Most studies have been prior to the cyclosporine era. Whether
cyclosporine based immunosuppression alters the course or the develop-
ment of chronic liver disease is not entirely clear. A total of 55 hepatitis B
surface antigen (HBSAg) positive recipients of live-related donor renal
allografts were studies. They either received azathioprine-prednisolone
(AZA) (33 patients) or cyclosporine (CsA) (22 patients) based immuno-
suppression. The mean follow-up was 37.8 + 17 months and 58.2 + 22.6
months for the AZA and CsA groups, respectively. Coincident infection
with hepatitis C was not uncommon (10%). Chronic liver disease devel-
oped in 47% of the HB5Ag positive renal allograft recipients. All patients
with HCV coinfection developed chronic liver disease. Liver biopsies were
performed in 15 patients. The biopsies revealed chronic active hepatitis 8,
chronic persistent hepatitis 1, cirrhosis 1, granuloma 2, cholestasis 2 and
normal 1. Nine patients died, 6 from the AZA group and 3 from the CsA
group. Liver cell failure with septicemia was the cause of death in 8
patients. Hepatitis B virus associated chronic liver disease, a major cause
of morbidity and mortality after renal transplantation in India, is not
significantly different with either of the currently available immunosup-
pressive regimes.
Mechanism of Na transport inhibition during chronic volume expan-
sion. AZ. Gyoiy, N. Salipan-Moore and S. Reddy, Departments of Medicine
and Renal Medicine Royal North Shore Hospital arid University of Sydney,
NSW, Australia. In acute extracellular fluid volume expansion (AcVE),
proximal tubular Na transport inhibition has two components: a 20%
inhibition when measured with a fluid resembling proximal tubular fluid
(ATF) and an additional 30% inhibition with native harvested proximal
tubular fluid (HTF). Because the natriuresis in chronic volume expansion
(ChVE) is more modest than in AeVE, different tubular mechanism may
be involved in the inhibition of Na transport in these two models. To test
this, a ChVE model (4% MaCI diet) was set up in rats to examine proximal
tubular Na transport with ATF and HTF Plasma volume was expanded by
13% as assessed by changes in Ht and serum albumin concentration was
maintained at normal levels (48.1 1.0 in ChVE and 46.6 3.4 g/liter in
controls, P = 0.46). Proximal tubular Na transport (iv, mm3 mm2 sec I)
was measured with the shrinking drop technique. With ATF, proximal
tubular Na transport was 3.67 0.09 * io (N = 74) in ChVE rats and
3.70 0.26 * iO (N = 18) in controls (P = 0.89) and 2.78 0.07 * 1O(N = 92, P < 0.0001) with I-ITF, compared to ATF in the ChVE rats. This
reduction of transport to 75.6% agrees closely with that obtained previ-
ously with HTF alone in AcVE. Intracellular Na measured with electron-
microprobe analysis was increased in ChVE (20.2 0.08 vs. 18.0 0.7,
P = 0.044), while Cl, P and dry weight decreased significantly, the latter
two indicating cell swelling. In conclusion: (1) proximal Na transport was
only inhibited with HTF providing evidence that, at least in proximal
tubules, with HTF, similar mechanisms are involved in the Na transport
inhibition in both types of VE; and (2) that this transport inhibition is
accompanied by evidence of Na pump inhibition.
Is the K conductance of the proximal tubule regulated by cytosolic
pH? M. Bleich, M. Hug, A.Z. Gyoty, and R. Greger, Albert-Ludwigs.
Universitbt, Freiburg, Departments of Medicine University of Sydney, NSW,
Australia. A high K' conductance of proximal tubule cells isa prerequisite
for luminal Na uptake and basolateral NaHC03 cotransport. Patch-
clamp and fluorescence measurements were performed on freshly isolated
proximal tubules of rat kidney to study if there is a link between
intracellular pH and cellular K -conductance. Basic properties of freshly
isolated proximal tubules: the membrane voltage (Vm) was —57 2 mV
(N = 40), an increase of extracellular K by 20 mmol/liter depolarized V,
by 19 2 m (N = 19), and glucose (10 mmol/liter) depolarized V0, by 12
2 mV (N = 19). In fluorescence measurements the effects of changes in
extracellular pH or CO2 and HCO3 on intracellular pH were examined
(changes in emission ratio (&atio) are given as a measure of intracellular
pH). The effects on V,,, and single channel open probability (Pt,) were
determined in separate experiments. Cells were alkalinized by an increase
in extracellular HCO1 and CO2 at constant external pH: ratio of
fluorescence measurements was 13 2% (N = 11), membrane potential
hyperpolarizcd: Vm = —7 2 mV (N = 30) and channel open
prahability increased: P0 changed from 0.26 to 0.56 (N = 2). Intracellular
pH was also increased by reduction of CO2 at constant external HC03:
&atio = 18 3%(N = 3)Vm = 8 I mV(N = 5), and hyDlDS(1(Y4
mol/liter ratio = 6 2 (N = 8), V,,, = 41 mV (N = 4). Cells were
acidified by an increase in CO2 at constant HC03: ratio = —17 2%
(N = 6), V,,, = + 12 2 mV (N = 4), P0 changed from 0.27 0.08 to
0.08 0.03 (N = 3). Intracellular pH was also decreased by removal of
CO2 and 11C03 at constant pH: ratio = 20 2 (N = 4), Vm = +8
I mV (N = 5) and P0 changed from 0.23 to 0.11 (N = 2). The usc of the
ammonium pulse technique for variation of intracellular p1-I could not be
applied because NH4 7NII3 itself blocked K channels (N = 3) in this
preparation. The present data indicate that proximal tubular K -conduc-
tance is pH-regulated. Membrane potential may serve as a direct feedback
signal for basolateral electrogenic NaIICO3 transport maintaining
intracellular pH in a physiological range despite of high HC03 transport
rates.
Is one mechanism of Na transport inhibition by volume expansion via
the apical Na/H exchanger or basolateral Na[HCO]3 cotransporter? A.
Gyo,y, M. Bleich, M. Hug, and R. Greger, Albert-Ludwigs-Universitat,
Freiburg, Germany, and Department of Medicine, University of Sydney,
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Australia. In acute sustained extracellular fluid volume expansion (AcVE),
the mechanism of proximal tubular (PT) Na transport inhibition has two
components: a 20% inhibition measured with a fluid resembling proximal
tubular fluid (ATF) and an additional 30% inhibition with harvested
proximal tubular fluid (HTF). In transfer experiments we have shown that
the former is an expression of a PT epithelial change, whereas the latter
is due to a factor contained in PT fluid of AcVE animals. Patch-clamp and
fluorescence measurements were performed on freshly isolated proximal
tubules of control (Co) and acutely volume expanded (Ex) rat kidneys.
Basic properties of freshly isolated proximal tubules: membrane voltage
(Vm) was —57 2 mV (N = 40), an increase of extracellular K by 20
mmol/liter depolarized V,,, by 19 2 mV (N = 25), and glucose (10
mmol/liter) depolarized Vm by 15 3.5 mV (N = 25). In fluorescence
measurements the effects of changes in extracellular pH or CO2 and
HC03 on intracellular pH were examined [changes in emission ratio (
ratio) of BCECF dye are given as a measure of intracellular pH]. AcVE
cells were acidotic when compared to controls (by unpaired initial
emission ratios). Cells were alkalinized by an increase in extracellular
HC01 and CO2 at constant external pH, but AcVE cells significantly less
than Co (P < 0.01) indicating a reduced Na[HCO1]3 cotransporter
activity. DIDS (5 * iO M), a stilbene inhibitor of the cotransporter,
alkalinized both types of cells equally and prevented further cell alkalini-
sation by an increase in extracellular HC01 and CO2 at constant external
pH. The present data suggest that the apical Na/H rather than the
basolateral Na[HCO1]3 cotransporter was primarily inhibited during
AcVE. Further experiments are needed to confirm this observation.
The action of circulating growth factors tested in primary culture of rat
proximal tubular cells. MS. Nobes, CA. Pollock, P. T. Heng, and Mi Field,
Department of Medicine, University of Sydney, Royal North Shore Hospital
St. Leonards, Australia. Compensatory renal hypertrophy following ne-
phrectomy may be regulated by circulating serum factors and local growth
factors. Thus, the effects of addition of specific antibodies against known
growth factors to serum harvested from either sham-operated (Sx) or
unilaterally nephrectomized (Nx) animals were tested in culture. The cell
growth parameters determined after 7 days were cell proliferation or
hyperplasia, using cellular thymidine incorporation, and increased cell size
or hypertrophy, using cellular protein content. Epidermal growth factor
(EGF) and insulin-like growth factor 1 (IGF-1) induced Ityperplasia (P <
0.0001 and P < 0.01 respectively), while transforming growth factor j3
(TGF-f31) potently inhibited hyperplasia (P < 0.0001). IGF-1 also induced
hypertrophy (P < 0.01). All cell growth effects were neutralized by each
growth factor's specific antibody (Ab). Compared to 10% serum from Sx
rats, 10% serum from Nx rats significantly enhanced hyperplasia (P <
0.01) and hypertrophy (P < 0.0001). The addition of anti-EGF Ab to
either sera did not affect hyperplasia or hypertrophy. The addition of
anti-IGF-1 Ab to Sx and Nx sera did not affect hyperplasia, but did reduce
hypertrophy by 12% (P < 0.02) and 30% (P < 0.001), respectively. Similar
effects were noted with anti-IGF-1 Ab + anti-EGF Ab to those using
anti-IGF-1 Ab alone, except that Nx serum-induced hyperplasia was
reduced by 36% (P < 0.02). Conversely, the addition of anti TGF-/3 Ab to
Sx and Nx sera increased hyperplasia similarly by 63% (P < 0.001) and
59% (P < 0.01), respectively, yet did not alter hypertrophy. In conclusion,
IGF-1, EGF and TGF-131 have direct effects on rat renal tubular cell
growth that can be neutralized by their specific antibodies. Growth
promotion by serum from normal rats is likely to involve IGF-1-induced
hypertrophy and be limited by TGF-f3-induced antiproliferation. Aug-
mented growth by serum from rats undergoing compensatory renal
hypertrophy most likely involves enhanced hypertrophy due to IGF-1, and
cell proliferation due to both IGF-l and EGF despite TGF-/3-induced
antiproliferation.
Effect of serum on secretion of prostacyclin and endothelin-1 by
decidual endothelial cells from human pregnancies. J. Rowe, S. Campbell
T. Hawkins, and E.D.M. Gallery Department of Renal Medicine, Royal North
Shore Hospital St. Leonards, NSW Australia. It is widely felt that maternal
endothelial cells are centrally involved in pre-eclampsia, and that a
factor(s) in serum from women with pre-eclampsia alters endothelial cell
function. The purposes of this study were: (a) to examine secretion of
vasoactive substances by decidual endothelial cells from normal and
pre-eclamptic pregnancies, in response to serum from gestation-age-
matched normal and pre-eclamptic women; (b) to compare them with
umbilical vein endothelial cells, widely used as a general surrogate
endothelial cell; and (c) to determine whether responses are amplified by
48 hours-pre-incubation for in test sera. Endothelial cells isolated from
umbilical veins (HUVEC), and from decidual biopsies collected at
caesarean section delivery, from both normal (N DEC) and pre-eclamptic
(PE DEC) women, were maintained in culture until passage 2, when their
secretion of the vasodilator prostacyclin (measured as its stable metabo-
lite, 6 keto PGFI a), and the vasoconstrictor endothelin-1 was compared,
in the presence of serum from pre-eclamptic (PE) or gestational age-
matched normal (N) pregnant women. Prostacyclin secretion (pg/b6
cells/24 hr) was higher by all endothelial cell populations incubated in
serum from pre-eclamptic women, than in serum from normal pregnant
women (Group A: no pre-incubation; Group B: pre-incubation)
Cells serum N HUVEC PE N
(A) 24 hr
(B) 24 hr
(Mean % change A-B)
840 101
826 185
—2%
1172 160
1186 254
+1%
250 70
235 111
—6%
Cells serum N DEC PE N PE DEC PE
(A)24hr(B) 24 hr
(Mean % change A-B)
360±55
306 87
—15%
289±186
377 100
+30%
541±83
790 180
+46%
Pre-incuhation of PE DEC (% change A-B) in pre-eclamptic serum
amplified prostacyclin secretion (N < 0.01). Values for endothelin were
not different in serum from normal or pre-eclamptic women. Pre-eclamp-
tic serum contains a factor(s) which stimulates PGI2 secretion from
HUVEC and DEC. Cells from pre-eclamptic women were more suscep-
tible to perturbation of secretion by this factor. Pre-eclamptic serum did
not specifically affect endothelin-1 secretion.
Monocyte chemoattractant protein-i mRNA expression in rat kidney
proximal tubules cultured in protein-concentrated media. J. Chen, L.
Chen, Y -Y Ng, Y -C. Tay, D. C.H. Harris, Department of Renal Medicine,
Westmead Hospital NSW Australia. Cytokines play a pivotal role in
synthesis and deposition of kidney extracellular matrix in chronic renal
disease. The proinflammatory properties of monocyte chemoattractant
protein (MCP-1) make it an ideal candidate cytokine for the production of
interstitial inflammation. To investigate the possible role of proteinuria in
inducing proximal tubular (PT) cytokine production, cytokinc mRNA
levels were measured by Northern blot in rat PT isolated by collagenase
digestion and Percoll gradient centrifugation. PT were cultured (PTCC)
for 5 days to confluence in plastic dishes coated with rat tail collagen in
Dulbecco's Modified Eagle's medium and nutrient F-12 Ham (1:1), and
then in serum-free medium containing a variety of proteins. MCP-I
mRNA was produced by PTCC following 4 or 8 hrs exposure to bovine
serum albumin (BSA, 3.7—30 mg/mI), delipidated BSA (dBSA), apotrans-
ferrin and holotransfcrrin (Tf, Tf-Fe, 2—8 mg/ml), heat-inactivated rat
plasma (50—100%) but not nitrilotriacetate-Fe (200 jrM). MCP-I mRNA
expression peaked within 2—4 hrs of dBSA exposure, was maintained for
at least 48 hrs with continued exposure, and was reduced within 4 hrs of
dBSA removal. Fibronectin and transforming growth factor f3 mRNA
expression was detected in PTCC, but not increased by exposure to
protein. In summary, MCP-l mRNA expression is induced by proteins in
concentration found in pruteinuric urine, and is independent of iron and
cytotoxicity. This effect could explain the link between proteinuria and
interstitial inflammation in chronic renal disease.
Prostanoid secretion by normal and hypertensive placental villous
trophoblasts. E.D.M. Gallery, Z.Q. Ding, J. Rowe, M.J. Sinosich, D.M
Saunders, Department of Renal Medicine, O&G, Royal North Shore Hospi-
tal NSW, Australia. Placental villous trophoblasts are thought to be
implicated in the pathogenesis of pre-eclampsia. We have developed
methods for isolation and culture of these cells. The aim of this study was
to compare the secretion of prostanoids by villous trophoblasts from
normal pregnancies and those complicated by pre-eclampsia or chronic
essential hypertension. Placentas were collected at delivery from normal
(N, N = 8), pre-eclamptic (PE, N = 8) and chronically hypertensive (CH,N = 5) pregnant women, and villous trophoblasts isolated and purified as
described previously. Cells (1 X 106/ml) were cultured (serum-free
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DMEM, 37°C, humidified 5% C02/95% air) on Matrigel-covered cover-
slips. Media was changed every second day and supernates assayed for
prostacyclin (PGI2), prostaglandin E2 (PGE2) and thromboxane (TXB2)
by radioimmunoassay. Trophoblasts secreted low amounts of PGI2, PGE2
and relatively larger amounts of TXB2. Cells from all groups secreted
diminishing amounts of prostanoids as they matured from cyto- to
syncytio-trophoblasts over 7 days in culture. TXB2 secretion by PE
trophoblasts was significantly greater than by N trophoblasts (P < 0.001).
There was no difference in TXB, secretion between trophoblasts from N
and CH pregnancies, or in PGI2 or PGE, from all three patient popula-
tions.
N PE CFI
TXA2 309 108 1236 428° 122 67
P01, 8± 10 9± 12 5±3
POE2 16 15 14 13 5 7
injections of anti-FxlA. At 5 days, rats with PHN had 30—170 mg/24 hours
of proteinuria whereas normals had <1 mg/24 hours. Glomerular prepa-
rations were prepared by differential sieving. Contamination with tubular
fragments was approximately 10%. mRNA was prepared from total RNA
using oligo-dT magnetic beads and pools were then made from 3 rats to
minimize variation between animals. Two separate pools of mRNA from
PHN rats and two from normals were analyzed to assess reproducibility of
the results obtained by DDRT-PCR. DDRT-PCR was performed using a
variety of 3'-primers and 5-primers and the bands displayed on sequenc-
ing gels. Reproducibility of displays was excellent. Approximately 6,000
separate eDNA species have been compared so far and there were no
consistent differences between PHN and control groups. Since each cell
type is considered to possess about 10—20,000 different mRNA species,
about 40% of the mRNA species present may have been screened. The
absence of any differences suggests that a change in the concentration of
an individual mRNA species in PHN kidneys may not be detectable unless
the diseased cells can he separated from the normal cells. This finding has
important implications for the increasing use of this assay in comparing
normal and diseased tissues.
__________
Day 3
N PE CH
TXA, 18 6 183 193 9 8
P012 (1.6 0.8 1.7 2.7 0.7 0.3
POE2 1.5 1.9 1.4 1.9 0.6 0.8
In conclusion, since substances secreted by cytotrophoblasts have access to
the maternal circulation, the elevated secretion of thromboxane by PE
cells could be involved in initiating the maternal coagulation and endo-
thelial cell damage characteristically seen in pre-eclampsia.
Regulation of glycine tRNA synthetase by TGF-p in cultured human
mesangial cells. J. Williams, S. Osvath, T Khong, M. Pearse, and D. Power,
Department of Clinical Immunoloi, St Vincents Hospital, Fitzroy, Victoria,
Australia. In studies whose aim was to identity mRNA species regulated by
cytokines in human mesangial cells, a previously unknown eDNA frag-
ment was isolated. By Northern blot the eDNA hybridized with a
transcript of 2.6 kb. Sequencing of clones obtained from eDNA libraries
revealed a predicted open reading frame of 685 amino acids which was
60% identical to silk moth glycine tRNA synthetase (GRS), the enzyme
which charges tRNA with glycine, the dominant amino acid in collagens.
Expression of this species in bacteria produced a protein of 90 kDa,
including the 13 kDa protein tag introduced by the expression vector,
which was immunoprecipitated by a polyclonal rabbit antiserum against 20
amino acids from the predicted sequence and by a human autoantihody
against GRS (Dr. I. Targof). Bacterial lysates from the cells expressing
putative ORS also had 10-fold greater glycine tRNA synthetase activity
than control cell lysates. This species is, therefore, believed to encode
human GRS. By Northern blot analysis, GRS mRNA transcript numbers
in mesangial cells were increased three-fold by stimulation with the
fibrogenic cytokine transforming growth factor-3. Regulated expression of
GRS is likely to be a response to an elevated requirement of tRNA
molecules charged with glycine for the synthesis of collagen. GRS is,
therefore, another molecule whose expression may he increased as part of
the fibrotic response. To characterize the mechanism of regulation, a
genomic clone has been isolated which contains the 5' end of the eDNA
species; studies required to isolate the promotor are continuing.
Dill'erential display reverse transcriptase polymerase chain reaction
(DDRT-PCR) in the study of glomerular disease. K. Paizis, S. Osvath, T
Khong, J. Williams, M. Pearce and D. Powei; immunology Research Centre,
St. Vincent's Hospital, Fitzroy, Victoria, Australia. Whatever the initiating
event in glomerulonephritis, many studies have shown that cytokines and
other inflammatory molecules contribute to the subsequent pathogenesis
of the renal lesion. It is not clear, however, whether there are any
mediators produced only by glomerular cells. To determine whether this is
the case, we have used the new technique of DDRT-PCR to compare
mRNA obtained from the isolated glomeruli of rats with passive Heymann
nephritis (PHN) and normals, searching for novel mRNA species. The
PHN model was chosen because there is no significant leukocyte infiltrate
to complicate analysis. PHN was induced in Sprague-Dawley rats with two
Type VIII collagen is produced by and is a structural constituent of
normal mammalian glomeruli. N.S. Greenhill, B. Roger, Q. Hasan, P.F
Davis, R.P. Murray-Mcintosh, P.R. Dunhar and Ti. Neale, Department of
Medicine, Wellington School of Medicine, Wellington South, New Zealand.
We have reported that connective tissue mast cells and foreskin and
gingival fibroblasts produce type VIII collagen. This short chain collagen
variant is a prominent interstitial component in human diabetic nephrop-
athy. Using monoclonal antibodies (6A2, 9H3), specific for the ol chain of
type VIII collagen, enhanced immunohistochemistry has shown that this
collagen is localized to paramesangial and subendothelial sites in normal
adult bovine, fetal and adult rat, fetal and adult ovine and adult human
glomeruli. Two polyclonal antibodies raised against the al and the a2 type
VIII collagen chains prepared from ovine Deseemet's membrane showed
strikingly different localizations, e.g. in ovine kidney, optic nerve and
aorta, suggesting that the al and a2 chains exist as two distinct homotri-
mers rather than as a single heterotrimer. Pepsin extracts of isolated
normal human glomeruli immunoblotted with all four antibodies, yielded
reactive polypeptides of 101, 76 and 55 kDa. Cultured rat and human
mesangial cells stained positively for ol and a2 chains and secreted a 61
kDa u2 polypeptide into the culture media. However, under the culture
conditions used, the a1 variant was retained intracellulary in both cell lines
as degraded limit polypeptides of 40 and 31 kDa. Using synthetic
oligonucleotide in Situ hybridization, mRNA of al type VIII collagen was
localized in normal human kidney to interstitial cells (mast cells and
fibroblasts) but not to glomeruli. RT-PCR did not produce al type VIII
collagen eDNA products from normal human kidney, but consistently did
so from diabetic kidney in which the protein also showed increased
expression. We conclude that in the normal glomerulus type VIII collagen
is a structural component of mesangial and suhcndothelial areas contrib-
uting to the integrity of the glomerulus and is presumably turned over very
slowly. In response to injury (e.g. diabetes, IgA nephropathy) increased
message and protein result. Our data suggest that the al and a2 chains are
individual proteins possibly with separate functions and that the mesangial
cell produces both chains.
Abnormalities in type IV collagen in the glomerular basement mem-
brane of bull terrier hereditary nephritis. H. Brooks, G. Jennings, A.
Hendtlass, J. hood, C. Huxtahle, W Robinson, and J. Savige, Molecular
Medicine University, Department of Medicine, Austin Hospital, Melbourne,
Victoria, and Veterinary School, Murdoch University, Perth, WA, Australia.
Bull terrier hereditary nephritis is an autosomal dominantly-inherited
disease with a lamellated GCBM identical to that seen in human X-linked
Alport syndrome. However unlike Alport syndrome, both the Goodpas-
tore and Alport antigens are present in the GCBM of animals with Bull
terrier hereditary nephritis. The aim of this study was to determine the
abnormal basement membrane protein in this disease. The distribution of
the major GCBM proteins and alpha 1(IV) and alpha 2(IV) collagen
chains were determined using immunohistochemistry on tissues sections
from affected and normal dogs; and amounts were quantitated using
extracted GCBM proteins in an ELISA. The collagen chains were further
examined using SDS-polyacrylamide gel electrophoresis. There were no
significant differences in the distribution or amounts of laminin, fibronec-
tin, heparin sulphate or nidogen, in the GCBM of affected and unaffected
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dogs with immunohistochemistry or between the amounts of these pro-
teins or type IV collagen chains in the ELISAs. However, the 28 kDa
monomer corresponding to the non-collagenous domains of the alpha 3 or
4 chains of type IV collagen appeared to be absent from the collagenase-
digested affected GCBM in a 15% polyacrylamide gel. The mutation in
bull terrier hereditary nephritis probably affects the gene for the alpha
3(IV) or alpha 4(IV) collagen chain; and this disease represents a model
for autosomally inherited Alport syndrome and allows us to investigate
how an abnormal collagen chain interferes with the structure of the
GCBM.
Basic fibroblast growth factor expression in a remnant kidney model of
glomerulosclerosis. A. Tzanidic, AM. Walker, AN. Stein-Oakley, N.M.
Thomson, Department of Medicine, Monash Medical School, Alfred Hospi-
tal, Melbourne, Australia. Glomerular hypertrophy and subsequent accu-
mulation of extraeellular matrix proteins are characteristic features of
progressive glomeruloselerosis. The present study sought to describe the
role of basic fibroblast growth factor (bFGF) in the development of
disease, in an experimental remnant kidney model of glomerular sclerosis
and interstitial scarring. Male inbred SD rats underwent either 7/8
nephrectomy by infarction (Nx) or sham laparotomy (Sh). Animals were
killed at regular intervals over a 12 week period and 4 to 5 animals were
assessed at each time point. The tissue expression of bFGF protein was
determined by immunocytochemistry on snap-frozen tissue sections.
bFGF messenger RNA was measured by a semi-quantitative reverse
transeription-polymerase chain reaction (RT-PCR) technique. Reduction
nephrectomy (Nx) resulted in early glomerular hypertrophy (week I
post-Nx) and the development of focal and segmental glomeruloselerosis
and interstitial damage beyond the 3rd postoperative week. In normal
tissue immunohistochemieal studies demonstrated a cellular localization
of bFGF protein within glomeruli. Vascular expression was also noted
with some outer medullary vessels showing nuclear bFGF staining. There
was also strong interstitial cellular bFGF expression between tubules
within the inner medulla. Sham operated animals demonstrated normal
bFGF expression. In diseased animals, glomeruli demonstrated (as early
as 1 week post-nephreetomy) a diffuse staining for hFGF of mesangial
matrix which coincided with the onset of glomerular hypertrophy but not
with the development of glomerular sclerosis. bFGF was also expressed by
glomerular parietal epithelial cells. In addition to this increase in glomer-
ular bFGF, there was a generalized increase in interstitial cellular staining
for bFGF throughout the cortex and medulla with marked increases in
areas of interstitial fibrosis and tubular damage. No changes in vascular
staining were noted. Initial RT-PCR studies of renal tissue throughout the
development of disease showed a 1.5—3-fold increase of bFGF mRNA as
from the 3rd postoperative week compared to normal controls. These
results suggest bFGF may be implicated in the initial hypertrophic
response of the remnant kidney and in the pathogenesis of interstial
damage of progressive renal disease.
Cytotoxicity of reabsorbed protein in proteinuric chronic renal disease.
L. ('hen, J. Chen, Y-C. Toy, Y-Y Ng, and D.C.H. Harris, Department of
Renal Medicine, Westmead Hospital, NSW, Australia. Proteinuria is a
marker of poor prognosis in progressive renal disease, and proteinuria per
se may cause renal injury. The toxicity and mechanisms whereby individual
proteins cause proximal tubule injury have not been defined. In the
present study, primary culture of proximal tubular (PT) cells was em-
ployed to differentiate the effects of individual proteins. Proximal tubule
segments were isolated by collagenase digestion of rat renal cortex
followed by Pereoll density gradient centrifugation, and were plated onto
plastic culture dishes coated with rat-tail collagen in a mixture of
Dulbeeco's Modified Eagle's medium and nutrient F-12 Ham (1:1).
Individual proteins were added to confluent PT cells in serum-free
medium on day 5. Cell toxicity was assessed by LDH leakage into the
medium and eleetronmieroscopy, and lipid peroxidation by malondialde-
hyde (MDA) production. Both LDH leakage from and MDA production
in cells treated with transferrin-Fe (200 rM) for 8 hours and 12 hours in
pH 6.0 (to allow dissociation of Fe from transferrin) were significantly
(P < 0.001; P < 0.01 respectively) higher than control (pH 6.0). No toxicity
or peroxidation was seen in cells treated with transferrin-Fe (200 rM) in
pH 7.4, transferrin (200 /LM) or albumin (30 mg/mI) in both pH 6.0 or 7.4.
Fe-induced peroxidation occurred before LDH leakage, and Fe-induced
toxicity was reduced by procysteine, a natural scavenger of reactive oxygen
species. Results with transferrin-Fe (pH6) were similar to those obtained
previously with nitrilotriacetate-Fe. These results suggest that: (1) Fe,
which is released from transferrin at low pH (similar to that of PT lumen),
is responsible for the toxicity induced by transferrin-Fe in PT cells; (2)
apotransferrin and albumin are not toxic to PT cells; and (3) Fe causes PT
cell damage by lipid peroxidation.
Interstitial myofibroblasts (MF) in experimental renal infection and
scarring. TD. Hewitson, H. Wu, G.J. Becker, Department of Nephrolo,
Royal Melbourne Hospital, Victoria, Australia. Although fibroblasts from
diseased kidneys have been studied extensively in vitro, almost no data
exist on fibroblasts in situ. We have examined the temporal and spatial
distribution of myofibroblast like cells, a phenotype with fibrobiast and
smooth muscle features, in an experimental model of renal infection. E.
coli (X105) were inoculated directly into the renal cortex of Sprague
Dawley rats (270 g). Saline was substituted in a control group (C). Animals
were sacrificed at 5 time points up to day (D) 24 (E. coli N = 8, C N = 3
each interval). MF were identified by morphology and immunohistochem-
istry for xsmooth muscle actin (OcSMA) and compared with staining for
Mø (ED-I) and collagen III. Nuclear bromodeoxyuridine (BrdU) incor-
poration was used with SMA to identi' DNA replication in MF.
Histological changes included a focal lesion in E. coli animals. Interstitial
SMA staining was confined to spindle shaped cells resembling MF.
Percent fractional area (FA) of °SMA staining in the lesion increased
from 0.12 0.09 Dl to 20.0 7.1 at D3 (P < 0.005), decreasing
progressively to 2.0 2.6 by D24. This paralleled BrdU incorporation in
MF at Dl 0.4 0.5, D3 97.3 37.5, and D24 2.6 2.2 cells/0.25 mm2.
ED-I +ve cells increased from 371 185 Dl, to 894 88 at D3 (P <
0.005), declining to 230 108/0.25 mm2 by D24. Intracellular collagen III
and SMA staining was co-localized in spindle shaped cells at D3. FA of
collagen III increased by D24 (P < 0.05). In conclusion, MF accumulate
transiently during renal interstitial fibrosis and are derived at least in part
from local proliferation. Time course parallels that of Mø infiltration.
Double labelling suggests that MF may be synthetically active.
Both glomerular and interstitial injury are induced by anti-Tamm-
Horsfall protein (THP) antibodies. Q. Song, Dl. Nikolic-Paterson, R. C.
Atkins, and H. Y Lan, Department of Nephrology, Monash Medical Centre,
Clayton, Victoria, Australia. Several groups have previously described
tubulointcrstitial nephritis (TIN) induced by the injection of anti-THP
antibodies into experimental animals. However, little data are available
regarding glomerular changes in this model. The aim of this study was to
examine the nature of glomerular changes in a model of TIN. Rats were
injected i.v. with 5 mg purified sheep anti-rat THP IgG once a week for up
to 5 weeks. Groups of 5 rats were killed on day 1 and on weeks 2, 4, 6, 8
and 10. Urinary protein excretion increased from 10.1 3.2 mg/day on
week 2 (normal 3.9 2.2 mg/day) to 98 35.4 mg/day by week 10 (P <
0.05 vs. normal). Animals also developed a T cell response to THP as
demonstrated by a positive skin DTH reaction which was absent in normal
rats. In the interstitium, granular deposition of sheep IgG, rat IgG and C3
was apparent on the tubular basement membrane of THP positive tubules.
This deposition was maximal by week 4 and remained strong until week
10. Associated with sheep IgG deposition was a focal intense leukocytic
infiltrate. However, renal injury was not restricted to the interstitium as
previously suggested. In the glomcrulus there was also granular deposition
of sheep IgG, rat IgG and C3 on the GBM. This deposition was maximal
at week 4 and was associated with a mild glomerular macrophage infiltrate
and declined thereafter. In conclusion, these results demonstrate that
injection of anti-THP antibodies induces both immune complex glomer-
ulonephritis and TIN. Hence, caution must be used when interpreting
results from anti-THP antibody studies as pertaining to only interstitial
disease.
Glomerular tuft hypertrophy precedes glomeruloscierosis in rats
treated with puromycin aminonucleoside. MM. Cahill, J.F. Bertram, and
G. B. Ryan, Department of Anatomy and Cell Biology, University of Mel-
bourne, Parkville, Victoria, Australia. Recent interest has focused on the
role of glomerular hypertrophy in the development of focal and segmental
glomeruloselerosis (FSG). We used unbiased stereological methods to
investigate whether glomerular hypertrophy precedes, accompanies, or
follows the development of FSG in a puromycin aminonucleoside (PAN)
model previously believed to involve no glomerular hypertrophy. Female
Sprague Dawley rats weighing 200 g received subcutaneous injections of
PAN (2 mg/100 g bodyweight) at weeks 0, 1, 2, 4, 6, 8 and 10. Control rats
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received an equivalent volume of normal saline. Kidneys were perfusion
fixed at weeks 7 or 13. Tissue was embedded in glycolmethacrylate and
glomerular tuft volume estimated as deseribed by Bertram et al. Glomer-
ular tuft volume (mean so) in PAN-treated rats at week 7 was 48%
greater than in saline-treated rats [10.45 2.58 (N = 6) versus 7.05 107(N = 8) mm3 x 10 "i. At week 13, glomerular volume was 63% greater
in PAN-treated rats than in saline-treated rats [12.85 2.90 (N = 7)
versus 7.90 0.80 (N = 8) mm3 X io—j. Two-way analysis of variance
indicated significant effects of PAN (P < 0.001) and time (P < 0.05) on
glomerular volume. Glomerulosclerosis, assessed in paraffin Sections
stained with PAS, was absent at 7 weeks and minimal at 13 weeks. These
results indicate marked glomerular tuft hypertrophy in a PAN model of
FSG. In addition, the results indicate that glomerular hypertrophy pre-
cedes FSG in this model. In studies in progress we are assessing the
contribution of glomerular matrix expansion and glomerular capillary
growth to this glomerular hypertrophy.
Podocyte morphology in puromycin aminonucleoside-treated rats co-
administered tungsten or allopurinol. S.D. Ricardo, J.F. Bertram, and G.B.
Ryan, Department of Anatomy and Cell Biology, University of Melbourne,
Parkville, Victoria, Australia; Division of Nephrology and Hypertension,
Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA. Numerous
studies have implicated reactive oxygen species (ROS) in the structural
and functional alterations seen in the glomeruli of rats treated with
puromycin aminonucleoside (PAN). Several studies have suggested that
the xanthine oxidase pathway is the source of the ROS, but the evidence
has primarily been based on the observation that administration of
allopurinol (a xanthine oxidase inhibitor) to PAN-treated rats reduces
glomerular injury. However, allopurinol and its chief metabolite oxypuri-
nol have antioxidant properties. In the present study, we compared the
effects of allopurinol and tungsten (a specific xanthine oxidase inhibitor)
on podocyte ultrastructure, renal xanthine oxidase and xanthine dehydro-
genase activity, and urinary protein excretion in PAN-treated rats. Female
Sprague-Dawley rats received a single i.v. injection of either PAN (5
mg/100 g body wt) or an equivalent volume of saline. Co-administration of
allopurinol (single i.p. injection 4 hours before PAN) to PAN-treated rats
reduced proteinuria by approximately 70% over the 10 days (day 0 to day
10) studied, and reduced podocyte foot process effacement as assessed by
electron microscopic morphometry by approximately 40%, compared to
rats that received PAN alone. Co-administration of allopurinol to PAN-
treated rats did not reduce xanthine oxidasc activity, but did reduce the
combined activity of xanthine oxidase and xanthine dehydrogenase on day
5. Co-administration of tungsten (0.7 g/liter of drinking water from 7 days
before PAN injection to sacrifice) to PAN-treated rats did not reduce
either proteinuria or foot process effacement. Rats co-administered
tungsten and PAN had significantly reduced renal xanthine oxidase and
combined xanthine oxidase and xanthine dehydrogenase activities on days
5 and 10, compared to rats treated with PAN alone. These results provide
evidence that the structural and functional protection provided by allo-
purinol in PAN-treated rats is due to the antioxidant properties of
allopurinol, rather than to its activities as a xanthinc oxidasc inhibitor.
Alternative sources of ROS in PAN-treated rats most therefore he
considered.
Increased expression of TGFl mRNA in a remnant kidney model of
glomeruloscierosis. A. Tzanidis, AM. Walker, and N.M. Thomson, Depart-
ment of Medicine, Monash Medical School, Alfred Hospital, Melbourne,
Australia. Chronic renal injury is characterized by progressive accumula-
tion of extracellular matrix (ECM) proteins within glomeruli. Although
many cytokines may be involved in this process, TGFJ31 is likely to be a
major player in the regulation of ECM production and the development of
glomerulosclerosis. This study describes the role of TGFI31 in the rat
remnant kidney model of glomerulosclerosis and interstitial scarring and
the influence of Angiotensin I converting enzyme (ACE) inhibition on the
expression of TGFpI. Male inbred SD rats were randomly allocated into
three groups: Group 1 animals underwent 7/8 nephrectomy by infarction
(StNx); Group 2 animals underwent 7/8 nephrectomy and were treated
with enalapril (ENx); and Group 3 underwent a sham ncphrectomy
(StSh). Renal function, urinary protein excretion and systolic blood
pressure were monitored for a 12 week period. Animals were killed at
regular intervals over a 12 week period and TGF1 messenger RNA
(mRNA) was quantified by Northern blot analysis. Reduction nephrec-
tomy (StNx) resulted in early glomerular hypertrophy (week 1 post-Nx)
and the development of focal and segmental glomerulosclerosis from the
third postoperative week. ENx demonstrated a reduction in glomerular
sclerosis score by week 12 compared with the StSh group (P < 0.01). Sham
operated animals did not develop glomerulosclerosis. TGFPI mRNA
levels increased with disease progression, with a 4-fold increase by week 12
(P < 0.005) compared to sham controls. TGF1 mRNA levels in enalapril
treated animals also rose by week 12 (P < 0.005), hut this rise was
significantly less than that seen in the StNx group (P < 0.005). TGFl
mRNA levels did not change in StSh control animals. These data suggest
a possible role for TGFI3I in the development of the sclerotic changes
seen in this experimental model of glomerulosclerosis, and that the
protective effect of ACE inhibition may be secondary to the reduced
expression of TGFf31.
EGF and tubular proliferation in experimental glomerulonephritis.
G.H. Tesch, H.Y Lan, R.C. Atkins, and D.J. Nikolic-Paterson, Department
of Nephrology, Clayton, Victoria, Australia. The relationship between renal
epidermal growth factor (EGF) production and tubular proliferation is
unclear. Studies of experimental acute tubular necrosis and ischemic
injury have found that EGF synthesis is down-regulated during the period
of epithelial cell proliferation which follows tubular injury, yet EGF is
known to he a growth factor for tubular epithelial cells both in vitro and in
viva. EGF expression and tubular proliferation were examined in anti-
Thy-i nephritis by means of two-color immunohistochemistry staining of
cryostat tissue sections. Groups of 5 rats were injected with a single
intravenous dose of 5 mg/mI OX-7 IgG and then killed on days 1, 4, 6, 8,
10, 14, 21 and 28. In addition to the well-described mesangial lesion, mild
tubular injury was evident in this model. While distribution of EGF
expression was unaltered during the disease, the level of tubular EGF
mRNA and protein expression was reduced by 30—50% over days 1—14,
returned to normal levels on day 21, and rebounded to levels 2-fold
greater than normal on day 28. There was a significant increase in the
percentage of proliferating (PCNA+) cortical tubular cells on day 8 of the
disease (P < 0.05)—the time of minimal EGF expression—which returned
to normal levels by day 14. The increase in epithelial cell proliferation was
restricted to tubules lacking EGF expression (mostly proximal tubules),
with no change in proliferation of the EGF+ tubules. However, on day 28
there was an increase in proliferation in EGF+ tubules (but not EGF—
tubules) coincident with the time of the rebound in EGF expression.
EGF-receptor (EGF-R) expression was also analyzed by immunohisto-
chemistry. In normal kidney there was strong EGF-R expression within
the glomerulus (mostly podocytes) and weak expression by EGF+ tubules.
There was no change in tubular EGF-R expression during the disease. In
conclusion, these results suggest that proliferation of EGF+ tubules is
related to the level of EGF expression and that proliferation of EGF—
tubules appears to be unrelated to renal EGF expression.
The tissue inhibitor of the metalloproteinases type I (TIMP-l) in
experimental nephrosis. CL. Jones, J. Forbes, A. Haralambous-Gasser, K
Kelynack, R. Walker, T. Hewitson, and G. Becker, Victorian Paediatric Renal
Service, Royal Children s Hospital and Royal Melbourne Hospital, Parkville,
Victoria. Previous studies of rats developing renal interstitial fibrosis with
nephrosis, induced by the aminonucleoside of puromycin (PAN), have
found increased amounts of the tissue inhibitor of the metalloproteinases
type I (TIMP-1) in the kidneys. The aim of these studies was to determine
the location of TIMP-1 and the matrix metalloproteinase (MMP) enzymes
that TIMP-1 inhibits. An acute model of PAN was created in female
Sprague Dawley rats by performing a unilateral nephrectomy and 1 week
later giving an intraperitoneal (i.p.) injection of 15 mg/l00 g body weight
of PAN in experimental rats and i.p. vehicle alone in control rats. Groups
(N = 5) of PAN and control rats were sacrificed at 1, 2, 4 and 5 weeks.
Northern blotting and in situ hybridization for the mRNA for TIMP-1, and
immunohistological and zymography demonstration of MMP1, MMP2
and MMP3 were performed. The expression of mRNA for TIMP-1 was
increased by 10-fold at I and 2 weeks and was reduced towards control
levels at 4 and 5 weeks. In situ hybridization revealed mRNA for TIMP-1
in the perivascular tissues of major vessels in controls, and extending up
small arterioles, including the afferent arteriole, in PAN rats. MMP's were
colocalized with TIMP-1 by immunohistology. Functional activity of the
type IV collagenases was increased (4-fold control levels at weeks 1 and 2).
These results localized TIMP-1 in the kidney for the first time, indicated
the potential importance of the perivascular tissues in renal interstitial
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fibrogenesis, and demonstrated the inhibitor was colocalized with its
potential substrates.
Interstitial mucinosis: Extension of the concept. J.P. Dowling and J. TV
Agar, Anatomical Pathology, Alfred Hospital, Melbourne; and Renal Unit,
Geelong Hospital, Geelong, Victoria, Australia. Renal interstitial mucinosis
(TM) was first noted in a patient with acute renal failure (ARF) developing
after ingestion of a single dose of Diclofenac on two separate occasions;
medullary TM was the main finding on biopsy taken after this second
episode. This change, although distinct from the recognized forms of
NSATD toxicity, seems to be especially related to the use of NSAIDs but
is not specific to these drugs; TM has been seen in two patients with ARF
due to mushroom poisoning and in a patient presenting with ARF after
paraquat ingestion with subsequent recovery of renal function. The
NSAID-related TM may occur in several settings: (1) The ARF presenta-
tion within 1—2 days following ingestion of usual doses of medication in
which the main pathology is medullary TM. (2) Persistent but varying
degrees of renal failure associated with protracted though perhaps inter-
mittent ingestion of NSAIDs; moderate medullary and lesser cortical TM
is accompanied by considerable interstitial sclerosis with minor chronic
inflammation, and in one instance, papillary necrosis. (3) Hypersensitivity-
type acute interstitial nephritis with blood and tissue eosinophilia with IM
as a marker for NSAID ingestion. (4) IM associated with invasive
transitional cell carcinoma of the renal pelvis subsequently found on
questioning to have occurred in a chronic user of Naprosyn. The mecha-
nism of accumulation of mucin (glycosaminoglycan, mostly hyaluronan) is
unknown. TM may develop following a cessation of normal physiological
mucin excretion in the urine or possibly due to excessive production by
renal interstitial cells.
Parenchymal renal veins—A renal Trojan horse. J. P. Dowling, Anatom-
ical Pathology, Alfred Hospital, Melbourne, Victoria, Australia. Little atten-
tion has been paid to the development of pathology related to the
intrarenal arcuate and interlobar veins in descriptions of changes seen in
renal biopsies. Observation suggests that renal vein alterations are not
uncommon in a variety of glomerulonephritides, related or not to the
coagulation abnormalities of the nephrotic syndrome. In occasional
instances chronic venous obliteration may be central to progressive
deterioration of renal function as illustrated by the following patient: A 51
year-old developed nephrotic syndrome with swollen ankles and a urinary
protein of 5.5 g/day with normal renal function; investigations for second-
ary causes such as lupus erythematosus were negative. Renal biopsy
showed stage 2 membranous nephropathy with subepithelial spikes and
granular deposits of IgG and C3 predominantly on direct immunofluores-
cence. One interlobular vein showed near-obliteration related to active
cellular thrombophlebitis. No treatment was administered. Approximately
two years later persistent proteinuria of 3.5 glday and a deterioration of
renal function to 2.4 mmol/liter were noted and a second biopsy showed a
slight advance in the stage of membranous nephropathy without increased
glomerular obsolescence; an easily discernible increase in interstitial
fibrosis and mild to moderate venous mural sclerosis without obliteration
were noted. The latter may have resulted from the previously seen
intrarenal thrombophlebitis. Other venous-related pathologies that have
been noted on biopsy are thrombosis perse usually in the context of the
nephrotic syndrome, partial venous obliteration as demonstrated by
elastin stains, linear venous scars following complete obliteration of the
vein, and Tamm-Horsfall thromhi related to tubulovenous communica-
tion.
Tubulointerstitial damage is a better predictor of progressive renal
failure in the rat remnant kidney model. L.L. Wu and C.J. Roe, University
of Melbourne, Department of Medicine, Heidelberg Hospital, Victoria, Aus-
tralia. Research suggests tubulointerstitial pathology rather than glomer-
ular sclerosis better correlates with progressive renal failure. This study
correlates the sequential glomerular and tubulointerstitial changes with
functional outcomes in a rat variable remnant kidney model. Male
Sprague-Dawley rats weighing 200—250 g were randomly divided into 5/6
(FSN, N = 40) and 1/6 ablation (OSN, N = 40). Ten rats from each group
were killed at 4, 8, 12 and 16 weeks post-surgery. Remnant kidney weight
(Kwt), systolic blood pressure (BP), 24 hour urine protein (Us,) and
serum creatinine (Se,) were measured at each time point. Tubulointersti-
tial damage (TID) (tubular dilation, casts, tubular atrophy, interstitial
infiltrate, interstitial fibrosis) was quantitated by point-counting and 50
glomeruli per kidney were evaluated semiquantitatively for glomerular
sclerosis (GS). The dependency of Sr on each histological variable was
assessed using multivariate analysis. Six FSN and one OSN died. At each
time point Kwt, BP, Upr and Se.,. were significantly higher in FSN. There
was significantly more GS and TID and less normal tubules and glomeruli
in FSN. Se., was dependent on percentage of remaining normal tubules
and amount of interstitial fibrosis using multivariate stepwise linear
regression analysis. Group data (mean SEM) are in the table.
Normal
Group
Scr
tunol/liter
tubules
(%)
Fibrosis
%
GS/50
glum
FSN (N = 34) 110 5 53.0 3.2 4.5 0.8 47.6 4.7
OSN (N = 39) 60 1 80.6 0.5 0.1 0.0 4.1 0.9P <0.001 <0.001 <0.001 <0.001
We conclude that in the rat remnant kidney model there is renal
hypertrophy and progressive renal damage. The decline in renal function
is predicted by the reduction in normal tubules and the amount of
interstitial fibrosis rather than by glomerular sclerosis.
The application of Laser Scanning Confocal Microscopy to human
renal pathology. K Kelynack, K. Nicholls, J. Bertram, J. Hill, and G. Becker,
Department of Nephrology, Royal Melbourne Hospital, Department of Anat-
omy, University of Melbourne, Department of Surgery, Royal Melbourne
Hospital, Victoria, Australia. While the use of the Laser Scanning Confocal
Microscope (LSCM) in the examination of human kidney sections has not
previously been widely reported, its advantages over routine histological
procedures suggest potential value in renal pathology. One particular
advantage of the LSCM is the ability to screen biopsy specimens using a
single Hematoxylin and Eosin (H&E) section. Biopsies of kidneys of
living-related renal donors were taken at the time of transplantation. A
single biopsy section with a minimum of 10 glomeruli per patient was
examined using light and confocal microscopy. The parameters deter-
mined were glomerular profile area (GPA), mean glomerular volume
(MGV), and interstitial area (IA). The same H&E section was used to
measure glomerular basement membrane (GBM) thickness on the LSCM
to compare with measurements obtained from electron microscopy (EM)
using the orthogonal intercept method (epon resin embedded, one
glomerulus/patient). A Spearman Rank test for correlation was used for
data analysis. Results indicated a poor correlation between point counting
on light microscopy (LM) and confocal microscopy for interstitial area (R2
= 0.333).A strong correlation was found for MGV as determined by point
counting (R2 = 0.952, P < 0.01). A weak correlation for MGV was also
found between the image analysis (LSCM inbuilt software) and LM
methods (R2 = 0.539). There was no correlation between GBM thickness
measurements by the two methods used (R2 0.115). We conclude that
LSCM does not replace traditional methods of renal morphometric
measurement. It cannot be used to determine accurately the GBM
thickness in renal biopsy material. However, in the future the LSCM may
be used as a diagnostic screening tool for samples requiring EM, provided
that absolute numbers are not critical.
Extracellular matrix (ECM) degradation in cyclosporine A nephrotox-
icity. C.L. Jones, J. Fecondo, K Kelynack, J. Forbes, R. Walker, and G.
Becker, Victorian Paediatric Renal Service, Royal Children s Hospital and
Royal Melbourne Hospital, Parlcville, and Department of Chemistry, Swin-
hurne University, Victoria, Australia. The mRNA and protein expression of
the tissue inhibitor of the metalloproteinases (TIMP-1) was examined in
the rat model of cyclosporine A nephrotoxicity (C5AN). A model of CsAN
was created using daily intraperitoneal injections of IS and 25 mg/kg body
weight of CsA, and controls received i.p. injections of vehicle alone.
Groups of 5 experimental and 5 control rats were sacrificed at 1, 2, 3, 4 and
6 weeks. Northern blotting was performed for TIMP-1, procollagen al(T),
procollagen csl(IV), TGFp1, and the 72 kDa type IV collagenase.
Quantitation of mRNA bands was done by densitometiy with respect to
the l8S RNA band. The protein expression of TIMP-1 and collagenases
were quantitated by immunohistochemistiy using point counting. A
peptide of TIMP-1 (19 amino acids long) and a peptide common to rat
stromelysin and interstitial collagenase (14 amino acids long) were syn-
thesized, coupled to KLH, then the coupled peptide was used to raise
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polyclonal antisera in rabbits and affinity purified antibody was isolated
using the peptide coupled to Affigel. Increased amounts of mRNA for
TIMP-1 were found at all time points (in all cases 2—5 X control amounts).
The mRNA for procollagen ol (I) was increased at all time points, but that
for procollagen al(IV) was only increased at weeks I and 2 (P < 0.05 in
all cases). No change in mRNA amounts for TGFI3 and type IV
collagenase was found. Increased expression of TIMP-1 protein was found
on immunohistochemistiy, but no increase in collagenase was found
(Mann Whitney U test, P < 0.05). There was colocalization of TIMP and
collagenase in both controls and experimental animals. The location of the
TIMP was in the interstitial spaces, little was found in glomeruli, and it was
dense about the adventia of vessels. These results support an important
role for the inhibition of ECM degradation in the progressive accumula-
tion of scar tissue in CsA.
Treated end-stage renal disease (ESRD) in aborigines in the top end of
the Northern Territory (NT), 1978—1993. W. Hoy, B. Hayhurst, J. Mathews,
andD. Pugsley, Menzies School of Health Research, Darwin, NT; and Renal
Unit, Queen Elizabeth Hospital, Woodville, SA (DP), Australia. The NT's
Top End ESRD treatment program was started by DP in 1978. Based in
Darwin, it serves a 1991 population of 105,405 non-Aborigines (NA) and
25,387 Aborigines (A) over a very large area; most A must move
permanently from their families and isolated communities to receive
treatment. A total of 83 A and 44 NA had been treated through December
1993, with 46 A and 23 NA alive at that point. New A cases are increasing
rapidly, and have exceeded NA cases since 1989. The average annual
incidence for 1988—1993 was 38 per million (pm) for NA and 440 pm for
A, (358 pm for nonTiwi A, and 1636 pm for Tiwi A). The age-adjusted rate
in A was 17.4 times that of NA (14.1 for nonTiwi A, and 59.6 for Tiwi A).
Most A with ESRD were much younger than NA (mode 35 vs. 65 years).
Male:female ratio was 0.8:1, vs. the male dominance for NA (1.8:1). A had
a higher proportion of GN-ESRD (52% vs. 29%), and diabetic ESRD
(21% vs. 9%); 5% had amyloid associated with lung infections, TB and
leprosy. Most subjects received hemodialysis, and a few received perito-
neal dialysis. Twenty-one NA (48%) and 18 A (only 23%) received
transplants (TP), with clinical ineligibility being a major obstacle. TP
survival was 100% at 5 years for NA, but was 58% and 24% at 2 and 5
years for A; noncompliance, rejection, intensified immunosuppression and
exacerbated comorbidities was the common sequence leading to death. In
December 1993, 70% of NA hut only 13% of A had functioning TPs.
Fewer A with ESRD had preexisting vascular disease, but more had
chronic lung infections, rheumatic heart disease, TB, hepatitis B, healed
leprosy, alcohol abuse, and morbid obesity. Deaths in A were less often
due to heart disease than in NA (30% vs. 50%), and more often due to
infections (24% vs. 12%), and withdrawal from treatment (23% vs. 6%).
Withdrawal reflects poor tolerance or compliance with treatment and lack
of social and family supports. High rates of albuminuria and clinical
nephropathy in A are compatible with their high ESRD rates. Treatment
choices and results reflect their profoundly inferior health status and
socioeconomic deprivation. A 2.5—fold increase in A ESRD is projected by
the year 2000. Precursors of ESRD must be studied, and widespread
screening and renalprotective treatment introduced, along with intensified
and innovative efforts to improve the health and welfare of the entire A
population.
Acute renal failure after cardiac surgery: Incidence, outcomes and risk
factors G. Mangos, M.A. Brown, W. Chan, D. Horton, P. Trew, and J.A.
Whitworth, Departments of Renal Medicine, Medicine and Cardiothoracic
Surgery, St. George Hospital and University of New South Wales, Kogarah,
New South Wales, Australia. Although acute renal failure (ARF) has long
been recognized as a potential consequence of cardiac surgery, the
incidence of this complication has varied widely in published literature and
no Australian data have been gathered to help predict the risks of ARF in
patients with pre-existing renal disease. We therefore determined the
incidence, outcome and risk factors for ARF in a retrospective case
control analysis of 903 consecutive patients who had cardiac surgery (795
CABG, 68 valves, 40 combined valve/CABG) from 1992—1993. ARF was
defined as a doubling of serum creatinine to >0.13 mmol/liter if renal
function was normal pre-operatively, or else a rise in serum creatinine by
>0.10 mmol/liter after cardiac surgery. Ninety percent had "normal"
pre-operative renal function (serum creatinine 0.13 mmol/liter). ARF
developed in only 1.1% of these subjects, none required dialysis, and
mortality was 0.7%. ARF developed in 16% of those with impaired
pre-operative renal function; 20% of these required dialysis and 13% of
this whole group died. The risk of ARF rose from 10.4% in those with
pre-operative serum creatinine 0.14—0.20 mmol/liter to 36.8% if creati-
nine was >0.20 mmol/liter (P < 0.01). Mortality was significantly higher(4.2% vs. 0.7%, P < 0.01) and length of hospital stay longer [15 vs. 9 days(median), P < 0.0011 in those with impaired pre-operative renal function.
Case control analysis showed that ARF was more likely in those over 65
years, if valve surgery was included; cardiopulmonary bypass time was
prolonged or LV dysfunction was present pre-operatively. These data
confirm that ARF following cardiac surgery is unlikely without impaired
pre-operative renal function but has a mortality rate of 13%. Moreover,
impaired pre-operative renal function alone is associated with higher
mortality and prolonged hospital stay. Pre-operative assessment of renal
function should be mandatory in patients having cardiac surgery, and
studies to prevent ARF in this setting should focus on the high risk subsets
described in this study.
Effect of pre-operative supplementation with s-tocopherol and ascorbic
acid on markers of renal and myocardial injury in patients undergoing
cardiac surgery. J. Westhuyzen, S.J. Fleming, D. Cross, M. Frenneaux, F.A.
Khafagi, A. Cochrane, P.J. Tesar, and T Mau, Conjoint Renal Laboratory,
Department of Pathology, and Departments of Renal Medicine, Cardiology,
and Nuclear Medicine, Royal Brisbane Hospital; Department of Cardiac
Surgery, The Prince Charles Hospital, Brisbane, Australia. Cardiac surgery
employing cardiopulmonary bypass (CPB) is associated with oxidative
stress. Pretreating patients with a-tocopherol (vitamin E) and ascorbic
acid (vitamin C) may augment the patient's antioxidant defenses and
confer increased protection against free radical-mediated injury to inter
alia heart and kidney. We undertook a double-blind, randomized trial of
69 patients undergoing coronary artery bypass grafting, utilizing CPB and
monitoring indices of renal and myocardial injury. Subjects were randomly
assigned to receive placebo or 750 IU dl n-tocopherol supplements/day for
7—10 days, and I g ascorbic acid 12 hours prior to surgery. Plasma
a-tocopherol concentrations, raised four-fold by supplementation, fell by
70% in the supplemented group and to negligible levels in the placebo
group. Relative to urinary creatinine, the excretion of N-acetyl-3-D-
glucosaminidase, adenosine deaminase binding protein, and y-glutamyl
transpeptidase increased significantly following surgery (P < 0.001; no
differences between groups). There were also no significant differences
between the groups with respect to release of creatinine kinase MB
isoenzyme, nor in the extent and severity of the myocardial perfusion
defect determined by Thallium-201 uptake and ECU analysis. We con-
clude that pretreating patients undergoing elective cardiac surgery with
antioxidant vitamins offers no additional protection to the myocardium or
renal proximal tubules than standard practice.
Primary focal sclerosing glomerulonephritis. L.S. Ibels, D.A. Waugh,
R.J. Caterson, J.F. Mahony, and C.A. Pollock, Department of Renal Medi-
cine, Royal North Shore Hospital, New South Wales, Australia. In an
endeavour to determine the natural history and factors of importance in
the progression of primary focal sclerosing glomerulonephritis, 54 patients
(34 M, 20 F) aged 8—70 (mean 42) years were studied over a period of
1—204 (mean 79) months from presentation. Features at presentation
included hypertension (67%), nephrotic range proteinuria (44%), raised
serum creatinine (48%), hypercholesterolemia (65%), and a family history
of nephritis (15%). Progression to end-stage renal failure occurred in 14
(26%), patients, 1—173 (mean 55) months post-presentation and a >20%
decline of renal function occurred in a total of 33 patients (62%). The
cumulative renal survival was 79.7% at 5 years and 75.9% at 10 years after
presentation. Factors significantly associated with an adverse outcome on
initial presentation, included a longer duration of symptoms, hyperten-
sion, and age <30 years; on initial laboratory evaluation, the degree of
impairment of renal function, the degree of proteinuria, nephrotic range
proteinuria, and serum cholesterol concentrations; on renal biopsy, the
percentage of glomeruli with global or segmental sclerosis, the degree of
tubular atrophy/interstitial fibrosis, the degree of interstitial inflammation
and the degree of arteriolar thickening; and during follow-up, the degree
of proteinuria and persistence or development of hypertension. Primary
focal sclerosing glomerulonephritis may he familial in over 15% of
patients and has a guarded prognosis, particularly in patients with heavy
proteinuria, hypertension, renal impairment and age <30 years at presen-
tation. Identification of patients with a poorer prognosis should assist in
making therapeutic decisions to retard the progression of disease.
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Renal tubular acidosis in primary Sjogren's syndrome. P. T.H. Coates,
TP. Gordon, G. Talus, and L.J. Barratt. Department of Medicine, Flinders
Medical Centre, Clinical Immunology and Clinical Chemistiy, Flinders
University of South Australia, Bedford Park, Australia. Interstitial nephritis
and a distal renal tubular acidosis (RTA) arc reported to occur with
primary Sjogren's syndrome (SS). We have used a sensitive measure of
distal hydrogen ion secretion to estimate the prevalence of acidification
defects SS. Fifteen subjects with primary SjOgren's syndrome were studied
with ammonium chloride loading tests and oral sodium bicarbonate
loading tests. In the ammonium chloride test, minimal urine pH after a
three day oral load was measured (normal results <5.5). After oral sodium
bicarbonate load, urine and blood pCO2, pH and bicarbonate were
measured (normal results, pH >7.6, then pCO2 >70 and urine-blood
pCO2 >20). A group of normal controls were also studied. Nine subjects
have evidence of impaired distal hydrogen ion secretion when assessed by
bicarbonate loading testing, with urine pCO2 <70 and urine-blood pCO2
<20 in an alkaline urine. Two of the nine subjects had complete distal
acidosis, one had latent renal tubular acidosis with an inability to secrete
an acid load and inability to generate an elevated urine pCO2. Six subjects
were able to secrete acid but unable to generate an elevated urinary pCO2
(rate related RTA). Six subjects were normal on both tests. Urinary
acidification defects are common in primary SS (60%). We have provided
the first description of rate related RTA in pSS. These results support the
thesis that SS is a generalized disorder of epithelial cells.
Should all children with a urinary tract infection be investigated? J. C.
Craig, L.P. Roy, J.F. Knight, L.M. Irwig, Department of Nephrology, Royal
Alexandra Hospital for Children & Department of Public Health, University
of Sydney, Sydney, NSW, Australia. The investigation of all children with a
urinary tract infection (UT!) is advocated for the detection of renal tract
abnormalities such as vesicoureteric refiux (VUR), urinary obstruction
and renal parenchymal abnormality. The data of a prospective cohort of
280 preschool children with their first proven UTI were analyzed to
determine whether this expensive and invasive approach is valid. UTI was
defined as any growth in a bladder tap or catheter sample and >108/liter
in a voided urine sample. A radiological Contrast MCU was used for the
detection of VUR, which was present in 27% of children (72/265). Renal
parenchymal abnormality was defined as an abnormal 99"Tc-dimercapto-
succinic acid scan (DMSA). This was present in 40% of children (108/272).
1.1% (3/280) had associated urinary tract obstruction. This diagnosis was
considered if there was significant pelvicalyceal or ureteric dilatation on
renal tract ultrasonography and confirmed by 99"Tc-diethylenetriamine-
pentacetic acid scintigraphy, with pre-hydration and frusemide washout.
Multivariate analysis of all variables at presentation by logistic regression
confirmed that a history of fever was the strongest predictor of VUR and
abnormal renal parenchyma. If children under 3 months were excluded
(fever is an unreliable sign of sepsis in young infants), 42 of the 212 older
patients (20%) did not have a history of fever. Only I child in this group
had renal parenchymal abnormality and VUR. The strength of this
association between fever and VUR, and fever and abnormal renal
parenchyma are given.
Relative risk
(95% CI) P value
<0.0001
Sens. %
98.2VUR 17(2—130)
Abnormal DMSA 35 (4—263) <0.0001 98.8
Spec.
%
Post-test
probability if
fever present
%
Post-test
probability if
fever absent
%
VUR 24 32 2.2
Abnormal DMSA 29.4 46 2.2
These data strongly suggest that children over 3 months of age who
present with a UT! without a history of fever are very unlikely to have
either VUR or abnormal kidneys. If prospective follow-up of this cohort
confirms that the renal tracts of this group remain normal, a renal
ultrasound examination to screen for the rare but treatable entity of
urinary tract obstruction may he all that is required to investigate this
group of children.
A comparison study of amitriptyline vasopressin, and amitriptyline
with vasopressin in nocturnal enuresis. JR. Burke, V. Mizusawa, A. Chan,
K Webb, Royal Children's and Mater Children '1 Hospitals, Brisbane,
Australia. Forty-five children aged 6 to 14 years with primary nocturnal
enuresis were randomized to determine whether desmopressin is more
effective than amitriptyline, and whether the combination of amitriptyline-
desmopressin is more effective than amitriptyline or desmopressin alone.
The amitriptyline dosage was 25 mg for children 6 to 10 years and 50 mg
aged 10 to 14 years. Desmopressin 20 .tg was given for all age groups.
After a run in period of two weeks, children were treated for 16 weeks and
then observed for 12 weeks. In the amitriptyline group mean wet nights
per week decreased from 5.8 0.9 to 3.3 1.9 (P < 0.0005); in the
desmopressin group mean wet nights per week decreased from 6.0 0.9
to 4.7 1.7 (P < 0.02); in the amitriptyline-desmopressin group, mean wet
nights per week decreased from 6.3 0.9 to 3.3 2.5 (P < 0.0006). When
comparing the groups, mitriptyline-desmopressin and amitriptyline were
statistically more effective than desmopressin in week 6 (P < 0.009), week
8 (P < 0.03), and week 10 (P < 0.04). No significant side effects occurred.
At this dosage, amitriptyline was more effective than desmopressin and the
combination of desmopressin with amitriptyline did not confer any
additional benefit.
Oxidation ofLDL in renal failure. W.H.F. Sutherland, R.J. Walker, M.J.
Ball, S.A. Stapely, M.C. Robertson, Department of Medicine, Otago Medical
Schoo4 Dunedin, New Zealand. Renal failure is associated with an
increased risk of atherosclerosis. Peroxidation of LDL may be a contrib-
uting factor. We determined the susceptibility to copper ion catalysed
oxidation, vitamin E content, and chemical composition of LDL isolated
from patients with chronic renal failure on haemodialysis (HD 13), or
CAPD (7), or with a renal transplant (RT 18) and 15 healthy controls (C).
Lag time in conjugated diene formation during oxidation was significantly
(P < 0.011) shorter (66 mm) in LDL from RT mainly due to significantly
(P < 0.01) shorter lag times in women (47 mm, N = 7) compared to C (83
mm), compared to HD (91 mm) and CAPD (82 mm). Triglyceride content
in LDL was abnormally high (7.3% vs. 5%, P < 0.001) in these women
compared to controls and was correlated significantly with lag time in RT
(r = 0.5, P = 0.034). Vitamin E content in LDL from RT women was not
significantly different from C. The maximum rate of conjugated diene
formation (nmol/min/mg) was significantly slower (P < 0.050 in all groups
(HD 7.44 1.56, CAPD 7.43 2.2, RT 8.28 1.12) compared to C
(9.44 1.64) probably due to lower linoleic acid content in LDL
particularly in HD and CAPD. Lag time, max rate in diene production and
the elevated lipid peroxide content in LDL (45 8 nmol/mg) did not
change before, at the end or 24 hours post-HD. These data suggest that
dialysis may not alter LDL susceptibility to oxidation, while LDL from RT
women is abnormally susceptible to oxidation possibly due to high
triglyceride content. This may contribute to the increased risk of athero-
sclerosis in RT.
Chronic inhibition of neutral endopeptidase by Oral SCH34826 in the
rat remnant kidney model. K Jandeleit-Dahm, M. Kanazawa, D. Casley, B.
Jackson, CI. Johnston, Department of Medicine, The University of Mel-
bourne, Austin Hospital, Heidelberg, Victoria, Australia. Atrial natriuretic
peptide (ANP) is intimately involved in volume and salt homeostasis. The
neutral metalloendopeptidase (NEP, EC 3.4.24.11) degrades ANP. NEP
inhibition may promote ANP accumulation, and thus natriuresis. We
examined the effect of 5CH34826, an orally active NEP inhibitor, in rats
with the subtotal nephrectomy model of renal impairment. SCH34826 (90
mg/kg twice daily, P.0) was administered for 3 days to rats (N = 7)
subjected 4 weeks previously to subtotal nephrcctomy, and effects were
compared with placebo treatment. NEP in the kidney was inhibited by
some 60% (in vitro autoradiography method). Urinary ANP (pg/24 hr)
increased from 3930 295 to 9094 1089 (P < 0.01). In the treatment
group there was a natriuresis (pre-treatment 2.03 0.23 mmolNa/24 hrs
to 3.18 0.37, P < 0.01) not seen in the placebo group, and an increase
in protein excretion (279 77 mg/24 hr to 35! 123, P < 0.05). There
were no differences in glomerular filtration rate, systemic blood pressure,
or plasma ANP concentration. Chronic SCH 34826 inhibited renal NEP
and modulated sodium excretion without apparent systemic hemodynamic
effects in this model of renal impairment.
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Renal osmolytes in baboons (Papio hamadryas). S.M. Marshall, N.S.
Willis, G. C. Duggin, iS. Horvath, D.J. Tillet; A. G. Gillin, Department of
Renal Medicine, Royal Prince Alfred Hospital, NSW, Australia. Urinaiy
concentration relies on the ability of the inner medullary cells to withstand
the high extracellular osmolality during antidiuresis. Various osmolytes
accumulate intracellularly to balance extracellular osmolality. Rat and
rabbit osmolytes have been widely studied; however, these species may not
he good models of human medullary function. Baboons offer a source of
primate renal tissue that may better help understand human medullary
function. This study aimed to measure the concentration of organic
osmolytes in kidneys from baboons and to compare them to similar tissue
from rats. Prior to harvesting tissue, animals were allowed water ad
lihitum. Kidneys from 5 baboons (Papio hamadtyas) and 5 rats (Wistar)
were collected following anaesthesia with Ketamine (6 mg/kg i.v.i.) and
Pentobarbitone (350 mg i.p.), respectively. Tissue was dissected from the
cortex (C), Outer medulla (OM) and inner medulla (IM), and weighed.
After protein extraction the samples were analysed by an accepted HPLC
method for inositol, glycerophosphorylcholine, sorbitol, urea and betaine.
The results are reported as mean SCM mmol/kg wet weight of tissue. The
same organic compounds were detected in baboon renal tissue that were
present in rat tissue. The renal distribution pattern of urea and sorhitol
were similar in both baboon and rat. Differences in OM concentrations for
glycerophosphoryleholine (baboon, 1,556 232; rat, 3,910 150), hetaine
(baboon, 257 30; rat, 3,680 77) and inositol (baboon, 1,058 82; rat,
2,730 59) were apparent. This HPLC method is suitable for the analysis
of organic osmolytes in baboon renal tissue. There are notable distinctions
in baboon osmolyte accumulation in the OM. The reasons for these are
not clear but may include differences in diet, state of diuresis as well as
species differences.
Effect of an antiserum to vasoactive intestinal peptide (VIP) in two rat
models of cirrhosis. MA. Lonergan, S. Aglihut, and M.J. Field, Department
of Medicine, University of Sydney, Concord Hospital, Sydney, NSW Austra-
lia. It has been proposed that elevated levels of VIP, due to impaired
hepatic clearance may contribute to the disturbance of sodium and water
homeostasis that occurs in cirrhosis. To explore this possibility, we
conducted clearance studies in cirrhotic Sprague-Dawley rats using a
purified antiserum to VIP. Two models of cirrhosis were utilized, namely
carbon tetrachloride-induced cirrhosis (CCI4) and common bile duct
ligation and resection (CBDL). Animals were studied under mactin
anaesthesia after 16 weeks (CCI4) and 5—6 weeks (CBDL). The response
to an acute saline load was assessed in a protocol involving infusion of
Ringer's solution at 4% body weight/hr following a baseline infusion at 1%
body weight/hr. VIP antiserum was administered prior to the commence-
ment of the equilibrium period. Sham-treated animals for both models
also received the same volume of VIP antiserum. The animals receiving
VIP antiserum were compared to control groups receiving acute volume
loading alone. Tritiated inulin and 4C p-aminohippuric acid were in-
cluded in the infused fluids to permit calculation of GFR, fractional
electrolyte excretion rates, renal plasma flow and filtration fraction (FF).
In the CCI4 study, infusion of the VIP antiserum resulted in a small
increase in the capacity for excretion of the saline load, fractional
excretion of sodium (FEN,) rising above baseline by 1.4 0.8% of filtered
load (P < 0.05), compared to 0.53 0.2 in CCI4 rats without antagonist.
A similar response occurred in absolute sodium excretion. Urine flow also
increased over baseline by 13.9 6.4 j.d/min/100 g, compared to 3.6 0.14
in the CCI4 rats without the antagonist. The diuretic response of the
antagonist-treated group remained significantly less than that of the
sham-treated controls. In the CBDL study, in the presence of VIP
antiserum a non-significant fall occurred in sodium and water excretion. In
both models, VIP antiserum did not alter the response of the sham-treated
group to saline loading. We conclude that VIP may play a role in the
sodium and water retention in CCI4-induced cirrhosis.
Sodium depletion reduces plasma and renal concentrations of the
natriuretic hormone vasoactive intestinal peptide. KA. Duggan, G.J.
Macdonald, and V.Z. Ye, University Department of Medicine, Prince Heniy
Hospital, Sydney, Australia. Vasoactive intestinal peptide (VIP) is a 28
amino acid peptide of the secretin glucagon group that causes natriuresis
when infused intrarenally or intravenously. Variations in dietary sodium
intake have been shown to affect the plasma concentration, metabolic
clearance rate and secretion rate of VIP. In this study we sought to
determine the effect of sodium depletion on the concentration of VIP in
plasma and kidney. Male Sprague-Dawley rats were placed on low
(0.008%) or normal (2.2%) sodium diets and drinking water ad libitum. A
third group were placed on the low salt diet and in addition were given
lasix 1 mg/kg/day in the drinking water. After seven days the rats were
sacrificed, blood sampled and kidneys harvested. VIP concentrations were
determined by radioimmunoassay on unextracted plasma and in kidneys
after extraction. There were significant differences between the three
groups in the concentration of VIP in both plasma (P < 0.025) and kidney
(P < 0.005). In the group which had received the lasix and low salt diet the
renal concentration of VIP (68.34 9.49 fmol/g tissue) was significantly
less than both the low sodium (139.82 11.78 fmol/g tissue, P < 0.001)
and normal sodium (116.95 14.15 fmol/g tissue, P < 0.01). In the plasma
the concentration of VIP was also lower in the lasix group (12.45 5.74
pmol/liter) than in either the low sodium (53.35 8.60 pmol/liter, P <
0.01) or normal sodium (35.02 11.85 pmol/liter, P < 0.05). The lower
concentrations in the lasix group may be a response to sodium depletion
per Se. Alternately, they may be a response to the presence of a competing
agonist as both VIP and lasix increase sodium excretion by affecting the
sodium potassium chloride co-transporter in the loop of Henle.
Authentic ouabain is not detected in human plasma. L.K Lesvis, TG.
Yandle, J.G. Lewis, G.B. Pidgeon, R.J. Kaaja, AM. Richards, M.G. Nicholls,
Endocrinology Department, Christchurch Hospital, Christchurch, New Zea-
land, and Helsinki University Central Hospital, Finland. The aim of this
study was to develop a method for measuring plasma ouabain levels in
healthy volunteers, in patients with disorders of electrolyte balance or
arterial pressure, and following ouabain injection, to assist in determining
if ouabain is a biologically important circulating hormone. The assay
involved extraction of plasma through a C18 column using 25% acetoni-
trile, 0.1% trifluroacetic acid as the eluting solvent. The cluate was run
through an HPLC column (4 to 16% isopropanol gradient), and fractions
were analyzed for ouabain content by an indirect ELISA. Cross-reactivity
of the locally raised ELISA antibody was ouabain 100%, ouabagenin 77%,
strophanthidin 70%, digoxin 1% and less than 0.1% for various adrenal
and ovarian steroids and their glucuronides. Assay sensitivity was less than
0.04 nmol/liter. Without HPLC, immunoreactive ouabain was detected in
plasma and diluted in parallel with standards, but intra-assay CVs were
extremely variable (up to 45%). Furthermore, ELISA after HPLC sepa-
ration revealed no ouabain in plasma from healthy or pregnant subjects, or
in patients with heart failure, renal failure or hypertension of pregnancy,
yet ouahain was readily detected in plasma drawn from volunteers at
intervals after ouabain injection and in plasma spiked with ouahain down
to a concentration of less than 0.1 nmol/liter. In conclusion, plasma from
volunteers and various patient groups did not have detectable ouahain as
analyzed by ELISA after HPLC, suggesting that the immunoreactive
substance in plasma is not authentic ouabain.
Role of the aldose reductase pathway in the pathogenesis of diabetic
complication. H.D. Yan, ID. Zajac, ME. Dunlop, and R. G. Larkins,
University Department of Medicine, Royal Melbourne Hospital, Victoria,
Australia. The aim of this project is to transfeet Chinese hamster ovary
(CHO) cells with human aldose reductase (AR) gene as a model system
for studying the interaction of the AR pathway and to study the effect of
AR overexpression on prostaglandin synthesis. To define more precisely
whether overactivity of AR pathway is a major contributor to the
pathogenesis of diabetic complications, we have begun characterization of
biochemical effects of overexpression of the AR gene in cell culture using
molecular genetic methods. The full length hAR eDNA was inserted into
the mammalian expression pc DNA-neo vector, which contains CMV
promoter and the selection marker, neo. The AR eDNA was also inserted
in antisense orientation, or vector alone as controls. Cl-b cells were stably
transfeeted by high capacitance electroporation with the above constructs.
Seventeen sense, 13 antisense and 5 vector alone clones were chosen for
measurement of sorhitol using a radioisotopie method for measurement of
NADH generated by the action of the enzyme sorhitol dehydrogenase on
cellular sorbitol. One of the sense-construct clones has shown a high
sorbitol level. To determine whether the overexpression of the AR gene is
correlation with high sorbitol levels we have performed Northern blots to
measure mRNA expression in the transfected cells. We found that the
sense cell line had about 2.5-fold higher basal expression of AR mRNA
than found in antisense or vector alone. Furthermore, in a direct AR
enzyme assay, measuring NADPH oxidation in the presence of a galactose
substrate, this cell line had twofold higher activity (86.59 mU/mg proteins)
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in response to the high glucose condition (50 mM) than the controls (43.28
mu/mg proteins). To confirm our hypothesis we measured the prostaglan-
din (PG) production by using specific radioimmunoassay at low (5.6 mM)
and high (25 mM) glucose conditions. We found that the sense cell line had
threefold higher PG level (1040.62 pg/mg protein/mi) in high glucose
condition than the controls (368.26 pg/mg protein/mi). These results
demonstrate that AR ovcrexpression in CHO cell is a cause of increased
PG synthesis, and this provides a potential link between increased AR
activity and functional and structural changes in tissues susceptible to
diabetic complications.
Effect of inhibitors of arachidonic acid metabolism on IGF-1-induced
growth of proximal tubular cells in primary culture. M. Gekie, P. T Heng,
CA. Pollock, Department of Medicine, Royal North Shore Hospital, St.
Leonards, NSW Australia. Insuhn-hke growth factor I (IGF-1) is involved
in the regulation of kidney growth during maturation as well as during
regenerative processes. One site of action of IGF-1 are cells of the
proximal tubular epithelium. The action of IGF-1 is mediated by plasma
membrane receptors with kinase activity. Aithough the subsequent events
of intracellular signal transmission in proximal tubular cells have not yet
been elucidated in detail, some observations point to eicosanoids as
possible mediators. We investigated the effects of different inhibitors of
arachidonic acid (AA) metabolism on IGF-I-induced hypertrophy (in-
crease in cell protein) and hyperpiasia (increase in cellular thymidine
incorporation and cell number) of rat proximal tubular cells in primary
culture. All results are expressed as versus control (mean SEM).
Forty-eight hour incubation with IGF-1 led to an increase of cellular
protein (+36 5%, N = 25), cellular thymidine incorporation (+74
10%, N 20) and cell number (+27 6%, N = 13). The hypertrophic
effect of IGF-1 was abolished completely by 50 mol/liter dibucaine
(inhibitor of phospholipase A2) or 10 jrmol/liter proadifen (inhibitor of
cytochrome P-450 enzymes). Ten rmol/liter of ciotrimazole (inhibitor of
epoxygenase) did not abolish, but reduced the hypertrophic response
significantly to +21 4%, N = 13. Indomethacin (10 and 100 jmoi/hter,
inhibitor of cyciooxygenase) or NDGA (10 and 100 j.mol/hter, inhibitor of
lipoxygenase) did not reduce IGF-1-induced hypertrophy. The IGF-1-
induced increase in thymdine incorporation was abolished completely in
the presence of 50 jmol/liter dibucaine and significantly reduced in the
presence of 10 jrmol/liter proadifen (+20 11%, N = 9) or 10 mol/1iter
clotrimazole (+25 13%, N = 10). Indomethacin did not affect the
hyperplastic response, whereas NDGA reduced it slightly but significantly
to +43 8%, N 7. We conclude that the action of IGF-1 on growth of
proximal tubular cells is, at least in part, mediated by metabolites of
arachidonic acid. The differential effects of the inhibitors of AA-metabo-
lism suggest that the cytochrome P-450 products (such as epoxids and
HETE) serve as intracellular signals for IGF-1. To a lesser extent products
of the lipoxygenase may be involved in the mediation of the hyperplastic
effect of IGF-1.
Effects of an insulin-like growth factor-I variant in rats with acute
tubular necrosis. H.M. Healy, C.M Gillespie, iC. Wallace, A.A. Martin,
CRC for Tissue Growth and Repair, Department of Biochemistry, University
of Adelaide, and Child Health Research Institute, North Adelaide, SA,
Australia. Insulin-like growth factor-I (IGF-I) has been shown to enhance
the recovery of rats from acute tubular necrosis following an episode of
renal ischemia. In this study we administered the LR3- variant of IGF-I to
rats by continuous subcutaneous infusion (1.5 mg/kg body wt/day) for 7
days after a 45 minute period of bilateral clamping of the renal arteries. A
similar group of rats was treated with vehicle alone. At the end of the 7 day
treatment period, histological examination of the kidneys of the LR3IGF-
I-treated rats demonstrated a significantly greater degree of tubular
necrosis than the vehicle-treated animals. Protein and DNA content of the
kidney increased in the 7 days of recovery, with no differences between the
two treatment groups being apparent. Expression of the protooncogenes
e-myc and c-jun was elevated in the kidney during the early period of
recovery (3 days) in vehicle-treated rats, while LR3IGF-I administration
resulted in prolonged expression of both protooncogenes for the full 7
days of observation. Renal angiotensinogen mRNA levels were decreased
in both groups at 3 days, but levels increased markedly towards normal at
7 days with administration of the IGF analogue. Renin mRNA was
unaffected by either treatment. Plasma renin activity was reduced at 3, but
not 7, days in vehicle treated rats, with LR3IGF-I treatment having no
significant effect. Plasma levels of IGF-I were decreased in the analogue-
treated rats at 3 days, with hepatic levels of IGF-I mRNA also being
reduced at this time. These data suggest a deleterious effect on repair of
acute tubular necrosis by LR3IGF-I administration throughout the recov-
ery period.
Efficacy and renal toxicity of a new 23Na-NMR spectroscopy shift
reagent, TmDOTP5. IA. Leditschke, G.J. Cowin, D. Willgoss and Z.H.
Endre. Renal Research Unit, University of Queensland Department of
Medicine, Royal Brisbane Hospital, Herston, Brisbane, Australia. Transcel-
lular sodium gradients reflect cellular energetics and are a marker of early
cellular injury in experimental acute renal failure. 23Na nuclear magnetic
resonance (NMR) spectroscopy can monitor these gradients non-inva-
sively on a biologically useful time-scale. However, renal studies have been
limited by toxicity of the shift reagents (SR) needed to distinguish the
intracellular sodium signal from that of the extracellular compartment.
Nephrotoxicity was manifested by increased renal vascular resistance
(RVR) and fractional sodium excretion (FENa) and a reduced inulin
clearance. We assessed the new SR, TmDOTP5, in the isolated perfused
rat kidney, and demonstrated excellent resolution (—3 ppm) of intra- and
extraceliular sodium signals at perfusate concentrations as low as 4
mmol/liter. To assess renal toxicity, right kidneys from male Sprague-
Dawley rats were perfused with Krebs Henseleit buffer with 6.5% albumin
and gassed continuously with 95% °2/% CO2. Perfusion pressure, flow
and oxygen tension were continuously monitored. Changes in renal
function (inulin clearance, sodium and potassium excretion) were com-
pared in normal eontrols (N = 4) and the treatment group (N = 5)
perfused for 60 minutes prior to the addition of TmDOTP5 to a
perfusate concentration of 4 mmol/liter. At 120 minutes kidneys in both
groups were freeze clamped for adenine nucleotide assay. There were no
significant differences between the two groups (by paired t-test) in inulin
clearance, FENa and FEK, adenine nucleotides or RVR. We conclude that
this is a promising new shift reagent with improved resolution of intra- and
extracellular sodium signals, and with no evidence of renal toxicity at a
relatively low perfusate concentration. TmDOTP5 should prove very
useful in the further elucidation of the role of sodium gradients in renal
physiology and pathophysiology.
Parathyroid hormone (PTH) effects on skeletal muscle bioenergetics.
C.H. Thompson, YS. Green, G.J. Kemp, G.K Radda, MRC Biochemical
and Clinical Magnetic Resonance Unit, Oxford Radcliffe Hospital, Oxford,
England, United Kingdom. Skeletal muscle cytosolic inorganic phosphate
concentration ([Pu) is relatively insensitive to changes in plasma [Pi]
because cell [Pi] is controlled by a Na-Pi co-transporter with a Km in vitro
of 0.1 to 0.3 mrvt. PTH has been shown to reduce Pi transport in the kidney
and to cause mitochondrial impairment in skeletal muscle in vitro.
Disordered skeletal muscle Pi homeostasis may underlie the myopathy
that occurs in primary hyperparathyroidism or in the secondary hyper-
parathyroidism of chronic renal failure. We studied Wistar rats (200 g)
injected i.p. with either PTH (200 U) or saline for 4 days. 3'P magnetic
resonance speetroscopy allowed measurement of the concentration of
resting skeletal muscle, cytosolic Pi and the rates of oxidative (Q,,,,
mmol/kg/min) and anaerobic ATP turnover of the muscle during sciatic
nerve stimulation at 2 and 10 Hz and during recovery. PTH caused a 22%
reduction in plasma [Pi] and a 40% reduction in intracellular [Pi] (both
P < 0.05). This disproportionate reduction in cell [Pi] suggests that the
Na-Pi co-transporter is down-regulated. Despite this reduction in (meta-
bolically-active) cell [Pi], there was no alteration in muscle aerobic (Qmux
21 2 in PTH-injected ef 19 3 in controls) or anaerobic performance
during exercise or recovery. Proton efflux from the muscle (mmol/kg/min)
was unchanged (13 5 in PTH-injected cf 18 5 in controls). Reduced
mitochondrial function in vitro following 4 days of PTH injection is not
confirmed in vivo. The myopathy of hyperparathyroidism may not be due
to changes in cell [Pi] or to elevation of circulating levels of PTH per se.
Acute effect of parathyroid hormone (PTH) on urine concentration. S.L.
Carney and A.H.B. Gillies, Department of Medicine, University of Newcastle,
NSW 2305, Australia. Hormones other than arginine vasopressin (AVP)
may directly alter distal nephron water transport although their physio-
logical importance is unclear. While PTH has been shown to act as a
partial agonist to AVP in viva, in vitro studies with PTH and PTHrP have
been contradictory in experimental animals. Therefore, the following
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experiments were performed in anaesthetised water diuretic thyropara-
thyroidectomized rats to evaluate the effect of PTH on urine concentra-
tion, in the presence and absence of AVP. A maximal phosphaturic
concentration of rat PTH (2 j.tg/kg) reduced urine flow from 125 7 to
81 9 trl/min within 10mm (P < 0.01). Addition of a maximal antidiuretic
concentration of AVP (100 nglkg) produced a delayed and diminished
antidiuretic response when compared to a group of rats not pre-treated
with PTI-1 (47 5 compared with 27 5 .rl/min, P < 0.01). However, a
supramaximal AVP concentration (1000 ng/kg) produced a maximal
antidiuretic effect in the presence of PTH. In further experiments, a
submaximal AVP Concentration (7.5 j.rglkg) produced a similar antidi-
uretic effect to 2 ng/kg PTH. The addition of a maximal antidiuretic dose
of AVP (100 nglkg) to both groups was significantly blunted in animals
pre-treated with PTH. These studies demonstrate that high physiological
concentrations of PTH have a significant direct antidiuretic effect and can
also interfere with the action of AVP supporting a partial agonist role.
Acute effect of lithium administration on renal Ca, Mg and P04
transport in the rat. S. Carney and P. Jackson, Department of Medicine,
University of Newcastle, NSW 2305, Australia. Lithium (Li) treatment is
known to cause a form of hyperparathyroidism in humans and experimen-
tal animals. However, the mechanism for the hypercalcaemia and in-
creased parathyroid hormone (PTH) secretion is unclear, partly due to
different experimental protocols. Because a direct effect of Li on PTH
induced Ca transport has not been studied, thyroparathyroidectomized
(TPTX) and intact rats were studies following the administration of Li. In
addition, TPTX Li infused rats were studied following the addition of
PTH at maximal phosphaturic doses (2 pg/kg). While Li produced a
diuresis and natriuresis in both intact and TPTX rats as well as a
phosphaturia, Li also appeared to increase the FE of Ca (2.2 0.2 to
3.7 0.3% P < 0.01) and Mg (12 2 to 18 3%;P < 0.01) only in intact
rats. Li pretreatment blunted the effect of PTH on Ca and Mg reabsorp-
tion by approximately 50% (P < 0.01). These results suggest that part of
the hyperparathyroidism produced by Li treatment is due to an inhibition
of the action of PTH within the nephron. A clearer understanding of the
mechanism by which Li inhibits the action of PTH may help to define the
etiology of primary hyperparathyroidism.
Ganglioside GM2 activator protein gene expression in sheep kidney. A.
Butkus, J. Haralambidis, GB. Ryan, and J.P. Coghlan, Howard Florey
Institute and Department of Anatomy, University of Melbourne Parkville,
Victoria, Australia. Lysosomal glycolipid storage diseases have been rec-
ognized for a long time because of their catastrophic neurodegenerative
presentation, for example Tay Sachs disease. Three genetically distinct
forms of GM2 gangliosidosis, including Tay-Sachs disease, exist. One is
the so-called AB variant, where excessive accumulation of the GM2
ganglioside results from a defect in the activator protein. The richest
source of this protein is the kidney, then brain and liver; large quantities
are found in urine. Much earlier, we had isolated from sheep kidney an
enriched granular fraction, which on 2D gel electrophoresis yielded a
series of unknown proteins with an apparent molecular weight of 18—22
kDa. Recent sequence comparison of this protein revealed its close
homology to the now recognized human GM2 activator protein. As the
kidney is a rich source of the activator protein, then the question arises as
to whether it is made in the kidney or transported there from other
sources and excreted. We used Northern gels and then hybridization
histoehemistry to demonstrate that the gene encoding the activator
protein is expressed in all the major renal arteries and arterioles, and to a
lesser extent in the interlobular arteries. Antibodies raised against the
GM2 activator protein confirmed that the protein was present at the same
sites. These are the first studies showing the location of the GM2 activator
gene expression in the mammalian kidney. The arterial site of production
has implications for local action and receptor function or an important
role in membrane integrity throughout the kidney.
TGF-13 type II receptor mRNA in the embryonic rat kidney: An in situ
hybridization study. A.T. Clark, M.D. Ford, V. Nurcombe, D. Alcorn, B.
Key, and J.F. Bertram, Department ofAnatomy and Cell Biology, University
of Melbourne, Parkville, Victoria, Australia. The transforming growth
factor-/Is (TGF-/Is) are a family of peptide growth factors that influence
cell proliferation, differentiation, extracellular matrix synthesis and turn-
over. and angiogenesis in many tissues. Recently, TGF-/I1 was shown to
inhibit tubule branching in the developing rat metanephros. However, the
localization of TGF-/I receptors in metanephroi remains unknown. The
aim of the present investigation was to identify those cells in developing
rat metanephroi that express the mRNA for the TGF-p type II receptor,
which is specific for the TGF-/I family. Metanephroi from embryos of
time-mated Sprague-Dawley rats at days 16 (E16), 18 and 20 were fixed in
4% paraformaldehyde and embedded in paraffin. In situ hybridization was
performed using sense and antisense biotinylated riboprobes. TGF-/I type
11 receptor mRNA was detected in ureterie epithelium, cells of the
nephrogenic zone, vesicles, comma-shaped bodies, and the distal portion
of S-shaped bodies. However, the mRNA was not detected in the lower
limbs of S-shaped bodies, in maturing glomeruli, interstitial cells, or
proximal tubules. These results indicate that expression of the TGF-13 type
II receptor is developmentally regulated. In particular, expression is
down-regulated in the lower limb of S-shaped bodies and in glomeruli. A
similar down-regulation of expression in the lower limb has recently been
described for the DNA binding protein Pax-2. Manipulative studies
utilizing both in vitro and in vivo models are needed to define fully the role
of these molecules in metanephric development.
Transforming growth factor J3 (TGFP) in compensatory renal hyper-
trophy (CRH): An electron microprobe study. CA. Pollock, M. Nobes, P. T.
Heng, A.Z. Gyoty, TtI. Berkahn, A. Ortis, and M.J. Field, Department of Renal
Medicine, Royal North Shore Hospital and Electron Microscope Unit,
University of Sydney, Sydney, Australia. Following a reduction in renal mass,
immediate adaptive changes occur in glomerular and tubular function,
which allow homeostasis to be maintained. Paracrine and autocrine
factors are elaborated which initially stimulate kidney growth and later act
to limit the growth response. Evidence exists that TGF/I may play a role
in limiting the renal tubular proliferative response. The following exper-
iments assessed the effect of TGFP on cell transport in renal hypertrophy,
by measurement of intracellular electrolyte concentrations using electron
microprobe analysis (EMPX) in proximal tubular (PT) cells of animals
undergoing CRH. Four male Wistar rats underwent right unilateral
nephrectomy and simultaneous implantation of an osmotic minipump
delivering TGFII at a rate of I ng/hr (UNx TGF/3). Control animals
underwent uninephrectomy and infusion of vehicle alone (UNx). One
week later animals were anesthetised and infused with Ringers solution at
1.2 ml/100 g/hr. After equilibration, three 30 minute clearance collections
were done, after which isotonic RhCl was infused at 0.5 mmol/kg over 30
seconds, as a marker of K transport, and the kidney immediately removed.
Clearance data demonstrated a lower GFR in UNx TGF/I compared with
UNx animals (0.54 0.07 vs. 1.16 0.31 ml/100 g/min; P < 0.05).
However, no significant differences were evident in the urine flow (3.3
0.35 vs. 7.2 2.3 p.1/mm; P = 0.07) or fractional excretion of Na (0.07
0.02vs. 0.16 0.08; P = 0.2). EMPX analysis of PT cells revealed a similar
[Na11 in both UNx TGF/3 and UNx groups (15.7 0.5 vs. 159 0.5;P =
NS). The UNx animals had a high cellular dry weight indicative of cell
shrinkage, consistent with previous reports of stimulation of Na,K ATPase
in the early post-nephrectomy period. However, the UNx TGF/I animals
had a significantly lower dry weight of the PT cells (20.2 0.3 vs. 27.5
0.7; P < 0.0001), similar to that seen in two-kidney control animals. Thus,
despite a similar [Nal in UNx TGF/I and UNx animals, there is a higher
absolute amount of intracellular Na in the TGF/I treated animals,
consistent with reversal of the stimulated Na,K ATPase in CRH. The
hypothesis that TGF/I acts primarily to inhibit basolateral Na,K ATPase
activity was confirmed as intracellular Rh accumulation was significantly
reduced in the UNxTGF/I animals (5.2 0.3 vs. 6.3 0.4; P < 0.05).
Thus, the present study indicates that limitation of nephron hyperfunction
in CRH may he mediated by TGFI3.
Effect of angiotensin II infusion on plasma erythropoietin in healthy
volunteers. GB. Pidgeon, R.R. Bailey, K.L. Lynn, AM. Richards and MG.
Nicholls, Departments of Nephrology and Cardiology, Christchurch hospital,
Christchurch, New Zealand. Evidence suggests that angiotensin II (Ang II)
may be an important secretagogue of erythropoietin (EPO), both of renal
and extrarenal origin. Studies confirming this have not been performed in
human subjects. We have tested the plasma EPO response to short-term
infusions of both Ang II and noradrenaline (NA) in seven healthy
volunteers. In single-blind, randomized, cross-over studies, subjects on a
controlled sodium diet were pretreated with either ouabain (Ou) or
placebo. On each study day subjects received incremental infusions of Ang
11(2, 4, and 8 ng/kg/min, 30 mm each dose) and NA (5, 15, and 45
ng/kg/min, IS mm each dose). Mean arterial pressure (MAP) and EPO
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responses were measured. Pretreatment with Ou did not affect EPO
response and the achieved concentrations of Ang 11 and NA were similar
on each study day. Data from the two study days have therefore been
grouped. Mean plasma EPO concentrations increased from 14.4 2.5
mU/mI to 16.4 2.2 mU/mI during the Ang II infusion (P < 0.05) and
declined after the Ang 11 infusion to 14.3 2.1 mU/mi (P 0.01). Plasma
EPO concentrations did not change significantly during the NA infusion.
The mean maximum increase in MAP was 18.4 1.2 mm Hg during the
Ang II infusion and 10.5 1.3 mm Hg during the NA infusion. This study
confirms that short-term infusion of Ang II at pressor doses leads to a
significant increase in circulating EPO concentrations. Further placebo-
controlled studies are required to establish the mechanism of this effect
and its role in normal physiology.
Interaction between prostaglandins and the renin-aldosterone axis in
the natriuresis following saline infusion. G. S. Stokes, J. C. Monaghan, E. C.
Burke, and D.N. PilIai, Hypertension Unit, Royal North Shore Hospital, St.
Leonards, and Department of Clinical Chemistty, Prince of Wales Hospital,
Randwick, Australia. Interest in renal effects of prostaglandins has been
renewed by reports of reversible oliguria associated with the use of
ketorotac, an NSAID widely used in pen-operative pain relief. As NSAIDs
inhibit the synthesis of prostaglandins, we investigated the role of prosta-
glandins, and of other hormones important in renal Na handling, in the
first 6 hours after iv. Na* loading. Eleven normal volunteers (8 M, 3 F;
mean age 24 2 years) were given an iv. infusion of 2 liters 0.9% saline
from 1000 hours to 1300 hours on two study days more than a week apart.
Following Li2CO3 500 mg p.o. on the preceding evening, urine was
collected every 90 minutes from 0830 to 1600 hours. Placebo or indometh-
acm 50 mg was administered p.o. at 0745 hours. Renal tubular Na
reabsorption was fractionated into proximal and distal components using
Lit, Na and creatinine clearances. On the placebo day only 14 2% of
the Na load was excreted in the first 6 hours. Net Na retention was
associated with stepwise decreases in plasma albumin concentration, renin
activity and aldosterone, whereas urinary dopamine and plasma ANP
increased. Indomethacin decreased urinary PGE2, but produced a dis-
tinctly bimodal response in urinary Na excretion, which decreased
sharply in 7 subjects (Group A) and was unchanged in 4 (Group B). In
Group A, distal tubular fractional Na reabsorption was increased; overall
this was highly correlated with the indomethacin-induced change in
urinary Na excretion (r =
—0.96, P < 0.0001). In Group B, plasma renin
and aldosterone decreased after indomethacin (P < 0.05), whereas there
was no such effect in Group A. We conclude that prostaglandmns may be
involved in off-loading Na after iv. NaCI infusion whether prostaglandin
inhibition interrupts natriuresis appears to depend on the response of the
renin-aldosterone axis.
Glomerular number and size following enalapril treatment in postnatal
rats.J.E. McCausland, J.F. Beriram, GB. Ryan, and D. Alcorn, Department
of Anatomy and Cell Biology, University of Melbourne, Parkville, Victoria,
Australia. Chronic angiotensin converting enzyme inhibition (ACEI) in
maturing rats (weeks 4 to 10) has been shown to retard the growth of
glomeruli but to have no effects on renal vascular hemodynamics. Inter-
ruption of the renin angiotensin system during early postnatal develop-
ment in rats has been shown to cause functional and structural renal
abnormalities. The purpose of this study was to examine the effect of
chronic ACEI on glomeruli during early postnatal development in the rat.
Newborn Sprague-Dawley rats were injected with 10 mg/kg/day enalapril
(N = 6) or saline (N = 7) from day 3 to 21. At day 28, rats were
euthanased with 60 mg/kg nembutal IP and the kidneys were perfusion
fixed with 4% paraformaldehyde for stereological analysis. Using a
physical disector/fractionator combination at the light microscopic level,
glomerular number and volume were estimated. Enalapril treatment did
not alter glomerular number (control 26,780 3,193 (mean so);
enalapnil 26,299 2,030) or glomerular tuft volume (control 2,974
0.555 x i0 mm3, enalapril 3,471 0.714 X i0 mm3). In summary,
enalapril treatment had no effect on glomerular number, indicating that
angiotensin II is not essential for postnatal glomerulogenesis in the rat.
The failure to detect any changes in glomerular volume indicates that
angiotensin II has different effects on glomerular growth at immature
versus mature stages of development.
Renal, cardiac and vascular angiotensin converting enzyme (ACE) in
Goldblatt hypertension. B. Jackson, K Jandeleit-Dahm, M Hettiarchichi,
D. Paxton, RB. Perich and CI. Johnston, Department of Medicine, The
University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australia.
The tissue renin-angiotensin system may participate in the regulation of
cardiac, vascular, and renal changes associated with hypertension. Tissue
ACE is a key component of the tissue renin-angiotensin and is increased
in some models of cardiac and vascular hypertrophy. We have undertaken
studies in Goidhlatt hypertension to dissociate activity in the tissue renin
angiotcnsin from the circulating renin-angiotensin system and to examine
the effects of hypertension on kidney, heart, and vessel hypertrophy.
Tissue ACE was measured in mesenteric vessels, kidney and hearts of
hypertensive rats eight weeks following clipping one renal artery (2KIC)
or clipping one renal artery and excision of one kidney (1K1C) (N = 12
each). Hypertension was similar in both models. Plasma renin, angiotensin
1, and angiotensin II concentrations were elevated in 2KIC, and low or
normal in 1K1C compared with shams (N = 6/group). Hypertrophy of
mesenteric vessels and the heart was similar in both models, however,
tissue ACE was increased only in the 1K1C model, where tissue ACE was
directly correlated with the degree of hypertrophy (r = 0.8, P < 0.01).
Tissue ACE in the 1K1C rat was unchanged, but was increased in both
kidneys of 2K1C rats (P < 0.05). Changes of tissue ACE in kidneys, heart
and vessels appears to be dependant on the hypertension model, and not
an obligatory accompaniment of cardiovascular or renal hypertrophy
associated with Goidblatt hypertension.
Effects of an AT1 antagonist on glomerular size and number in
maturing SHR and WKY rats. MM. Kett, D. Alcom, J.F. Bertram, and W.P.
Anderson, Dept. of Anatomy and Cell Biology, University of Melbourne,
Parkville, and Baker Medical Research Institute, Prahran, Victoria, Australia.
Previous reports have suggested that there is a reduction in glomerular
number and changes in glomerular size in the kidneys of the spontane-
ously hypertensive rat (SHR), indicating a possible glomerular pathogen-
esis in the development of hypertension. In this study we used newly
developed, unbiased stereological techniques to examine glomerular
numbers and dimensions in the SHR. The effects of chronic AT1 blockade
on these characteristics were also investigated. Four groups of rats (N =
6) were studied: SHR and Wistar-Kyoto rats (WKY) treated with the AT1
antagonist TCV-116 (3 mg/kg/day p.o.; SHR-T and WKY-T) and SI-IR
and WKY administered the vehicle (gum arabic p.o.; SHR-C and WKY-
C). Treatment was from 4 to 10 weeks of age at which stage the kidneys
were perfusion thced at pressures corresponding to the systolic blood
pressure (BP) of each rat. Kidneys were then analysed using a physical
disector/fractionator combination for estimation of glomerular number
and glomerular tuft volume. Systolic BP (mm Hg) was: SHR-C 156 12
(mean so); WKY-C 134 9; SHR-T 137 13; WKY-T 103 10.
Two-way ANOVA found no significant effect of either strain or treatment
on glomerular numbers: SHR-C 25,075 1,628; WKY-C 25,754 2,749;
SHR-T 27,104 4,136; WKY-T 24,447 2,743. Similarly, there was no
effect of strain on glomerular tuft volume, however treatment with
TCV-1 16 significantly (P < 0.05) reduced glomerular tuft volume; SHR-C
7.24 0.6 )< iO mm3; WKY-C 7.18 0.97 >< iO mm3; SHR-T 6.51
1.2 >< iO mm3 and WKY-T 5.72 1.25 X i0 mm3. We found no
differences in either glomerular numbers or dimensions between SHR and
WKY rats to account for the hypertension seen in the SHR. Furthermore,
chronic blockade of the AT, receptor resulted in reduced glomerulan tuft
volume in both SI-IR and WKY rats supporting a role for Ang II mediated
glomerular growth via the AT, receptor.
Characterization of a nonpeptide orally active endothelin (ETA and
ETB) receptor antagonist. J. Risvanis, PA. Phillips, K Aldred, and L.M.
Burrell, Department of Medicine, University of Melbourne, Austin Hospital,
Victoria, Australia. Endothelin (ET)-1I has been shown to play a role in
modulating the homeostatic control of blood pressure via its ETA and ETh
type receptors. We have assessed the in vivo and in vitro binding
characteristics of a novel orally active non peptide ETA and ET receptor
antagonist, bosentan (Ro 47-0203), in mesentenic vascular membranes and
hepatocyte membranes from Wistar-Kyoto rats (=200 g). Maximum
inhibition of ['2311ET-1 binding in mesentenic vascular membranes by
bosentan (100 mg/kg) occurred at 1 hr post-dosing returning to control
levels within 4 hr. Maximum inhibition of ['2511ET-1 binding in hepatocyte
membranes by hosentan occurred at 4 hr post-dosing and persisted to
beyond 8 hr. Scatchard analysis of saturation binding in mesenteric
vascular and hepatocyte membranes following oral administration of
bosentan (100 mg/kg) indicated an increase in the apparent kDa of the
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[1251]ET-l binding sites consistent with receptor binding by bosentan.
There was no significant change in endothelin receptor B,,,,, in either
membrane preparation. In addition, Scatchard analysis of saturation
binding in both membrane preparations in Vitro with bosentan at 10 ni
and 100 n doses demonstrated a dose dependent increase in the
apparent kDa of the [1251]ET-1 binding sites. There were no significant
differences in endothelin receptor Bmax in either membrane preparation.
Displacement of ['2511ET-1 from endothelin receptors in mesenteric and
hepatocyte membranes following coincubation with endothelin analogues
resulted in an order of potency for liver of ET-1 = ET-2 > ET-3 >
bosentan> IRL 1038 (an ETB receptor antagonist) > BQ 123 (an ETA
receptor antagonist) and mesenteric vessels of ET-1 > ET-2 > Bosen-
tan> BQ123 > ET-3 > IRL 1038. The respective 1C50 of bosentan from
liver and mesenteric vascular membranes was (liver: —2.6 X 10 M,
mesenteric vessels: —0.2 X i0 M). Bosentan, a novel, orally active
endothelin receptor antagonist is a competitive antagonist both in vivo and
in Vitro in the liver and the mesenteric vasculature.
Systemic endothelin in primate pregnancy and preeclampsia. A. Hen-
nessy, AG. Gil/in, J.S. Horvath, and D.J, Tiller. Department of Renal
Medicine, Royal Prince Alfred Hospital, Camperdown NSW Australia. An
association between increased venous endothelin (ET) concentration and
hypertension has been suggested in human pregnancy. The source of this
endothelin has not been elucidated. It is postulated that it is produced by
the uteroplacental unit in preeclamptic pregnancy. The aim of this study
was to examine the uteroplacental circulation in normal baboon preg-
nancy and experimental preeclampsia for changes in endothelin concen-
tration. Ten baboons were examined serially from 8 weeks gestation (P8)
and blood was collected each four weeks (P12, P16, P20 and P24). The
same baboons were tested non-pregnant (NP). Blood was collected from
the inferior vena cava, aorta and cephalic vein to represent uterine venous
effluent, arterial blood and peripheral venous blood respectively. In a
separate experiment, blood from these sites was collected in three
chronically catheterized animals, two with induced uteroplacental isch-
emia and evidence of preeclampsia and 1 sham-operated control. ET was
measured by radioimmunoassay. There was a slight increase in ET from
non-pregnant values to early pregnancy values in venous blood. Arterial
blood, however, showed a significant (P < 0.01) decrease from non-
pregnant values to the end of pregnancy with the lowest concentration
recorded in late pregnancy at all collection sites: 1.83 0.46 pmol/liter
(NP), 1.49 0.38 (P8), 0.88 0.10 (P12), 0.90 0.19 (P16), 0.92 0.15
(P20) and 0.68 0.15 pmol/liter (P24). There was an increase in ET
concentration from all sites in the chronically catheterized animals. The
animal with clinical evidence of severe preeclampsia (thrombocytopenia
and hypertension) showed a 2.5 x increase in arterial ET after induction
of ischemia and no change in uteroplacental ET concentration. This study
suggests a systemic role for ET in preeclampsia. Elevation of ET concen-
tration above non-pregnant levels in human pregnancy may be a marker of
preeclampsia and aid in diagnosis.
Endothelial dysfunction in cyclosporine A-induced hypertension in
rats. B. Bartholomeusz, P.A. Phillips, K Rolls, L. -M. Burrell, and KJ. Hardy,
Departments of Surgery and Medicine, Austin Hospital, University of Mel-
bourne, Victoria, Australia. Cyclosporine A (CsA) prevents organ rejection
but causes hypertension. CsA damages endothelial cells and may reduce
endothelial-derived nitric oxide (NO) release, contributing to the hyper-
tension. CsA increases endothelin-1 (ET-1) synthesis in rats in vivo and in
human cultured endothelial cells in Vitro. This study examines the effects
of NO enhancement with L-arginine and endothelin blockade with
bosentan (Ro 47-0203), an orally active, non peptide, ETA and ETB
receptor antagonist. Female Wistar rats received CsA (10 mg/kg/day, s.c.)
or Vehicle (polyvinylpyrrolidone, 400 pi) for 30 days. Tail cuff systolic
blood pressure (SBP) was measured twice weekly. During the last week of
CsA treatment, rats received either L-arginine (250 mg/kg/day, in saline,
i.p.), saline (0.6 ml), bosentan (100 mg/kg/day in arabic gum, by gavage) or
arabic gum (0.5 ml). SBP was measured daily during this last week. At the
end of treatment, rats in the NO groups were placed in metabolic cages for
24 hr and rats in the ET group had mean arterial pressure (MAP)
measured via a carotid artery cannula. Rats were killed and blood CsA,
and plasma creatinine, hormone and electrolyte concentrations were
measured. L-arginine lowered SBP in the CsA group (saline 134 2 mm
Hg vs. L-arginine 111 6 mm Hg, P < 0.01), to the level of the
normotensive control rats that received saline. L-arginine lowered SBP in
normotensive rats (P -zz 0.05). Bosentan lowered SBP in CsA-hypertensive
rats compared to vehicle by day 4 (134 2 vs. 122 3 mm Hg, P < 0.01),
but had no effect in the normotensive group. The MAP for the CsA-
treated rats that received bosentan was lower than that of the rats treated
with gum (bosentan 114 10 mm Hg vs. gum 129 9 mm Hg, P < 0.01).
Therefore, modulation of the endothelium-derived vasoconstrictor, ET-1
and vasodilator, NO lowered blood pressure in CsA-hypertension, sug-
gesting that changes in these two systems may contribute to the develop-
ment of CsA-induced hypertension.
Renal amylin binding site in rat models of hypertension. Z. Gao, P.J.
Wookey, R. Komers, and ME. Cooper, Department of Medicine, University
of Melbourne, Heidelberg Repatriation Hospital, Heidelberg West, Victoria,
Australia. Amylin, a 37 amino acid peptide, is cosecreted with insulin from
the pancreatic 13-cells. In the normal rat kidney, we have shown that high
affinity (< nM range) binding sites for amylin are associated with proximal
tubules in the outer cortex. Furthermore, these sites are functionally
significant, since amylin (10—p M) introduced on the basolateral side of the
epithelium in micropuncture experiments (shrinking oil drop) stimulated
sodium/water resorption by 30%, demonstrating that amylin is equipotent
in this regard with angiotensin II or endothelin. Low doses of amylin
stimulate plasma renin activity at least twofold in rats and human subjects.
These results suggest that amylin may play a role in the development of
hypertension, particularly common in type II diabetic and obese subjects,
in which amylin levels are elevated. We have explored the relationship
between amylin and hypertension, by assessing the high affinity amylin
binding site in rat models of hypertension and obesity. Animals were
anaesthetized with pentobarbitone (100 mg/kg, i.p.) and nephrectomized
by removal of one kidney and occlusion of two of the remaining three
branches of the renal artery (5/6th Nx model) or clipping renal artery
(Goldblatt model, 2 kidney/i clip) in 8-week-old Sprague-Dawley rats.
Blood pressure was monitored by tail cuff plethysmography every other
day, and after 4 weeks when blood pressure had risen to a maximum (>
190 mm), the animals were sacrificed painlessly (12 weeks total age) by a
single injection i.p. of nembutal (60 mg/kg). The kidneys were removed,
snap frozen in isopentane (—70°C) and 20 jrm sections mounted on glass
slides for binding studies with ['251]-amylin and [12511 AC512, a peptide
analogue of amylin. The net binding (total minus nonspecific binding) was
elevated in the outer cortex of the 5/6th Nx model compared to normal
kidneys, and this pattern of binding extended into the ischemic region.
However, with increasing competition provided by increasing concentra-
tions (10' to 10 M) of non-radioactive peptide, binding was reduced to
background levels in the healthy outer cortex, but was virtually unaffected
in the ischaemic regions, suggesting a change in the pharmacological
characteristics. In the Goldblatt model, there was no change in the binding
in the contralateral kidney but an apparent increased intensity of binding
in the stenosed, ipsilateral kidney. Furthermore, amylin stimulated adeny-
lyl cyclase activity in membranes from normal and the contralateral outer
cortex by two- to threefold. In tissue from the Goldblatt ipsilateral kidney,
the basal level of adenylyl cyclase activity was ten times that found in the
normal or contralateral kidney, and there was no apparent stimulation by
amylin. We postulate that amylin is an important hormone in renin
regulation and blood pressure control.
Noninvasive diagnosis of nephrosclerosis: Microvascular ischemic ne-
phropathy by renal duplex ultrasound. S.J. Chadban and R.S. Nanra,
Nephrology Unit, John Hunter Hospital, Newcastle, NSW, Australia. It has
been suggested that renal duplex ultrasound (RDU) signals from renal
cortex provide an index of cortical blood flow. The aim of this retrospec-
tive study was to evaluate the use of the ratio of diastolic to peak systolic
Doppler frequency signals (EDRs) obtained from renal cortex in a human
clinical model of hypertensive microvascular ischemic nephropathy
(HMIN), the contralateral kidney (RAS—) in unilateral significant renal
artery stenosis (RAS); the RAS+ protected kidney was used as control. Of
111 patients examined for RAS by RDU and angiography, 89 patients with
renal artery thrombosis, bilateral RAS, no RAS, primary renal disease, no
EDR values, single kidneys, or absence of hypertension, were excluded
from analysis. Thus, 22 hypertensive patients with angiographic unilateral
significant RAS (>50%) were analyzed: male:female ratio 1.4:1, mean age
64 years (SD 9), mean Cçr 41 ml/min/1.73 m2 (SD 13), mean duration of
hypertension 12 years (SD 11), mean MAP 121 mm Hg (SD 22), and mean
number of antihypertensive drugs 2.3 (SD 1.1). The mean EDR from
RAS— kidneys 0.26 (SD 0.09), was lower than the mean EDR from RAS+
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controls, 0.33 (so 0.09) (t = 4.35, P = 0.0003). In 9 patients in whom RAS
was invasively corrected, the mean pre-procedure EDRs, RAS+ 0.35 (SD
0.07) and RAS— 0.28 (SD 0.07), remained unchanged compared to
post-procedure EDRs, RAS+ 0.32 (so 0.09) and RAS— 0.28 (SD 0.13). An
EDR value sO.30 detected HMIN with a sensitivity of 77% and specificity
of 64%. It is concluded that EDR 0.30 is a useful additional test in the
diagnosis of HMIN. EDR may also assist in evaluation and management
of essential and renovascular hypertension, and in the diagnosis of other
forms of nephrosclerosis.
Effect of fiuvastatin on lipoprotein profiles in renal transplant patients
with dyslipoproteinemia. P.K T. Li, T WL. Mak, T.H. Chan, A.YM. Wang,
S.F. Lui, C. W.K Lam, and KN. Lai, Department of Medicine and Chemical
Pathology, Prince of Wales Hospital, Chinese University of Hong Kong, I-long
Kong. The objective of this study is to investigate the use of fluvastatin (F),
a new HMG CoA reductase inhibitor, in treating dyslipoproteinuria in
renal transplant patients. Sixteen renal transplant patients who were on
cyclosporine A (CsA) were studied. The patients had elevated plasma
cholesterol levels after diet control and required drug treatment. They
were studied for a period of 32 weeks with 4 weeks of baseline, 4 weeks of
placebo, 12 weeks of treatment with (F) 20 mg and then 12 weeks of
treatment with (F) 40 mg consecutively. Blood samples were obtained
4-weekly for the measurements of trough concentrations of CsA, renal and
liver functions, creatine phosphokinase (CPK) and lipoprotein profiles
which include total cholesterol (TC), triglyceride (TG), LDL-, HDL-,
HDL2-, HDL3-, VLDL-cholesterol, apolipoprotein A and B and lipopro-
tein (a) [Lp(a)1. Significant reductions of lipoprotein levels were observed
in TC, LDL-cholesterol and Apolipoprotein B (APB) between the treat-
ment and the baseline period (data as mean sEM):
Baseline F 20 mg F 40 mg
TC mmol/liter 6.69 0.16 5.81 0.13a 5.61 0.14
LDL-C mmol/liter 4.1 0.17 3.25 0.11" 3.01 0.14"
APB mg/liter 159.4 4.8 137.8 5.0" 132.5 5.5
ap <0.001
There was no significant difference in other lipid profiles comparing the
baseline and the treatment phases. Serum potassium level was reduced
from 4.2 mmol/liter to 4.0 with (F) 40 mg daily. No other significant
differences were found in the renal function and liver function tests, CPK
and CsA levels in the different periods. No patient complained of myalgia
or dropped out from the study due to side effects. Fluvastatin appears to
be a safe drug in treating dyslipoproteinemia in renal transplant patients.
Presence and significance of glomerular polymorphonucleocytes in
renal transplant insertion biopsy. P. TH. Coates, G.R. Russ, and A.E.
Seymour, Renal Unit, Flinders Medical Centre, Renal Unit, Queen Elizabeth
Hospital and Gribbles Pathology Services, Adelaide, South Australia, Aus-
tralia. The presence of glomerular polymorphonucleocytes (PMN) in
glomeruli in renal transplant insertion biopsy has been suggested to
correlate with graft survival and outcome. We reviewed 189 insertion
biopsies to document the number of PMN's and the clinical outcome. A
total of 189 insertion biopsies performed in our institution from 1986—
1990 inclusive were reviewed by two observers. The number of PMN's on
H and E stain in 20 glomeruli were counted and recorded for each patient.
Outcome data (serum creatinine and graft failure) was collected from the
ANZDATA registry. The average PMN count was 27.5 per 20 glomeruli
counted. Patients were divided into 2 groups with PMN count >40 (N =
36) and <40 (N = 163). In the first twelve months post-renal transplant
there were 7 graft failures in the first group and 16 graft failures in the
second (x2 = 2.2 1 DF 0.5 <P < 0.1, NS). Average serum creatinines at
1, 6 and 12 months were 193, 163, 152 and 212, 150 and 152 in the two
groups, respectively (NS). In the group with >40 PMN's there was no
relationship between absolute PMN count and graft outcome. In conclu-
sion, a high glomerular polymorphonucleocyte count on insertion biopsy
does not predict poor graft outcome or early graft loss.
Effect of cyclosporine (CsA) on genetic determinants of factor VIIc
(YIIC), fibrinogen (FIB) and cardiovascular disease (CVD) following
renal transplantation. A. Irish and F. Green, Renal Unit, Churchill
Hospital, Oxford, and Dept Medicine, UCL Medical School, London,
England, United Kingdom. Thrombotic risk factors Factor VII coagulant
activity (fVIIc) and fibrinogen (fib) were measured in 38 stable renal
transplant recipients (RTR) and compared with 31 controls (N) matched
for age and BMI. Genotypes for the /3-fib G/A455 and fy11 Arg/G1n351
polymorphisms were determined by PCR and restriction enzyme digestion
(HaeIII, Mspl).
Genotype
Flb (mean so) mg/dl
N RTR
GG
GA
ArgArg
ArgGln
267 46
270 65
278 54
236 39
351 58"
364 54"
372 48"
319 56"
Genotype
FVIIc % standard
N RTR
GG
GA
ArgArg
ArgGln
85±21
85±25
91 21
64±6
97±26
96±35
106 27"
71±21
"P  0.05 RTR vs. N
Fib was higher in RTR irrespective of genotype. Fib correlated indepen-
dently with CsA levels (r = 0.31, P = 0.07) but this effect was stronger in
the A allele (r = 0.50) than the 0 (r = 0.18). Interleukin-6 levets were
increased in RTR compared with controls (3.6 3.2 vs. 1.9 1.6 pg/ml,
P < 0.05), suggesting that a persistent acute phase effect contributes to Fib
elevation in RTR possibly mediated by CsA. Fib (392 50 vs. 345 54
mg/dl, P < 0.05) was higher again in those with CVD. D-Dimer (N: 0.08
0.03 vs. RTR: 0.21 0.31 mg/dl, P < 0.001) and Fl + 2 (N: 0.33 0.12
vs. RTR: 0.73 0.57 nM, P < 0.001) were also increased in RTR
consistent with a hypercoagulable state. However, FVIIc in RTR was
significantly higher than N only in the Arg homozygotes and 8/27 (30%)
ArgArg individuals compared with only 1/11(9%) Gln carriers had CVD
(P = NS). Mean fVIIc in Gin heterozygotes was around 2/3 that in Arg
homozygotes in both RTx and N, consistent with previous observations,
and Gin carriers also had lower Fib, Fl + 2 and D-Dimer consistent with
a hypocoagulable state. CsA correlated with activated factor XII (XIIa)
(r = 0.68) only in ArgArg individuals in whom the XIIa/VIIc correlation
was strongest (r = 0.75 ArgArg vs. 0.49 ArgGln), suggesting that CsA
induced activation of fXII may account for the increased Vile seen in
ArgArg RTR compared with N. The 13-fibrinogen G/A455 promoter
polymorphism is associated with small variation in Fib expression while
the fVII Gin353 allele with significantly decreased fVIIc and Fib, suggest-
ing that genetic factors influence the expression of the hypercoagulable
state and risk of CVD following renal transplantation, perhaps in part
mediated by allele specific responses to CsA and other environmental
factors.
Quantitation of T cell cytokine mRNA in the sheep model of renal
allograft rejection. 0. Patriclç J. Carter, R. Krishnan, M. Rao, and OR.
Russ, Transplantation Immunology Laboratory, The Queen Elizabeth Hos-
pital, Adelaide, SA, Australia. Tissue expression of cytokine transcripts in
allograft rejection may be transient and preceed clinical signs of rejection.
This study has quantified the temporal profile of T cell cytokine mRNA
expression (IL-2, IL-4, TNFa and IFNy) in relation to histological
evidence of rejection in renal biopsies from unmodified sheep renal
allografts. Renal allografts between pairs of alloreactive male Merino
sheep were biopsied daily. Samples were snap frozen in liquid nitrogen for
cytokine mRNA analysis or fixed in formalin for histological evaluation.
The reverse transcription-polymerase chain reaction (RT-PCR) was used
to amplify one xg of total RNA in the presence of tritiated dTTP and
specific primers for the 4 cytokines. Radiolabelled PCR product was
hybridized in liquid phase to a biotinylated oligonucleotide complemen-
tary to an internal sequence of the target eDNA and captured by
streptavidin-coated microfluor beads. The proximity of tritiated PCR
product to the fluor allows it to be detected by scintillation counting with
subsequent quantitation by reference to standard curves generated from
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PCR-scintillation proximity assay analysis of serial dilutions of plasmids
containing ovine cytokine cDNA. Results were obtained from I autograft
and 6 unmodified allografts. Peak copies of cytokine transcripts 1 SD
(relative to plasmid cDNA) per g of total RNA are shown in the table
with the day of occurrence (in brackets):
IL-2 IL-4
Autograft not detected 70.2 14 (no peak)
Allograft 1 1602 104 (3) 1590 46 (3)
Allograft 2 322 68 (5) 1279 372 (7)
Allograft 3 1044 82(3) 14498 948 (3)
Allograft 4 474 182 (5) 3211 440 (5)
Allograft 5 126 45 (3) 1844 780 (3)
Allograft 6 78 38 (3) 3230 617 (3)
IFNy < 1000) TNFa (Xl 000)
Autograft 0.4 0.2 (no peak) 5.5 1.3 (5)
Allograft 1 4.4 1.2 (3) 230 29 (1)
Allograft 2 32.6 7.6 (7) 63.5 19 (3)
Allograft 3 32.2 0.5 (7) 5.5 0.9 (5)
Allograft 4 22.8 5.5 (5) 5.6 2.9 (5)
Allograft 5 47.3 6.3 (7) 2.9 0.6 (7)
Allograft 6 3.1 0.2 (5) 1.0 0.3 (5)
Allograft histology showed increasing severity of cellular and vascular
rejection from day 2 post-transplantation until graft necrosis at days 8 to
9. In this model, acute renal allograft rejection is associated with a
significant increase in mRNA expression for IL-2, IL-4 and IFNy when
compared to the autograft. IL-2 mRNA was detected as early as day I in
the allografts. Correlation with the histological findings suggests a pivotal
role for IL-2 in the rejection process. TNFa mRNA expression suggests
that the presence of this cytokine within the graft may relate to the surgical
procedure. In conclusion, increased intragraft expression of IL-2, IL-4 and
IFNy message during acute renal allograft rejection suggests that the
alloimmune response involves activation of several subsets of functional T
lymphocytes.
Low bone mineral density in dialysis patients. MS. Stein, D.K. Pack-
ham, P.R. Ebeling, J.D. Wark, and G.J. Becker, Departments of Medicine,
Diabetes and Endocrinology, Nephrology, The Royal Melbourne 1-fospital,
Melbourne, Victoria, Australia. Dialysis patients are at risk of low bone
mineral density from a combination of factors including 1-a hydroxylase
deficiency, hyperparathyroidism and chronic heparin exposure. We as-
sessed the prevalence of low bone mineral density in 160 of our dialysis
patients having this measurement as part of their routine clinical manage-
ment. Bone densitometty was recorded on Hologic QDR1000W and
Hologic QDR2000PIus bone densitometers using dual energy X-ray
absorptiometry (DXA). Results are expressed as Z scores (standard
deviations from age-sex-matched means of a healthy reference popula-
tion). Patients are routinely scanned at the non-dominant forearm, hip
and lumbar spine. This preliminary communication reports results for the
hip and forearm. The mean Z score at the ultradistal radius (UD) Was
—0.98 (N = 142). The mean Z score at the femoral neck (FN) was —0.67(N = 155). The prevalence of patients with a Z score worse than —2 at the
ultradistal radius and femoral neck was 32 out of 142 (22%) and 23 out of
155 (15%), respectively. Overall, there is a linear correlation between
bone density at the forearm and hip sampled within an individual (r =
0.63, P < 0.001). There is also a correlation in bone density of both
compact and cancellous components at the same region: Ultradistal versus
1/3 radius, r = 0.64, and trochanteric versus intertrochanteric hip, r = 0.86.
One hundred and fourteen patients had never received a renal transplant.
For these patients Z score was plotted against time on dialysis. In this
cross-sectional analysis the time on dialysis was found not to be a strong
predictor of Z score. UD versus time r = —0.12 and FN versus time r =
0.14. Thus ostoepenia is a common problem in the dialysis population and
constitutes a significant site-specific increased fracture risk.
Safety and efficacy of enafapril and simvastatin in dialysis patients. J.F.
Collins, R. Robson, S. MacMahon for PERFECT Study Group, Department
of Medicine, Auckland Hospital, Auckland, Department of Nephrology,
Christchurch, New Zealand. Dialysis patients have an increased risk of
death from cardiovascular disease compared with age-matched normals.
Changes in lipoprotein metabolism and alterations in left ventricular (LV)
structure and function are common in these patients and likely to
contribute to the increased risk. The objectives of this multi-center
double-blind, randomized placebo (plac) controlled pilot study were to
determine in dialysis patients the effect of simvastatin (simv) on lipids and
enalapril (enal) on LV size, to assess the safety of these agents in dialysis
patients and to determine whether or not a large scale preventive trial was
practicable. Sixty patients on hemodialysis and 47 patients on CAPD were
randomized to receive 2 agents in a factorial design (simv, enal; simv, plac;
enal, plac; double plac). The initial enalapril dose was 2.5 mg daily titrated
up to 5 mg daily or down to 2.5 mg 3/weeks dependent on blood pressure
and symptoms, and simv 10 mg daily. Patients had a 2D echocardiogram
(echo) and plasma lipid studies (single lab) at baseline and after 6 months
of therapy. Hemoglobin, serum urea, electrolytes, albumin, liver enzymes
and CK were checked monthly. Analysis was on an intention to treat basis.
Lipids
Baseline
Simv Plac
HDL mmol/liter 1.02 1.00
LDL mmol/liter 4.14 4.34
Total cholesterol mmol/liter 6.25 6.35
Enal Plac
BP
Systolic 138 138
Diastolic 83 84
Hemoglobin glliter 101 105
ECHO
LVEDD cm 5.8 5.7
LVESD cm 3.9 4.0
LVMASS g 266 263
Enal Plac P
BP
Systolic 131 139 0.20
Diastolic 79 84
Hemoglobin g/liter 97 106 0.23
ECHO
LVEDD cm 5.7 5.6 0.96
LVESD cm 4.0 3.9 0.47
LVMASS g 254 244 0.72
A total of 30% of patients no the enalapril arm of the trial withdrew
because of hypotension. Simvastatin was well tolerated. In conclusion, low
dose simvastatin lowers total and LDL cholesterol in dialysis patients and
is well tolerated. As enalapril was withdrawn in one third of patients, the
possible beneficial effect on LV mass was not confirmed in this study.
Chronic volume expansion in patients with chronic renal failure:
Effects on blood pressure and vasoactive hormones. D.M. Voss, K.L. Lynn,
AL. Buttimore, and E.A. Espiner, Department of Nephrology, Christchurch
Hospital and Department of Medicine, Christchurch School of Medicine,
Christchurch, New Zealand. Blood pressure (BP) is critically dependent on
sodium status in patients with chronic renal failure. Extracellular fluid
volume (ECF) expansion increases BP but the relations between volume
change and change in BP and levels of vasoactive hormones are unclear.
We studied changes in BP and the plasma hormones ANP, BNP,
endothelin (ET), angiotensin II (Ang II) renin (PRA) associated with
Lipids
HDL mmol/liter
LDL mmol/liter
Total cholesterol mmol/liter
6 monthly
Simv Plac P value
1.02 0.9 0.45
3.12 3.86 0.003
5.06 5.85 0.001
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changes in ECF in four haemodialysis patients. Patients were studied on
regular dialysis (basal state), after 4 days of volume expansion (mean ECF
increase 5 liter > dry body wt) and after ultrafiltration. Supine mean BP
rose (2.2 to 23%) during volume expansion and fell to baseline at the end
of the study. Plasma Ang II and PRA values fell as expected during
volume expansion and ET values were unchanged. Before volume expan-
sion plasma levels of ANP and BNP (normal in 1) were raised in most
patients. ANP concentrations (34 to 117% above baseline) and BNP
concentrations (29 to 85%) rose further with fluid loading in 3 or 4
patients. Patient 4 had elevated ANP and BNP concentrations that did not
rise further with ECF expansion. ANP and BNP concentrations returned
to near baseline values after ultrafiltration. This study shows that chronic
ECF expansion in dialysis patients is associated with an increase in BP and
marked elevation in both plasma ANP and BNP without change in ET. In
contrast to ANP, increases in plasma BNP greatly exceeded those
observed by us in previous studies employing short-term (2 hr) periods of
ECF expansion. The biological relevance of these hormones changes
remains to be clarified.
L-cysteine improves growth of human peritoneal mesothelial cells
(HPMC) in vitro. S.D. Bird, A. Knight, M. Legge, and R.J. Walker,
Department of Medicine and Department of Biochemistry, Otago Medical
School, Dunedin, New Zealand. The effect of L-cysteine (Cys) and
epidermal growth factor (EGF) added individually to the culture medium
(M199) on HPMCs, was investigated. HPMCs were obtained from
omentum by enzymatic digestion and grown for one passage. Cells were
subpassaged and seeded into 24-well plates with M199 medium, 2.0% FBS
and L-glutamine plus the growth agents. Cell growth was measured by the
determination of total cell protein (pg welL') and cell counts. Morphol-
ogy was assessed with phase contrast light microscopy and scanning
electron microscopy. Intracellular redox status was determined of by
HPLC. Results are mean SCM, N = 4 omentum samples.
Time (d)
Day3
Total cell protein
Day9
Total cell protein
M199 control 24.6 2.0 43.9 2.4
Cys 40.5 4.4' 101.0 1.5"
EGF 28.7 1.9 65.3 1.0
ap <0.05, "P <0.01
HPMC exposed to Cys (30 jig/mI '), exhibited significantly improved
attachment and growth. Attached cells appeared flat and well spread out
shortly after seeding and produced a tight polygonal monolayer in 14 days
in contrast cells grown in M199 control medium which failed to reach
confluence. After an initial lag in cell growth, EGF (0,01 jsg/mL')
increased cell growth greater than that produced by Cys, however, this was
associated with significant changes in HPMC morphology. This study
shows that Cys improves the cellular redox status, giving rise to improved
cell attachment, growth and morphology of HPMC in Vitro, which may
have clinical relevance in the development of new dialysis solutions.
Determinants of CAPD peritonitis rates in Aboriginal and non-Aborig-
inal patients. J. Feutrill, L. Thomas, J. Lazherger, V Burke, J. Whishaw, D.
Camrthers, R. Offer, G. Rangan, A. Parnham, G. Thatcher, and M. Thomas,
Faculty of Medicine, University of Western Australia, University Department
of Medicine and Department of Nephrology, Royal Perth Hospital, Perth,
Australia. Data from 1989 —1992 from our Unit had shown a higher rate of
peritonitis in aboriginal (Ab) vs. non-aboriginal (non-Ab) CAPD patients.
To determine whether this was confounded by factors other than race per
se, results for all patients treated for >1 month on CAPD between 1.1.92
and 30.6.94 were analyzed. Patients were allocated to either disconnect
(Freeline Solo with K shield, or Y-set), or a long-line system (with UV
sterilizing devices) according to pre-dialysis assessment. Demographic,
medical, socio-economic and CAPD training/technique data were col-
lected prospectively from ANZDATA and Unit records. Socio-economic
status (SES) was determined by postcode (Aust Bureau of Statistics) for
metropolitan patients. The means of two CAPD nurses' independent
rating of current technique adequacy, understanding, compliance, per-
sonal hygiene, motivation, domestic support and home environment were
calculated. Chi-square and t-test were used for comparisons of categorical
and continuous variables, respectively. Thirty Ab and 76 non-Ab patients
were treated, with Ab patients being younger (47 vs. 59 years), having a
higher proportion of females (60% vs. 34%) and diabetics (53% vs. 21%)
and fewer not speaking English as a primary language (37 vs. 10%).
Disconnect systems were used in Ab patients more frequently (97% vs.
75%). After 5.5 2.7 days training (Ab = non-Ab), CAPD was performed
for 13.7 8.7 months in the study and 22.7 19.1 months in total, with
Ab patients showing significantly poorer socio-economic status, technique
and psycho-social factors than non-Ab patients. Peritonitis rates were not
different between Ab and non-Ab patients in this study (1.2 vs. 1.0
episodes/year), but were greater in patients aged over 50 years (1.3 vs. 0.6),
not using a disconnect system (2.1 vs. 0.8), having poor technique (2.1 vs.
0.7), performance (3.9 vs. 0.8), compliance (2.2 vs. 0.7) or motivation (2.7
vs. 0.7). After adjustment for age, sex, SES, diabetes and the use of a
disconnect system, only rating of performance and motivation remained
significant predictors of peritonitis. CAPD peritonitis rates are deter-
mined by individual factors independent of race, with disconnect systems
offering a significant protective benefit for those at risk.
Peritoneal catheters—Swan neck versus straight. Is there an advan-
tage? J. Collins, G. Gamble, and J. Lea,y for the NZ CAPD Registry, Renal
Unit, Auckland Hospital, Auckland, New Zealand. The New Zealand (NZ)
CAPD registry has collected comprehensive data on all NZ patients on
CAPD since 1986 (6 centers). A total of 487 new patients commenced
CAPD in NZ between October 1990 and November 1994 in whom the first
peritoneal catheter type was recorded. The two principle peritoneal
catheter types utilized (double cuff straight Tenkhoff, double cuff swan
neck) were compared in this analysis. Thirty-nine patients received an
alternative catheter. Patient death or transplant was not considered to
have caused catheter failure.
Double
Cuff
Straight
Double
Cuff
Swan
N 217 231
Age, median range 52 (4—79) 49 (10—74)
Sex % male 53% 57%
Connection system % disconnect 44% 52%
Race % Polynesian or Maori 44% 53%
Median years of catheter 1.6 0.7 1.3 0.7
survival SD
Median years to first episode of 0.8 0.4 0.9 0.5
peritonitis SD
Peritonitis rate months per episode 16.2 12.3
Migration rate episodes/100 patient years 10.8 7.1
P> 0.05
The causes of catheter failure were peritonitis (47%), catheter dysfunction
or leak (19%), exit site and or tunnel infection (11%), catheter migration
(5%) and other (18%). There were no significant differences between
these causes and catheter type. Despite comparable groups there were no
differences in catheter migration rate, time to first episode of peritonitis,
peritonitis rate or catheter survival. The sample, although not randomized
has 85% power to detect a difference of 6 months in catheter survival (a
= 0.05). In conclusion, these results suggest that double-cuff swan neck
catheters offer no advantage over double-cuff straight catheters.
Sclerosing peritonitis developing after the cessation of continuous
ambulatory peritoneal dialysis (CAPD). 5.1 Coulshed, L.S. Ihels, S.D.
Roger, and CA. Macadam, Department of Renal Medicine, Royal North
Shore Hospita4 St. Leonards, NSW, Australia. Sclerosing peritonitis (SP) is
a rare but devastating complication of CAPD, and has been seen in 3 of
240 CAPD patients at this hospital (incidence 1.25%). We report the case
of a 38-year-old man on CAPD for 9 years which was complicated by
recurrent exit site infections, peritonitis and then SP. The patient first
presented with hemoperitoneum in April 1993. He had recurrent episodes
of peritonitis until October 1993 when the catheter was removed due to
loss of ultrafiltration. In July 1994 he presented with 4 months of vomiting
and marked weight loss. Investigations showed a partial small bowel
obstruction with many multiloculated areas of fluid within the peritoneal
cavity, extensive vascular calcification, calcification of the peritoneal lining
and bowel and a thickened bowel wall. At laparotomy the entire small
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bowel was encased in a thick layer of inflammatory tissue up to 0.5 cm
thick. The post-operative course was complicated by an ileus, malnutrition
requiring prolonged TPN and repeated drainage of abscesses. The patient
was discharged malnourished at his request and has since had repeated
admissions for bowel obstructions, abdominal collections and cutaneous
fistulae. He will not accept home TPN. This case demonstrates the
devastating consequences SP that have not been improved by catheter
removal. It was associated with prior repeatcd episodes of exit site
infections, peritonitis, and poor compliance. Dialysis is adequate by
hemodiaiysis, however, malabsorption, repeated vomiting and recurrent
abscesses continue.
Experience with polyurethane (Thorateca) vascular access grafts for
hemodialysis. G. Passaris, E. Savdie, f.M. Hayes, J. Crozier, A. Meek, A.
Graham, R.S.A. Lord, and C. Turner, Departments of Renal Medicine and
Vascular Sutyeiy, St. Vincent's Hospital, Darlinghurst, NSW, Australia. A
new synthetic vascular access device made of polyurethane, the Thoratec®
VAG graft (PUG.), has been proposed by its manufacturer as an advance
on existing devices due to its sealing properties, which are said to enable
cannulation after insertion. To evaluate the device, it was used routinely in
all hemodialysis patients requiring A-V access, but unsuitable for native
A-V fistula formation, between 31/03/1994 and 30/11/1994. Seventeen
devices were placed in sixteen patients (8 male, 8 female; mean patient age
58.9 years) by four surgeons. All surgeons felt the use of a tunnelling
instrument was essential because of the high compliance of the PUG. At
surgery, heparin and antibiotics (cephalosporins or vancomycin amin-
oglycosides) were used in all patients. Eight grafts were functional after 3
months. During this time, four grafts were lost (2 because of recurrent
thrombosis; and 1 each removed because of infection and vascular
"steal"). The actuarial three month graft survival was 72.4%. Thirteen
grafts were successfully cannulated within four days of operation and
thereafter. Cannulation was delayed for 6, 7, 31, and 42 days in four
instances because of edema and/or hematoma. Eleven thrombotic epi-
sodes were observed in five patients; nine of these were successfully
treated by thrombectomy. In two cases, however, thrombosis resulted in
loss of graft. Often patients with previous access device thrombosis, four
had subsequent PUG. thrombosis. This compared with PUG. thrombo-
sis in one of six patients without previous access device thrombosis.
Nursing staff and patients reported that PUG. was easier to cannulate
and bled less after decannulation than polytetrafluroethylene (Goretex®)
grafts. Despite the uncontrolled nature of this study the data: (i) confirm
that in most cases the PUG. can be cannulated within days of placement,
dispensing with the need for temporary vascular catheters in many cases;
(ii) suggest a device survival for P.U.G. similar to Goretex®; (iii) indicate
that polyurethane has very acceptable physical characteristics for cannu-
lation and decannulation.
Endovascular procedure in the maintenance of arteriovenous tIstula
patency. R. Awardt, G. Fitt, and AK. Roberts, Renal Unit and Vascular
Units, Austin Hospital, Heidelberg, Australia. Endovascular procedures such
as angioplasty and intravascular stent insertion are increasingly being used
to treat arteriovenous fistula stenoses. Surgery may often he avoided and
distal veins can be preserved. In this study we have reviewed our
experience with these procedures to determine whether or not surgical
intervention can he successfully postponed for a significant period.
Twenty-four procedures were performed on 13 patients over a period of 2
years. All patients were followed for at least 6 months. Patients were
selected after intravenous venography if the lesions were suitable (that is,
if the lesion was short or of a proximal vein where surgical access would be
difficult). An intravascular stent was inserted if there was significant recoil
on post-dilation films. Ten of the dilations were of proximal veins and four
included stent placement. There was an initial success rate of 75% (18 of
24). The primary patency rate (defined as the percentage of flstulae patent
without any further intervention) after 15 months was 28.4%. The
secondary patency rate (defined as the percentage of fistulae patent
without any surgical intervention, that is, endovascular procedures were
allowed) after 15 months was 46.1%. These patency rates compare well
with other published series, and suggest that repeated endovascular
procedures of arteriovenous fistulae can significantly delay the need for
surgical revision and assist in prolonging fistulae life.
Use of a dialysate proportioner to calculate urea clearance. MB.
Fraenkel, and J.K Dawbom, Renal Unit, Austin Hospital, Heidelbeig,
Victoria, Australia. There has been increasing emphasis on the importance
of regular assessment of dialysis efficiency. We have compared three
formulae for calculating Kt/V (all of which can be processed using a
pocket calculator) to Kt/V derived from direct quantitation of urea
removed on hemodialysis. A "dialysis proportioner" was used to collect
1/25 of total dialysis effluent obtained during a four-hour mid-week
hemodialysis. The volume of effluent was measured and urea concentra-
tion determined. Pre- and post-dialysis body weights were recorded.
Formulae for calculating Kt/V were (1) W/5 + 2.5W [(U1 — U2)/t], (2)
1.18 X —In(R), (3) 2.2 — 3.3 X (R — 0.03 — Uf/w) where (W = dry
weight, U1 = pre-dialysis urea, U2 post-dialysis urea, t = time between
dialyses, R = urea reduction ratio, Uf = volume removed on dialysis.
Urea clearance (4) was calculated using V/U (V = total body water X
mean plasma urea during dialysis, U = total urea removed). Results in five
patients have been analyzed to date. There was no difference between
Kt/V calculated using (2) and (3) presumably because no patient had
weight loss of > 2.5 kg. There was close agreement in derived Kt/V using
(1) and (4). In two patients Kt/V derived using (1) and (4) were sufficiently
different from (2) and (3) to have influenced management. In conclusion,
use of the dialysis proportioner enables direct quantitation of solutes
(including urea) in dialysis effluent. Direct comparison between different
dialysis regimes will also be possible.
Continuous veno-venous hemodiafiltration (CVVHD) using bicarbon-
ate-containing dialysate in critically ill children. PH. Henning, D. Roy,
R.J. Hogg, P. Wilby, and K.F. Jureidini. Department of Nephrology, Women's
& Children's Hospital, North Adelaide, South Australia. To avoid the risk of
lactic acidosis when using lactate buffered dialysate for continuous arterio-
venous or veno-venous hemodiafiltration in patients (CAVHD or
CVVI-ID) with hepatic and renal dysfunction, we have used bicarbonate
buffered solutions. We report our experience with 11 children treated in
this manner between 1988 and 1994. The mean age was 4.5 5.5 years
(range 3 days to 14 years). Access was via dual-lumen external jugular or
femoral vein catheters. Hemofilters were chosen on the basis of patient
size and dialysis requirements. Bicarbonate buffered dialysis solution was
prepared in a novel fashion. Shortly before use supplementation of a
specially prepared base solution with commercially available electrolyte
solutions was used to achieve the desired electrolyte concentrations. The
mean ultrafiltration rate was 41.4 35 mI/hr. Urea and creatinine
clearances were 15.3 6.6 and 16.4 8.62 mI/mm, respectively. Metabolic
acidosis was readily controlled in all cases. Seven of the 11 patients
ultimately recovered normal renal functions.
Influence of volume status on echocardiographic findings in hemodial-
ysis patients. PG. Kerr, J. Gelman, and KC. Wong, with the technical
assistance of L. Donelan, Departments of Nephrolo' and Cardiolo',
Monash Medical Centre, Clayton, Victoria, Australia. Echocardiographic
(echo) assessment of the cardiac status of hemodialysis (HD) patients has
become a frequently used tool, in part due to the high incidence of
coexisting hypertension and vascular disease. The question addressed by
this study was whether the fluid shifts experienced during HD sessions
significantly influences the echo findings. Ten stable HD patients, mean
age 47 5 years (range 20—64), were randomly selected for study without
bias to patients with known cardiac disease. Transthoracic echo studies
were performed immediately prior to and after a standard dialysis session.
Standard echo parameters were assessed at each time point and the weight
loss achieved in the dialysis session was recorded. The results revealed a
significant reduction in chamber sizes following HD with a mean loss of
1.5 (1.3 kg: the LVED diameter fell from 5.02 0.20 to 4.60 0.16 cm
(P < 0.05), the LVES diameter from 2.84 0.22 to 2.47 0.22 cm (P <
0.05), and the LA size from 4.29 0.23 to 3.83 0.22 cm (P < 0.05).
Fractional shortening and wall thickness did not change. The isovolumet-
nc relaxation time and deceleration times were also unaltered by the fluid
shifts. On the other hand, the early diastolic filling velocity was signifi-
cantly altered by dialysis, being 0.73 0.05 m/sec pre-HD and 0.56 0.04
m/sec post-HD (P < 0.005), whereas the late diastolic (atrial) filling
velocity remained unchanged—0.82 0.05 m/sec pre-HD vs. 0.74 0.07
m/sec post-HD (P = NS). The early:late filling velocity ratio was low at
both time points, more so post-HD——0.91 0.06 pne-HD vs. 0.82 0.09
post-HD (P < 0.05). This latter ratio indicates impaired diastolic filling,
masked to a degree by volume overload pre-HD. There was no correlation
between any of the echo parameters and the weight loss achieved. These
findings suggest that although fluid shifts during HD do not grossly
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influence echo findings, comparative studies in a given patient should he
performed at the same point in the dialysis cycle. In addition, diastolic
filling impairment was common (8/10 patients post-HD) and this finding
may he masked by volume overload.
T cell depletion reduces augmentation of glomerular tissue factor and
glomerular fibrin deposition in crescentic glomerulonephritis. J. H. Erlich,
P. G. Tipping, and S.R. Holdsworth, Centre for Inflammatoty Diseases,
Monash University Department of Medicine, Monash Medical Center, Clay-
ton, Victoria, Australia. Augmented glomerular tissue factor (TF) activity is
associated with glomerular infiltration of macrophages, T cells and
prominent fibrin deposition in human and experimental crescentic gb-
merulonephritis (GN). Macrophages are responsible for this augmented
TF and its association with glomerular T cell infiltration suggests that
sensitized T cells may play an important role in augmenting macrophage
TF expression via a DTH like mechanism. Although T cells may direct
up-regulation of monocyte TF in vitro, their role in activating glomerular
macrophages and augmenting TF in vivo is uncertain. The role of T cells
in inducing glomerular fibrin deposition (GFD) and glomerular TF was
assessed in crescentic GN, induced in presensitised rabbits by i.v. injection
of 25 mg/kg of horse anti-rabbit gbomerular basement membrane globulin.
Rabbits were treated with either a monocbonal anti-rabbit CD5 or an
irrelevant monoelonal control antibody (50 mg/kg) one hour prior to
anti-GBM globulin, followed by a daily dose of 20 mg/kg. Depletion of
circulating T cells was assessed by flow cytometry of peripheral blood and
tissue depletion was assessed by immunostaining of the kidney and spleen.
T cell accumulation in glomeruli was prevented by treatment with
anti-CD5 antibody. On day 4 after anti-GBM globulin, glomerular TF
activity, assessed in a one stage prothrombin assay, was significantly
reduced (anti-CD5 treated 101 16 mU/lU3 glomeruli, control 202 17
mU/103 glomeruli, p 0.0015). GFD, assessed semiquantitatively by
immunofluorescence (0 to 3+), was also significantly reduced, although
this effect was relatively modest (anti-CD5 treated 1.49 0.04, control
1.75 0.06, P = 0.003). These data demonstrate that T cells significantly
augment glomerular TF expression in crescentic GN, providing evidence
for T cell directed macrophage activation akin to DTH in this disease. The
modest reduction in GFD suggests that either a profound inhibition of TF
expression is necessary to prevent fibrin deposition or other procoagulant
or fibrinolytic molecules such as PAl-I, not directly under T cell control,
play an important role in controlling GFD.
Expression of human CDS9 by transgenic mice. CA. Somerville, B. Van
Denderen, J. Allison, M. Pearse, and A.J.F. d'Apice, Department of Clinical
Immunology, St. Vincent s Hospital, Victoria Parade, Fitzroy, and The Walter
and Eliza Hall Institute, Parkville, Victoria, Australia. Xenotransplantation
would provide a solution to the ever worsening shortage of donor organs
for transplantation. However, its clinical application is prevented by the
invariable occurrence of hyperacute rejection. Species restriction of the
membrane hound complement regulatory factors (CRF), which include
CD59, may account in part for this phenomenon. This study was under-
taken to examine the effect of expression of human CD59 in xcnogenic
cells and organs on their susceptibility to attack by human complement.
Transgenic mice were created by microinjection of a construct in which
CD59 eDNA is under control of the H-2K" promotor. Transgenic mice
were identified by Southern blot of genomic DNA. Using flow cytomctry
two mice have been demonstrated to express human CD59 on peripheral
blood leukocytes, at 30% and 50% of the level on human peripheral blood
leukocytes. An immunohistological tissue survey has demonstrated CD59
expression on renal endothelium. Cytotoxicity assays have shown that
murine splenic leukocytes expressing human CD59 are partially protected
from lysis mediated by human serum and the level of protection appears
to be related to the level of expression of the transgene. However, in a
Langendorf cx vivo heart perfusion model, no significant protection could
be shown of transgenic hearts compared to non-transgenic hearts exposed
to human serum. An immunohistochemical study of the rejected hearts is
underway. Mice expressing the CRF CD55 in addition to CD59 have been
created and will he analyzed in an identical fashion. In conclusion,
although CD59 affords significant protection of murine cells against
human complement, it is likely that additional CRF's will he needed to
avert the hyperacute rejection of xenotransplantation.
Antibodies to endothelial cells (AECA) and epithelial cells (AEpCA) in
renal transplant recipients. L. M. Johnstone, R. G. Walker, and G.J. Becker,
Department of Nephrology, Royal Melbourne Hospital, Parkville, Victoria,
Australia. AECA have been described in different diseases affecting the
renal system, including renal transplantation (Tx). Their significance is
unclear, although it has been proposed that acute graft rejection may be
due to AECA. Rapid onset acute graft rejection has also been attributed
to AEpCA. The presence of AECA and AEpCA was investigated in 2
groups of patients: (i) Tx recipients with stable renal function compared
with controls (C); (ii) in sera from 11 patients who received renal
transplants studied at the time of an episode of acute rejection and
compared with pre-transplant sera. AECA and AEpCA were detected
using a cellular ELISA; AECA were tested against human unfixed
umbilical vein endothelial cells and AEpCA were tested against monkey
kidney epithelial cells (CSL) commercial cell line. Binding of cells was
exposed with goat anti-human immunogbobulin (IgG) and goat human
total immunoglobulin (Ig) with an alkaline phosphatase label. All sera
were tested in triplicate and ELISA ratio (ER) was calculated for each Set
of Sera, that is, ER (%) = [(sample OD — negative control OD)/(positive
control OD — negative control OD)] X 100. Results:
lgG % Total Ig %
AEpCA C (N = 22) 22.3 (0.0—88.8) 29.0 (0.0—90.6)
Tx (N = 41) 19.9 (0.0—74.6) 61.8 (0.0—369.0)
Median (range) P > 0.05. Wileoxon rank-sum test compared to C.
Eleven subjects studied at the time of an episode of acute biopsy proven
rejection and compared with pre-transplant levels showed no difference
between the pre-transplant ER and the rejection associated ER for both
TgG and total Ig for AECA and AEpCA (Wilcoxon matched paired test,
data not shown). It was concluded that both AECA and AEpCA did not
appear to play a role in acute allograft rejection and were not increased in
the general Tx population compared to C.
Gal alpha 1,3 Gal: The dominant xenoantigen. Its detection and role in
porcine and murine models of xenotransplation. M. Tange, Z. Zannettino,
A.M. Fournier, M.J. Pearce, R.J. Crawford, and A.J.F. d'Apice, Immunology
Research Centre, St. Vincent's Hospital, Fiztroy, Melbourne, and Bresatec
Ltd., Thebarton, Adelaide, Australia. Anti-Gal antibody, which binds to
terminal alpha 1,3 galactose (Gal), has previously been demonstrated to
bind to porcine organs and endothelium. It has a functional role in
xenotransplantation demonstrated in cytotoxicity assays of porcine aortic
endothelial cells (PAE) and in cx vivo models of xenotransplantation, lB4
lectin also binds to alpha 1,3 methyl galactopyranosyl sugars. A competi-
tion study of 1B4 lectin and anti-Gal antibody binding to PAE cells was
undertaken. Analysis of binding was determined by FACS. 1B4 bectin and
anti-Gal antibody both bind to PAE cells, but neither inhibits the binding
of the other, suggesting that they each bind at a different site on the Gal
epitope. Depletion of anti-Gal antibody was achieved by absorption of
human serum (NHS) on COS cells transfected with alpha 1,3 galactosyl-
transferase. COS cells, which are derived from an Old World monkey, do
not express Gal. This gene and a defective construct were transfected by
DEAE in a transient expression system. FACS analysis with 1B4 lectin
demonstrated Gal expression in COS cells transfected with alpha 1,3
galactosyltransferase. There was no expression in the cells transfected with
the defective construct. NHS was absorbed sequentially on 2 flasks of
transfected COS cells. Following absorption of the NtIS there was a 72%
decrease in IgG NHS binding to the pig kidney epithelial cell line (PKI)
and a 50% decrease in 1gM NIIS binding to PK1 cells. This supports the
role of anti-Gal as a major xenoantibody. The most effective means of
removal of alpha 1,3 Gal as a xenoantigcn will be by a gene knockout. The
129 SV mouse is an animal in which this technology is currently available.
A histological survey of 1B4 lectin binding in 129 SV mice was undertaken.
There is staining in the endothebium of all organs and in the glomeruli of
the kidney, in the bile ductules in the liver and in a perinuclear pattern in
the heart. Mouse lung stains strongly. This establishes the presence of
alpha 1,3 Gal.
The effects of chronic ouabain infusion in sheep. GB. Pidgeon, A.M.
Richards, M.G. Nicholls, R.R. Bailey, K.L. Lynn, L.K Lewis, and TG.
Yandle, Departments of Nephrology, Cardiology and Endocrinology,
AECA C (N = 22) 10.4 (1.4—37.0)
Tx (N = 53) 16.9 (2.5—87.0)
17.1 (5.3—48.2)
26.9 (0—75.9)
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Christchurch Hospital, Christchurch, New Zealand. To examine the contri-
bution of ouabain (Ou) to blood pressure control, we have studied the
haemodynamic, renal and hormonal effects of chronic Ou infusion in 8
Coopworth sheep on a controlled sodium diet. Placebo (5% dextrose) was
infused for 6 days, followed by Ou (0.25 mg/day) for 22 days, and then a
further 7 days of placebo infusion. Blood pressure (BP) and heart rate
(HR) were measured and 24 hr urine collections made daily. Weekly 24 hr
BP & HR recordings were made. The pressor response to infused
angiotensin II (All) was studied prior to, during, and after the Ou
infusion. Plasma concentrations of Ou and other vasoactive hormones
were measured. Mean Ou concentrations were greater than 1 nmol/l
throughout the infusion period but undetectable prior to commencing the
infusion. BP was unchanged by the Ou infusion, but HR was significantly
reduced during the first ten days of Ou infusion (P < 0.03). Mean 24 hr BP
was lower in the third week of Ou compared to either pre- or post-Ou
(P < 0.05), and mean 24 hr HR was lower in the first week of infusion (P <
0.02). The pressor response to All was similar in all phases of the study.
Daily urine volume fell below pre-Ou values in the first week of Ou (P <
0.01), and sodium excretion declined over the first ten days of infusion
(P < 0.05). Mean plasma renin activity & All concentrations decreased
after one week of Ou (P < 0.05), but aldosterone was increased (P = 0.05)
as was cortisol (P < 0.05). This study demonstrates, in sheep, that chronic
infusion of Ou does not cause hypertension nor alter pressor responsive-
ness, and it is not natriuretic. This study also fails to confirm reports that
Ou is an endogenous hormone.
A randomized, controlled trial comparing 1.25 mmol/Iiter calcium (Ca)
dialysate to 1.75 mmol/liter Ca dialysate in CAPD patients. D. W. Johnson,
R.J. Rigby, H.D. McIntyre, A. Brown, and J. Freeman, Department of
Nephrology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Effective control of hyperphosphatemia and hyperparathyroidism in
CAPD patients requires a combination of calcitriol and CaCO3, hut is
frequently limited by hypercalcemia. Reducing dialysate Ca concentration
may overcome this problem, but this has not been examined in a
controlled trial. Forty-five stable CAPD patients were randomly assigned
in a prospective, double-blind trial to either a study group (1.25 mmol/liter
Ca dialysate) or a control group (1.75 mmol/liter Ca dialysate) for 12
months. Twenty-three patients did not complete the study due to death
(9), transplantation (7), or conversion to hemodialysis (7). Eleven patients
in each group completed the study. Mean serum Ca, phosphate, ionized
Ca, aluminum, alkaline phosphatase and bone mineral density Z-scores
did not differ significantly at any time within or between the two groups.
Severe hypercalcemia was more common in the control group (11 vs. 2,
P = 0.027). Mean serum PTH and osteocalcin initially rose in the study
group, relative to controls at 3 months (40 7 vs. 12 3 pmol/liter, P =
0.004, and 33 5 vs. 15 2 jrg/liter, P = 0.002, respectively), but was not
sustained. Median weekly dosages of calcitriol and daily dosages of CaCO3
increased significantly in the study group (0 rg to I xg, P = 0.014 and
1260 g to 2520 g, P = 0.002, respectively), but not in controls. Supple-
mentary Al (OH)3 was required for phosphate control in both study (N =
5) and control patients (N = 4). In conclusion, lowering dialysate Ca
concentration reduces the frequency of severe hypercalcemia and allows
prescription of larger quantities of calcitriol and CaCO3. However, it may
potentially initially exacerbate secondary hyperparathyroidism. In this
study, there was no effect on bone mineral density or on A1(OH)3 intake.
Validation of BanW histological criteria for acute renal allograft rejec-
tion. W Hongwei, S.f. Chadban, R. Murugasu, A. Price, and R.S. Nanra,
Nephrology Unit and Division of Anatomical Pathology, John Hunter
Hospital, Newcastle, New South Wales, Australia. To validate the Banff
histological criteria for acute rejection, a retrospective study was under-
taken in 52 graft biopsies from 37 patients [mean age 43 years (SD 13) and
fema!e:male ratio 1.2:1] taken during acute rejection episodes (AREs). All
AREs were confirmed by: (1) acute rise in mean 5Cr from 171 (SD 85) to
338 (SD 268) jzmol/liter; (2) histological evidence of acute rejection by
standard criteria in adequate biopsies (7 glomeruli and arteriole/
section); and (3) decline in mean Sr to 141 (SD 83) xmol/litcr with
antirejection therapy, or graft loss with refractory rejection (7 cases).
Original standard grades rejection are as tabulated; all slides were masked
and graded independently by 4 blinded observers using the Banff Criteria:
Banff
rejection
grade
Observer Standard
rejection
grade1 2 3 4
Borderline 19 21 18 22 29 (Mild)
I 21 16 23 18 13 (Moderate)
II 8 9 6 7 4 (Severe)
III 4 6 5 5 6 (Vascular)
There were no significant differences between observers (P = 0.85) and
between Banff and standard rejection grades (P = 0.24). By Banif criteria
38% of AREs would receive no antirejection treatment compared to 0%
using standard criteria (P < 0.001). It is concluded that Banif criteria for
acute rejection are reproducible, hut may lead to undertreatment of mild
rejection episodes.
The pathogenetic mechanism of hepatitis B virus (HBV)-related gb-
merubonephritis. K.N. Lai, R. T.H. Ho, P. Li, and F.M Lai, Departments of
Medicine and Pathology, The Chinese University of Hong Kong, Hong Kong.
Glomerular deposition of HBV antigens is observed in chronic HB5Ag
carriers with different glomerulonephritides, yet the pathologic role of
HBV remains uncertain. We examined the paraffin section of kidney
biopsies from 40 chronic HB5Ag carriers with membranous nephropathy
(MGN), mesangiocapillary glomerulonephritis (MCGN), or IgA nephrop-
athy (IgAN) for HBV DNA using in Situ hybridization (IS H). Glomerular
HBV antigens were present in all biopsies by immunofluorescence.
HB5Ag or HBcAg mRNA was studied in RNA extracted from frozen
renal tissue using a two-step polymerase chain reaction (PCR) following
reverse transcription (RT). HBeAg were detected in 79%, 50%, and 28%
of sera from chronic HBsAg carriers with MGN, MCGN, and IgAN,
respectively. HBcAg or HBsAg DNA was not easily detected with ISH
alone, but was readily found in 31 biopsies (78%) following PCR. HBV
DNA was detected mainly in the cytoplasm of the proximal tubular
epithelia but not in glomerular cells. HB5Ag and/or HBcAg mRNA were
detected in 13 biopsies (33%). The PCR findings were further confirmed
by: (a) Southern blot hybridization using a cloned HBV probe; and (b)
absence of PCR product following treating RNA with RNase or omitting
the RT. The detection of HBV DNA and RNA in kidney tissue indicates
HBV viral replication in these HBV-related glomerulonephritides. The
localization of HBV only in renal tubular epithelia but not in glomerular
cells suggests these are circulating immune complex-mediated diseases.
The development of a particular glomerular pathology (MON. MCGN, or
IgAN) in any individual HBsAg carrier is likely, in part, influenced by the
HBeAg status in circulation.
Proteinuria in early aminonucleoside nephrosis (PAN) is associated
with in Situ glomerular reactive oxygen species (ROS) generation and lipid
peroxidation (LPO). T.J. Neale, P.F. Davis, N.S. Greenhill, B.M. Ruger, and
D. Kerjaschki, Wellington School of Medicine NZ, and University of Vienna,
Austria. ROS are implicated in proteinuria production in PAN, a model of
human minimal change GN. Up-regulation of respiratory burst cyto-
chrome b558 mRNA in PAN glomeruli, and increased b558 protein
expression in glomerular epithelial cells (GEC) 7 days after disease
induction, suggested an intrinsic glomerular cell origin for ROS. Macro-
phages/glomerular cross-section (gcs) were similar in PAN and controls
(1.25 0.10 vs. 1.40 0.10 macs/gcs; NS). Glomerular [H2O2] in vivo was
quantitated by catalase assay after aminotriazole administration (control
29.36 2.54 SEM vs. PAN 14.05 0.82 nrvi H2O2 consumed/mm/mg
protein; P < 0.005), and a viva by scopoletin assay (PAN 2.15 0.52 SEM
vs. control 0.29 0.05 nmol H2O2 production/mg glomeruli; P < 0.005).
H2O2 was localized by a vivo cerium EM histochemistiy to GBMs and
GEC in PAN but was absent in controls. Malondialdehyde (MDA) was
detected with antibody specific for MDA-lysine adducts in PAN glomer-
ular sections and denuded GBMs by IF. Lipid peroxides were quantitated
in glomeruli (PAN 209.4 6.9 vs. control 148.0 7.6 SEM nmol MDAJg
glomeruli; P < 0.005) and on isolated GBMs (PAN 16.93 0.33 vs.
control 12.40 0.02 SEM nmol MDA per mg protein; P < 0.005).
Immunoblot with anti-MDA antibody on PAN glomerular extracts indi-
cated that an --220 kDa protein (shown to be type IV collagen derivatized
in its NC-i and triple helical domains), received MDA adducts. The
functional role of LPO in PAN was proven by prior treatment with the
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anti-LPO agent probucol (P), which markedly reduced proteinuria (P-
treated 28 6 vs. PAN 186 8 mg protein per 24 hrs; P < 0.01), the IF
signal for MDA and the of MDA concentration within glomeruli (41.0
1.45 PAN vs. P & PAN 29 0.85 ng MDA/mg protein; P < 0.01).
Simvastatin pre-treatment (serum cholesterol reduction equivalent to
P-pre-treated rats) did not inhibit proteinuria in PAN. ROS are generated
in situ in PAN and LPO-induced MDA adduct formation on glomerular
cells, and type IV collagen within GBMs is associated with production of
proteinuria.
Expression of CD44 by mesangial cells in culture, in the THY 1.1 model
and in human mesangial proliferative glomerulonephritis. P. Roy-
Chaudhuiy, T. Khong, J.H. Williams, NE. Haites, B. Wu, and D.A. Power,
Departments of Medicine and Therapeutics and Molecular and Cell Biology,
University of Aberdeen, Scotland, United Kingdom, and The Immunology
Research Centre, St. Vincent's 1-lospital, Melbourne, Australia. Cytokines are
important in the pathogenesis of mesangial proliferative glomerulonephri-
tis (MPGN). Binding to proteoglycans in the extracellular matrix regulates
cytokine function. Since the transmembrane molecule CD44 is a receptor
for the proteoglycan hyaluronic acid and may itself possess glycosamino-
glycan side chains, we studied its expression by mesangial cells in
mesangial proliferative glomerulonephritis. Immunohistochemical stain-
ing for CD44 in the mesangium was markedly increased at 4 days after
induction of the rat Thy 1.1 model of mesangial proliferative glomerulo-
nephritis but declined over the next 5 days. This coincided with the peak
of mesangial cell proliferation and macrophage infiltration assessed by
staining for a-smooth muscle actin and proliferating cell nuclear antigen
(PCNA) and the macrophage marker ED-i. Fifteen human renal biopsies
with IgA nephropathy, however, showed no change in mesangial staining
for CD44 with two anti-CD44 monoclonal antibodies. There was strong
staining of infiltrating cells, cellular crescents and cells present within
tubules, confirmed by staining of another 64 renal biopsies with a variety
of diseases and compared with the pattern in 5 normal kidneys. Cultured
human mesangial cells expressed CD44 strongly when assayed by immu-
nohistochemistry, immunoprecipitation and Northern blot. Mesangial
cells expressed the 85 kDa protein and mRNA species of 1.6, 2.2 and 5.0
kb typical of mesodermal cells. CD44, therefore, is another example of a
protein strongly expressed by mesangial cells in vitro and weakly or not at
all in vivo, but which is up-regulated in a disease model. It was not,
however, up-regulated by mesangial cells in human mesangial proliferative
glomerulonephritis.
Gene expression of TGF-fi1 and SPARC in the rat remnant kidney. L.L.
Wu, A. Cox, R. Gilbert, M. Cooper, and Cf. Roe, University of Melbourne,
Department of Medicine, Heidelberg Hospital, Victoria, Australia. Over
production of cytokine transforming growth factor (TGF-p1) has been
found to promote matrix accumulation in several animal models of kidney
disease. The molecular mechanism involving interactions between growth
factors and extracellular matrix (ECM) remain unclear. Secreted protein,
acidic and rich in cystelne (SPARC), participates in tissue repair by
regulating the turnover of ECM and is itself regulated by TGF-j31. This
study evaluates the gene expression of TGF-p1 and SPARC in a rat
remnant kidney model following variable renal ablation. Male Sprague-
Dawley rats weighing 200 to 250 g were randomly divided into 5/6th (FSN,
N = 30) and 1/6th (OSN, N = 30)ablation. Ten rats from each group were
killed at 4, 12 and 16 weeks post-surgery. Remnant kidney weight, systolic
blood pressure, 24-hour urine protein and serum creatinine were mea-
sured. histologic abnormalities were quantitated by point-counting.
mRNA expression of TGF-1 and SPARC were evaluated by Northern
analysis. FSN developed progressive renal failure, hypertension and
proteinuria associated with marked tuhulointerstitial fibrosis and glomer-
ulosclerosis compared to OSN. There was a 2.0- (P < 0.05), 2.2- (P < 0.05)
and 1.8 (P < 0.01)-fold increase in mRNA TGF-p1 expression in FSN
versus OSN at 4, 12 and 16 weeks, respectively. SPARC was also increased
1.8- (P < 0.05), 1.6- (P < 0.05) and 1.9 (P < 0.01)-fold, respectively, in
FSN versus OSN. Interstitial fibrosis correlated with both TGF-1 and
SPARC expression. We conclude that in 5/6th renal ablation there is
persistent expression of TGF-1 and SPARC in association with progres-
sive renal failure and interstitial fibrosis. Further investigation of the roles
of TGF-p1 and SPARC in progressive renal failure is warranted.
Advanced glycation is an important pathogenic process in experimental
diabetic nephropathy. T. Soulis, S. Sastra, V. Thallas, J. Berka, B. Mc-
Wiliam, R.P. Mun-ay-Mclntosh, R. Gilbert, Ti. Neale, G. Jerum4 and ME.
Cooper, Departments of Medicine, Heidelberg Repatriation/Austin and Well-
ington Hospitals, Australia and New Zealand. Advanced glycated end
products (AGEs) that accumulate as part of a non-enzymatically mediated
reaction between glucose and proteins, are thought to play an important
role in the development of diabetic nephropathy. Our own studies have
shown an increase in AGEs, as measured by their specific fluorescence
(Ex370, Em 440 nm), after 32 weeks in the streptozotocin diabetic kidney
[Control (C) 6.5 1.0, Diabetic (D) 25.4 2.4 units/mg proteini, which
can be prevented by aminoguanidine, a phenyl hydrazine derivative [(DA)
7.7 0.9 units/mg protein]. These findings were confirmed by measuring
AGEs using a specific radioimmunoassay (C 2827 883, D 7765 492,
DA 3549 239 units/ng RNAase). A receptor for these AGEs known as
RAGE has been recently cloned from bovine lung. The present study has
explored the localization of both AGEs and RAGE in rat kidney.
Formahin-fixed and paraffin embedded tissue sections were cut from
normal Sprague-Dawley rats (N = 9), rehydrated, incubated in protein
blocking agent for 20 minutes at room temperature, washed in PBS, and
exposed to primary antibody (rabbit anti-AGE-KLH or anti-human
recombinant RAGE) for 30 minutes at room temperature. Samples were
washed again and incubated with biotinylated goat anti-rabbit IgG fol-
lowed by peroxidase-conjugated avidin. Diaminobenzidine tetrachloride
was used to reveal localization of peroxidase conjugates. There was
widespread staining in lung parenchymal tissue for RAGE (positive
control for RAGE) and AGEs. In the kidney, there was co-localization of
AGEs and RAGE in collecting ducts and distal tubules. In addition, there
was staining of the macula densa, afferent arterioles and the podocytes
within the glomeruli. There was no significant staining of proximal tubules.
There was also co-localization of both AGEs and RAGE in other tissues
that are susceptible to diabetic vascular injury such as the retina and aorta.
The co-localization of AGEs and their receptor in sites of diabetic
microvascular injury may indicate a mechanism for the genesis of diabetic
complications. Modulation of the receptor for advanced glycated end
products or inhibition of AGE formation with aminoguanidine have the
potential to influence the progression of diabetic nephropathy.
Heparin-binding epidermal growth factor (HB-EGF) mRNA expression
in mesangial cells and the THY 1.1 model. M. Polihronis, M. Pearse, B.
Murphy, and D. Power, Immunology Research Centre, St. Vincent's Hospital,
Fitzroy, Victoria, Australia. HB-EGF is a one of several ligands for the
epidermal growth factor receptor. It is a potent mitogen for smooth
muscle cells, fibroblasts and keratinocytes but not endothelial cells, and is
synthesized by smooth muscle cells and macrophages. To determine
whether this cytokine is involved in the pathogenesis of mesangial
proliferative glomerulonephritis, we have amplified a 510 bp eDNA
fragment encoding mature rat HB-EGF by PCR and cloned it into
pGEM-T. The fragment was completely sequenced on one strand and
found to be identical to the published rat sequence. This fragment was
labeled with 32P and used to probe Northern blots of total RNA from rat
mesangial cells. A 2.5 kb band was obtained in cells growing at confluence
in medium containing 10% fetal calf serum. mRNA for HB-EGF was not
detectable in serum-starved cells. Treatment of the cells with cyclohexi-
mide showed that HB-EGF is an immediate-early gene for these cells.
Cytokines (PDGF-BB, EGF, TGF-a, TNF-a, TGF-p) also induced its
synthesis but none was as effective as 10% serum. In situ hybridization
studies were then performed using the non-radioactive digoxigenin sys-
tem. mRNA transcripts were present in every cell of a population of
cycling niesangial cells by in situ hybridization, suggesting that HB-EGF
mRNA levels were not cell cycle dependent. In normal kidney, HB-EGF
mRNA transcripts were present in occasional tubules by in situ hybridiza-
tion and the glomeruli were negative. Within 30 minutes after induction of
the Thy 1.1 model, however, there was expression within the glomerulus,
Bowman's capsule and an increased number of tubules. Staining within
the glomerulus was more marked at day 4 after disease induction but
declined thereafter. These studies show that HB-EGF mRNA is produced
by cultured mesangial cells and suggest that HB-EGF may be involved in
the pathogenesis of the Thy 1.1 model of glomerulonephritis.
Local macrophage proliferation in glomerular crescent formation in
experimental anti-GBM glomerulonephritis (GN) in the rat. H.Y. Lan,
D.J. Nikolic-Paterson, M Mu, and R.C. Atkins. Department of Nephrology,
Monash Medical Centre, Clayton, Victoria, Australia. We have previously
demonstrated that macrophages are the major cell type within cellular
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crescents in experimental anti-GBM GN and that macrophages play an
important role in crescent formation and development. The present study
addressed the issue of whether macrophage accumulation within cellular
crescents was the result of cell recruitment or if local proliferation played
a role. Macrophage proliferation was investigated in rat accelerated
anti-GBM GN using a newly developed, sensitive double-immunostaining
method in which microwave oven heating was used to retrieve cytoplasmic
and nuclear antigens and to denature bound native antibodies/enzymes
during the first round monoclonal antibody (mAb) staining. This treat-
ment completely prevents antibody cross-reactivity during the second
round of mAb staining. Macrophages were detected by cytoplasmic
labeling with the ED1 mAb and proliferating cells were detected by
nuclear staining with a mAb (PCI0) against the proliferating cell nuclear
antigen (PCNA). This system allowed clear identification of ED1PCNA
double positive cells. Groups of 4 rats were killed on days 14, 21 and 28
after injection of anti-GBM serum. All animals developed significant
glomerular crescent formation (25—80%) and EDI + macrophages was the
major cell type involved, accounting for 50—80% of total crescent cells. A
dramatic finding was that 61 3.2% of EDI * macrophages within
crescents expressed PCNA, accounting for 73 1.1% of total PCNA
cells within crescents. The local nature of macrophage proliferation within
crescents was demonstrated by the complete lack of PCNA expression in
blood monocytes. In addition, proliferating macrophages were invariably
associated with areas of focal glomerular sclerosis and local Bowman's
capsular rupture, suggesting that these cells play an important role in
mediating severe local tissue injury. In conclusion, this is the first study to
demonstrate that local macrophage proliferation is a major mechanism in
macrophage accumulation during crescent formation and suggests that
proliferating macrophages also participate in mediation of severe tissue
injury.
Long-term follow-up of adults with reflux nephropathy. Y Y Zhang and
R.R. Bailey, Department of Nephrology, Christchurch Hospital, Christchurch,
New Zealand. To assess the long-term follow-up of patients with reflux
nephropathy, we reviewed 294 patients over 15 years of age (females 235;
Caucasians 288) who were on our departmental computer database on 28
Feb. 1994 and had not reached end-stage renal failure. The mean age of
the patients at first presentation was 17.3 years (SD 14.4 years; range 3
weeks—72 years). One hundred and seventy-six of the patients had
unilateral reflux nephropathy and 118 bilateral reflux nephropathy diag-
nosed on intravenous urography and/or DMSA scintigraphy. At initial
presentation the majority of patients, particularly women, presented with
a urinary tract infection, 25 (8.5%) had hypertension, 15 (5.1%) loin or
abdominal pain, 14 (4.8%) proteinuria and six (2%) renal insufficiency. At
the last follow-up (mean age 34.2 years; SD 13.7; range 15 to 81) 113
patients (38%) had hypertension or were on antihypertensive therapy.
This was significantly more frequent in those with severe bilateral renal
parenchymal scarring. Proteinuria was present in 92 (31%) patients; 40 of
these had a creatinine clearance <70 mI/mm. A total of 71 patients (24%)
had a creatinine clearance <70 mI/mm and 43 (15%) a urinary tract
infection. A urinary calculus had occurred in 18 patients (2%). Hyperten-
sion, proteinuria and renal insufficiency were significantly more frequent
in those with severe bilateral reflux nephropathy. We conclude that
patients with reflux nephropathy, and particularly those who have protein-
uria, hypertension or renal insufficiency, should be under long-term
nephrological follow-up.
Thin basement membrane disease—clinical features compared with
IgA nephropathy. R. Auwardt, J. Savige, R. Sinclair, W 1-leale, P. Miach,
and D. Wilson, Renal Unit, Austin Hospital, Heidelberg, Victoria, Australia.
Thin basement membrane disease and IgA nephropathy are recognized as
common causes of persistent hematuria. The full clinical spectrum and
prognosis of thin membrane disease, however, requires further definition.
This study aims to clarify this and compare the clinical features of the two
conditions. Available medical records of 71 patients with a pathological
diagnosis on electron microscopy of thin membrane nephropathy were
examined. Similarly, medical records of 32 patients with a diagnosis of IgA
nephropathy, made on the basis of renal biopsy histology and immuno-
flourescence, were also examined. The age range of the two groups of
patients are similar: 10 to 68 years (median 34 years) for thin membrane
disease and 5 to 61 years (median 31 years) for IgA nephropathy.
However, thin membrane disease was significantly more common in
females (84.5% female, 60 of 71) compared with IgA nephropathy (37.5%,
12 of 32). This may reflect a referral bias. There were statistically
significant increases in the amount of hematuria and proteinuria found in
patients with IgA nephropathy compared with thin basement membrane
disease (hematuria >100,000RBCs/ml; 83.4%, 26 of 31 vs. 44.6%, 25 of 56,
P < 0.001; and proteinuria >1 g; 11.3%, 8 of 71 vs. 40.6%, 13 of 32, P <
0.001). In addition, at the time of biopsy patients with IgA nephropathy
were more likely to have abnormal renal function (Cr >0.11 mmol/liter,
21.9%, 7 of 32 vs. 7.0%, 5 of 71, P < 0.05). At follow-up none of the 42
patients with thin membrane disease had progressed to a Cr >0.20
mmol/liter (followed for 6 months to 11 years, median 2.75 years) whereas
7 of 32 patients with IgA nephropathy had (followed for 7 months to 20
years, median 4.6 years, P < 0.05). Hypertension and macroscopic
hematuria were also more common at presentation in IgA nephropathy
but these differences were not statistically significant. In conclusion, the
patients with IgA nephropathy were found to have more significant renal
disease at the time of presentation and could progress to chronic renal
failure. However, patients with thin basement membrane disease were
characterized by microscopic or macroscopic hematuria with few other
renal findings. Proteinuria occurs but is not in the nephrotic range and
progressive renal impairment was not found. Although the long-term
prognosis of thin membrane disease appears good, further long-term
prospective follow-up studies are required.
Ocular abnormalities in thin basement membrane disease. J.A. Savige,
D. Colville, P. Branley, and D. Wilson, University Department of Medicine,
Department of Ophthalmopathy, Renal Unit, Austin Hospital, and Box Hill
Hospital, Melbourne, Victoria, Australia. Thin basement membrane disease
is a common condition that is characterized by diffuse thinning of the
glomerular basement membrane on ultrastructural examination. A
thinned glomerular basement membrane is also found in Alport syn-
drome, and retinal dots, corneal and lens opacities occur in this condition
because many structural proteins are common to Bruch's, Descemet's and
the glomerular basement membranes. We have examined the eyes of 16
patients with thin basement membrane disease, whose mean glomerular
basement membrane thickness was less than 250 nm. The patients had a
median age ut 48 years (range 30 to 63); 7/16 (44%) had glomerular
hematuria greater than 100,000 RBC/ml; 11/16 (69%) had proteinuria
greater than 0.15 g/24 hr and 5/16 (31%) had an elevated BP. Three
individuals (19%) had a positive family history. Vision was tested, and the
eyes examined by slit lamp, biomicroscopic examination and direct
ophthalmoscopy. Five patients (31%) had white corneal dots, one a
corneal dystrophy (6%) and lens dots were present in 2 patients (13%).
Retinal dots were present in 11/16 individuals (69%), the number varied
from 2 to 40, and they were principally located in the perimacular area.
There was no associated impairment of vision. There was no correlation
between the number of dots, and degree of glomerular hematuria or
proteinuria. These dots occur but much less often in patients with other
renal diseases. We are not certain of their origin but they may be
degenerate retinal epithelial cells. Retinal dots, and abnormalities of the
cornea and lens are common in patients with thin basement membrane
disease as well as in patients with Alport syndrome.
Ocular abnormalities in Alport syndrome. .1. Savige, D. Colville, D.
Wilson, P. Miach, W. Heale, G. Thomas, J. Agar, and P. Kerr, University
Department of Medicine, Ophthalmology Unit and Renal Unit, Austin
Hospital, Box Hill Hospital, and Renal Unit, Geelong Hospital and Renal
Unit, Monash Medical Centre, Melbourne, Australia. The characteristic
ocular abnormalities in X-linked Alport syndrome are anterior lenticonus,
and a dot and fleck retinopathy. We report here the ophthalmic findings
in patients with X-linked and autosomal Alport syndrome (6 patients from
5 families, and 2 unrelated patients, respectively). The eyes were studied
with a slit lamp, biomicroscopic examination with a 90D lens, direct
ophthalmoscopy and fundal photographs. In X-linked Alport syndrome,
anterior lenticonus was not observed, but a "scissor's reflex" suggesting
early lenticonus was present in one individual. Small white retinal dots
were demonstrated in all patients with X-linked Alport syndrome, even in
those individuals with normal renal function and hearing. Other abnor-
malities included corneal arcus, corneal dystrophy and dots, and lens
opacities. The patients with autosomal Alport syndrome had no anterior
lenticonus but retinal dots were present. We have observed these dots in
other individuals with and without renal disease and we are not certain of
their significance. Anterior lenticonus is uncommon in patients with
Alport syndrome. A florid retinopathy is found in some patients, but
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perifoveal retinal dots are common as are other abnormalities of the
cornea and lens.
Significance of focal and segmental hyalinosis and sclerosis (FSHS) in
IgA nephropathy. D.K Packham, H-D. Yan, T.D. Hewitson, KM. Nicholls,
P.S. Kincaid-Smith, and G.J. Becker, Department of Nephrology, Royal
Melbourne Hospital, Victoria, Australia. Between 1971 and 1991, 845
patients were diagnosed as having IgA glomerulonephritis on renal biopsy
performed at the Royal Melbourne Hospital. These patients were fol-
lowed for a mean period of 53 months post-biopsy (range 0 to 336
months). By the end of follow-up 147 (17%) of patients had developed
chronic renal failure (Cr > 0.2 mmol/liter) or end-stage renal failure.
Presenting creatinine >0.12 mmol/liter hypertension, nephrotic range
proteinuria, age >40 years and male gender, all correlated strongly on
univariate analysis with the development of chronic renal failure or kidney
disease (all P < 0.0001). However, a number of patients developing
chronic renal failure or end-stage renal failure already had renal impair-
ment (creatinine >0.12 mmol/liter at presentation). A separate compari-
son was performed of patients presenting with creatinine <0.12 mmol/liter
and either developing chronic renal failure or end-stage renal failure
within 5 years of biopsy (N = 18) and those with creatinine still <0.12
mmollliter after 5 years of follow-up (N = 186). Of the 18 patients who
deteriorated 6 (35%) were nephrotic at presentation and 9 (56%) had
focal hyalinosis and sclerosis on renal biopsy. This compared with 5 (3%)
patients with nephrotic range proteinuria and 16 (10%) patients with focal
hyalinosis and sclerosis among the 186 patients who did not deteriorate
(P < 0.0001). Thus, in patients with normal renal function at presentation,
the presence of nephrotic range proteinuria or focal hyalinosis and
sclerosis are strong predictors of adverse clinical outcome.
Tubular proteinuria as a marker of interstitial fibrosis in glomerular
and nonglomerular diseases. W. Hongwei, S.J. Chadban, and R.S. Nanra,
Nephrology Unit, John Hunter Hospital, Newcastle, NSW Australia. A
prospective cohort study was undertaken in 147 patients with renal
biopsies to define the association between interstitial fibrosis (IF) and
proteinuria (UPr); mean age 46 years (SD 18), female:male ratio 1:1.3, and
mean Sr 0.14 mmol/L (range 0.05—0.78). The biopsy diagnoses were:
primary glomerulonephritis, 94; chronic interstitial nephritis, 11; diabetic
nephropathy, 3; "normal', 6; and others, 29. IF and tubular atrophy (TA)
were graded semiquantitatively (Grades 0—3), and significant (P < 0.01)
ranked correlation coefficients were obtained between IF and S. (t
0.66), Upr/Cr (r = 0.31), albuminuria (UAIh)/Cr (r 0.35) and /32-
microblogulinuria (U<m)ICr (r = 0.36); similar results were obtained with
TA. % Global glomerular sclerosis (GGS) correlated only with S. (t =
0.49, P < 0.01). Forty of 147 biopsies obtained by graded random selection
were morphometrically analyzed, and significant correlation coefficients
were obtained between % interstitial volume (%IV) and 1/Se. (r =
—0.75,
P = 0.000), log Upr/Cr (r = 0.57, P = 0.000), log UAIS/Cr (r = 0.61, P =
0.000), log Ua2mICr (r = 0.56, P = 0.000), log% fractional excretion
(FE)a2,,, (r = 0.55, P < 0.001) and log% FEAIh (r = 0.68, P = 0.000).
%GGS correlated only with 1IS. (r =
—0.68, P = 0.000) and log% FEAIb
(r = 0.39, P = 0.022). Multivariable regression analysis of Upr indices with
morphometric indices gave significant results only between %IV and
logU2m/Cr (P = 0.048), and log%FEp2m (P = 0.001). U02m/Cr > 0.05
mg/mmol occurred in 44% of cases, and gave a sensitivity of 50%,
specificity of 91% in predicting Grades 2 and 3 IF. It is concluded that
increased Up2m excretion may be used as a marker of IF in renal biopsies,
particularly in giomerulonephritis, and therefore, represents an adverse
prognostic indicator.
Syndrome X and insulin resistance/hyperinsulinemia (JR/HI): The
basis of increased susceptibility of transitional populations to renal
disease (RD)? W. Hoy, Menzies School of Health Research, Darwin NT, and
The Lovelace Institutes, Albuquerque, New Mexico, USA. Australian Ab-
origines, U.S. Blacks and Hispanics, American Indians, Mexican Ameri-
cans, Europid Indians, and urban South African Blacks have rising rates of
type 2 diabetes and cardiovascular disease, and high rates of both diabetic
(D) and nondiabetic (ND) renal failure. This suggests a general suscep-
tibility to RD; it is probably marked by microalbuminuria/albuminuria
(MA/A), and a link to the metabolic/vascular syndrome through JR/HI is
proposed. JR/HI is widespread in these groups. In part familial, it
segregates with higher blood pressures (BP), dyslipidemia and cardiovas-
cular risk, and is necessary but not sufficient for development of hyper-
glycemia. MA/A is also widespread in both ND and D. It clusters in
families, marks the IR/HI and prediabetic states, increases with rising BP
and glycemia, and predicts, not only overt nephropathy, but also cardio-
vascular mortality, in both D and ND. Susceptibility to RD clusters in
certain D families, is marked by MA/A and associated with higher BPs;
biopsies often lack specific D changes. ND RD clusters in families, MA/A
marks the susceptibility, expression and progression are driven by BP
profiles, and immunologic and ultrastructural features can vary among
family members, and in individuals over time. Glomerulomegaly, often
with mesangial expansion, is frequent in D and ND subjects alike, and
perhaps is due to hyperperfusion or hypertrophy associated with IR/HI
and related growth factors. Other features are sometimes superimposed
(diabetic change, inflammation, immune deposits, etc.). The hypothesis is
supported by clustering of both D and ND RD in certain families, strong
family histories of D and ultimate development of D in many subjects with
ND RD, and submergence over time of ND-ESRD diagnoses within the
(presumed) D-ESRD category, as the epidemic of diabetes waxes in a
population. RD susceptibility thus becomes part of Syndrome X and its
vasculopathy, and amenable to the same interventions. RD expression,
like the progression of renal failure, becomes an interactive process,
relaxing constraints of current etiologic and morphologic categories.
Dyslipidemia and its relationship with parameters of coagulation and
fibrinolysis in renal disease. A.B. Irish, Oxford Renal Unit, The Churchill
Hospital, Oxford, England, United Kingdom. To define whether the dyslip-
idemia of chronic renal disease (CRD) and dialysis could contribute to
increased cardiovascular risk via induction of a hypercoagulable state;
lipids and lipoprotein(a) [Lp(a)], factor VII coagulant activity (fVIIc),
fibrinogen (fib), plasminogen activator inhibitor-i activity (PAIa) and
Prothrombin Fragment 1+2 (Fl +2) were measured in 134 patients with
CRD and compared with 32 healthy controls (N). Results by mode of
treatment [mean + SD except F1+2 and Lp(a) = median] are shown
below.
Mode (N) HD (28) CAPD (30)
Lp(a) 280 257
PAIa 8.0 4.2 12.9 7.4
Fib 339 51 417 88
fVIIc 167 64 189 48
F1+2 0.44 0.50
Mode (N) CRD (76) N (32)
Lp(a) 305 113"
PAIa 11.1 6.7 11.4 6.5
Fib 445 187 268 53"
fVIIc 176 63 139 39"
Fi+2 0.55 0.30"
Lp(a) mg/dl, tVIIc as %std, fib in mg/dl, Fl+2 flM and PAIa AU/mi.
"P < 0.05 by ANOVA between groups
Compared with N, all renal groups demonstrated increased fib, fVIJc and
Fl +2, consistent with a hypercoagulable state. All renal groups had
elevated triglycerides (TG) and Lp(a), but PAIa was not significantly
different from N. In all patients combined, fib correlated with LDL-
cholesterol (r = 0.45, P = 0.0001), fVIIc and PAIa correlated with TG (r =
0.30, P < 0.005 and r = 0.37, P < 0.001). Fi+2 correlated with age (r, =
0.41, P < 0.001) and modestly with fib and Vile (r = 0.20, r = 0.19, P =
0.08) but not with any lipid fraction or creatinine. Lp(a) correlated with
LDL (0.28, P < 0.05) and inversely with albumin (—0.22, P < 0.05).
Although the correlation of triglycerides with activation of factor VII and
with PAIa, and the increase in Fl +2 and fibrinogen in all groups suggests
that the hypercoagulability of CRD may, in part, be a consequence of the
dyslipidemia, prospective evaluation following lipid reduction is required
to establish whether these associations are causal, or arise from a common
response to metabolic perturbations of the uremic state.
Fatal calciphylaxis. G.S. Kirkland, R.D. Sinclair, H. Rotstein, and B.
Murphy, Departments of Nephrology and Dermatology, St. Vincents Hospital,
Fitzroy, Victoria, Australia. Calciphylaxis is a rare and often fatal condition
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most frequently seen in dialysis patients. It has been defined as a condition
of hypersensitivity with initial sensitization of the tissues and then
subsequent challenge with an agent with resultant calcium deposition. We
describe 2 patients with calciphylaxis in whom the sensitizing agent
appears to be hyperparathyroidism and the challenging agent warfarin.
The patients had similar characteristics: female; ages 47 and 57 years; a
long course of chronic renal failure before commencing hemodialysis; on
warfarin for aortic valve replacements for I and 2 years, respectively;
normal protein C and protein S levels; severe hyperparathyroidism;
calcium/phosphate products well controlled until the development of
symptomatic calciphylaxis; treatment with steroids before diagnosis made;
surgical parathyroidectomy and a fatal outcome from gastrointestinal
hemorrhage. Both patients exhibited very painful panniculitis, livedo
reticularis, ischemic ulcers with eschar formation and palbable cord-like
vessels with overlying cutaneous necrosis. The latter has not been previ-
ously described in calciphylaxis. We believe that the sensitizing agent in
these cases was hyperparathyroidism and the challenging agent may have
been long-term warfarin treatment. The latter has not been associated
with calciphylaxis previously, but has been associated with skin necrosis in
patients with protein C and S deficiency. In summary, we suggest that
dialysis patients with severe hyperparathyroidism starting on warfarin arc
at increased risk of fatal calciphylaxis.
Use of pamidronate in the treatment of bypercalcaemia associated with
renal failure. J. Kanellis, G. Mangos, J.A. Charlesworth, and B.A. Pussell,
Department of Nephrology, Prince Henry Hospital, Sydney, New South Wales,
Australia. The safety and efficacy of pamidronate (a bisphosphonate) are
well documented for the treatment of hypercalcemia of malignancy and
for decreasing the activity and hone pain of Paget's disease. The only
report of its use in renal failure has been in 10 patients on dialysis who
developed hypercalcemia due to the use of calcium-based phosphate
binders and vitamin D. We recently observed two patients with hypercal-
cemia and renal failure with Paget's disease and without evidence of
malignancy or sarcoidosis. Hyperparathyroidism may have been a contrib-
uting factor in one case but both patients had normal levels of parathyroid
hormone-related peptide. Serum calcium (Ca) decreased to normal levels
in both patients following intravenous (i.v.) pamidronate. The first patient
had widespread Paget's disease, significant renal impairment (creatinine
0.38 mmol/litcr) and hypercalcemia (corrected serum Ca 3.02 mmol/liter;
normal 2.10—2.55 mmol/liter) with marked hypercalciuria (24-hr urinary
Ca 10.9 mmol; normal 2.5 to 7.5 mmol). He had a 15 year history of
recurrent calculus formation and ureteric obstruction. Medications could
not be implicated in the cause of the hypercalcemia and there was no
history of immobilization. Following a single dose of 60 mg iv. pamid-
ronate, the serum Ca fell to 2.23 mmol/liter by day 7 and the urinary Ca
fell to 3.3 mmol/24 hr. The serum Ca remained in the normal range one
month after treatment. The second patient had Paget's disease localized to
the ilium and had been on hemodialysis for 5 months. He had not received
vitamin D supplements nor Ca containing phosphate binders. The cor-
rected serum Ca was elevated for several months (range 2.60—2.94
mmol/liter) hut rose further several weeks after commencing an alumi-
nium-containing phosphate binder (range 3.34—3.86 mmol/liter). The
parathyroid hormone level was not appropriately suppressed during this
time (3.6 pmol/liter, normal 0.5—4.9 pmol/liter). Following a total dose of
90 mg i.v. pamidronate over 5 days (3 equal divided doses) the serum Ca
fell to normal by day 10 and remained in the normal range two months
after treatment. There were no detectable adverse effects following
treatment in either patient. Intravenous pamidronate appears to be a safe
and effective therapy for a variety of causes of hypercalcemia in patients
with renal failure.
Partial parathyroid hormone (PTH) suppression by calcitriol in hyper.
calcemic renal transplant patients. D. W. Johnson, A. Brown, H.D. Mcin-
tyre, and C M. Hawley, Department of Nephrology, Princess Alexandra
Hospital, Brisbane, Queensland, Australia. Hypercalcemia due to persistent
hyperparathyroidism post-renal transplantation is common and can en-
gender significant bony morbidity. To assess the short-term efficacy and
safety of calcitriol as a potential treatment, we studied ten stable renal
transplant patients (3 males, 7 females) with good allograft function and
persistent hypercalcemia and hypcrparathyroidism for more than one year
after transplantation. Each patient received a 1 p.g oral dose of calcitriol
followed by regular biochemical monitoring of serum and urine for one
week. PTH fell significantly by 20% from 11.5 2.7 pmol/liter pre-
treatment to a nadir of 9.4 2.1 pmol/liter at 48 hours (P < 0.05), and
then returned towards baseline. Fractional excretion of calcium rose from
0.60 0.14% at baseline to 0.90 0.14% at 48 hours (P < 0.05). No
significant changes were seen in serum corrected calcium, free calcium,
phosphate or fractional excretion of phosphate throughout the study. We
conclude that post-renal transplant hyperparathyroidism is neither fixed
nor autonomous and can be partially suppressed by a single oral dose of
calcitriol without exacerbating hypercalcemia. Longer-term studies of the
role of oral calcitriol in post-transplant hypercalcemia are therefore
justified.
Role of dual.energy X-ray absorptiometry (DEXA) bone densitometry
in CAPD patients. D. W. Johnson, Ri. Rigby, H.D. Mcintyre, A. Brown, and
J. Freeman, Department of Ivephrology, Princess Alexandra Hospital, Bris-
bane, Queensland, Australia. To assess the clinical utility of bone densi-
tometry, we measured total body (TB), anteroposterior lumbar spine
(APL), femoral neck (FN), Ward's Triangle (WT) and skull hone mineral
densities (BMDs) using DEXA in 45 CAPD patients (19 males, 26
females). BMDs were then correlated with clinical, biochemical and
radiographic indices of uremic osteodystrophy. BMDs were not signifi-
cantly different from age- and sex-matched reference population data.
Considerable regional variation of BMD Z-seores were noted between FN
(—0.11 0.23), WT(—0.11 0.22) and APL (1.22 0.04). APL Z-scores
were significantly reduced in patients with prior fracture (—1.36 1.07 vs.
0.89 0.31), bone pain (—0.72 1.08 vs. 1.01 0.31) or steroid treatment
(—0.62 0.39 vs. 1.16 0.35). Increased BMD Z-scores for APL (1.82
0.57 vs. 0.38 0.29, P < 0.05), FN (0.32 0.36 vs. —0.38 0.29, P = 0.14)
and WT (0.45 0.38 vs. —0.45 0.26, P < 0.05) were found in patients
with radiographic hyperparathyroid bone disease. Both APL BMD Z-
scores and skull BMDs were weakly correlated with PTH (r = 0.33, P <
0.05 and r =
—0.33,P < 0.05, respectively) and with CAPD duration (r =
0.30, P < 0.05 and r = —0.30, P < 0.05, respectively). Generally, however,
TB and regional BMDs were poorly related to age, renal disease type,
CAPD and renal failure durations, serum aluminium, calcium, phosphate,
alkaline phosphatase, osteocalein and PTH. We conclude that the preva-
lence of osteopenia is not increased in (APD patients. Clinical and
biochemical parameters do not reliably predict BMD measurements, hut
prior steroids and bone symptoms are major risk factors for important
bone loss. Although DEXA can reliably detect osteopenia in different
skeletal regions, its usefulness in detecting osteodystrophy is limited by
confounding hyperparathyroid osteoscierosis.
Ultrasound assessment of joint involvement in dialysis related amy-
loidosis (DRA). R. Ptaznik, M. Lanteri and J.K. Dawborn. Department of
Radiology Austin Hospital and Renal Units, Fairfield and Austin Hospitals,
Melbourne, Victoria, Australia. DRA causes arthropathy, tendon thicken-
ing and damage, pathological fractures, carpal tunnel syndrome and
"amyloid hand." To plan treatment strategies it is important to clarify the
diagnosis and accurately define the structural changes in affected joints
and the extent of disease. We studied 25 chronic hemodialysis patients
with ultrasound to demonstrate changes in their shoulders, the most
commonly affected joint, as well as the hips and knees. Thirteen patients
demonstrated evidence of DRA in the shoulder, and symptoms related to
the severity of the US changes. These included: altered echogenicity of the
subscapularis and supraspinatus tendons (patchy hyper- and hypo-echoic
regions) in 22 joints; hypoechoic material surrounding the biceps tendon
in 19 joints; enhancement of cartilage reflection; punched-out erosions of
the humerus with soft-tissue intrusion; thickening and loculation of the
subacromial bursa and acromioclavicular joint, and thickening of the
tendons. Rotator cuff tears were present in 11 shoulders, and were
asymptomatic in 4, symptomatic in apparently normal tendons in 3 and
symptomatic in association with apparent DRA in 4. Hip and knee
symptomatology was not as pronounced, hut thickening of the periartic-
ular tissue of the hip was associated with evidence of amyloid deposition
in the shoulder. DRA can be demonstrated by US examination of the
texture and anatomy of the tissues of the shoulder joint and other affected
joints. These changes correlate with symptomatology, enabling non-
invasive diagnosis and assists in planning management and in study of the
natural history of the condition.
Changes in the carpal tunnel and hand in dialysis related amyloidosis
(DRA). M. Lanteri, R. Plaznik, and J.K. i)awhom. Renal Unit Fairfield
Hospital, Fairfield and Department of Radiology Austin Hospital, Heidelberg,
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Victoria, Australia. Recurrent carpal tunnel syndrome (CTS) is a common
manifestation of DRA in hemodialysis patients. They also develop a
stiffness of the hands and fingers interfering with hand function. Amyloid
deposition in the tissues of the wrist and hand is the main cause of these
syndromes. We have used ultrasound to study the wrists and hands of 25
chronic dialysis patients and correlate the changes related to amyloid
deposition with clinically relevant symptoms. Hypoechoic masses and
erosions of the radial cortex, and/or enlargement of a bursa above the
pronator quadratus muscle, were seen in 14 wrists, associated with CTS in
12 cases. In 6 other wrists with CTS these changes were not present, but
there was thickening of the tissues of the carpus when compared with
asymptomatic patients. The appearances suggest that amyloid is deposited
deep in the carpus, and would not be accessible to routine CTR and
perineural tissue sampling. Five patients with gross hand stiffness with
limitation of both flexion and extension of the fingers displayed amyloid
infiltration of the long flexor and extensor tendons and tendon sheaths in
the hand explaining their disability. DRA causing CTS and "amyloid
hand" can be simply and non-invasively demonstrated by ultrasound
allowing study of the natural history of the condition.
ATP synthesis in exercising leg muscle of dialyzed and undialyzed
uremic patients. C.H. Thompson, A. Irish, G.J. Kemp, B. Rajagopalan, P.
Styles, D.J. Taylor, and G.K. Radda, MRC Biochemical and Clinical
Magnetic Resonance Unit, Oxford Radcliffe Hospital, Oxford, England,
United Kingdom. Fatigue in chronic renal failure (CRF) may be partly due
to metabolic defects in skeletal muscle unrelated to any reduction in
hemoglobin (Hb). We used 31P magnetic resonance spectroscopy to study
bioenergetics in gastrocnemius in CRF during exercise until fatigue and
subsequent recovery. Dialyzed patients were compared with controls and
with undialyzed patients with CRF. Changes in pH and the phosphocre-
atine (PCr) concentration allowed measurement of the effective mito-
chondrial capacity (Q) (calculated from the PCr recovery rate) and the
rates of glycogenolytic (L) and oxidative (Q) ATP synthesis during
exercise. Near infrared spectroscopy estimated end-exercise muscle oxy-
gen supply.
Measurement
(mean SEM)
[Hh} gIdI
3 mm exercise
L mM/mm
Q mM/mm
Duration mm
Q mM/mm
P < 0.05 cf undialyzed, h P < 0.05 cf control)
After exercise, dialysed patients have reduced muscle re-oxygenation rate
as well as muscle blood flow. They show a significant reduction in effective
mitochondrial capacity resulting in a compensatory increase in glycogen-
olytic ATP synthesis. These bioenergetic abnormalities did not correlate
with exercise duration or with creatinine, [Hbj or re-oxygenation half-
time. Compared to controls, there was no metabolic abnormality in
undialyzed patients despite similar [FIb] to the dialyzed patients. Exercise
duration was significantly reduced in dialyzed patients but there is no
simple metabolic cause for this.
Acute bone edema in renal transplant recipients. H.L. Pilmore, and Ri.
Walker, Department of Nephrology, Dunedin Hospital, Dunedin, New Zea-
land. Acute migratory hone pain occurring in the early months post-renal
transplantation is unusual. We report two cases of acute severe bone pain
2—3 months post-living related kidney transplantation. The pain was
predominantly in the weight hearing joints and apart from the pain, there
were minimal clinical signs. Both recipients were on triple immunosup-
pressive therapy with normal graft function and no previous history of
renal bone disease. yclosporine was stopped in one case with no
alteration in symptoms. Plain X-rays were normal, and hone scans
demonstrated increased tracer uptake in all affected joints but were not
diagnostic. Bone alkaline phosphatase levels were markedly elevated.
Magnetic resonance imaging (MRI) defined the lesions more clearly.
There was decreased intensity in affected joints in TI weighted images and
enhanced brightness in T2 weighted and fat suppressed (STIR) images
consistent with bone edema. MRI allowed the differentiation between
migratory edema and the early development of avascular necrosis. In Case
1 the changes on MRI were poorly demarcated and serial scans demon-
strated changes in bone edema; the bone pain resolved spontaneously over
3 months. Case 2 had serial changes on MRI demonstrated demarcated
lesions in the femoral and tihial condyles of both knees highly suggestive
of early avascular necrosis. Surgical intraosseous pressures (elevated) and
intraosseous venography (diminished flow) and histology from decom-
pression bone cores confirmed early avascular necrosis. The bone pain
resolved over the next 3 months. These eases highlight the advantage of
serial MRI in the diagnosis and management of acute bone pain in renal
transplant recipients.
Recurrent pain in renal autotranspiants for loin pain hematuria
syndrome. A. Parnham, A.J. Low, D. Perlman, P. Finch, and M. Thomas,
Department of Nephrologv, Urology and Anaesthetics, Royal Perth Hospital;
and Perth Pain Management Centre, Perth, Australia. More than 50
autotranspiants have been performed worldwide for the loin pain hema-
tuna syndrome, with an estimated recurrence rate of 10%. The local
experience of autotransplantation for this condition was reviewed retro-
spectively. Over a two year period, 12 renal autotransplants, including one
sequential bilateral procedure, were performed on 11 women. The median
age was 42 years (29—48) and they had had intermittent loin pain for 2—28
years (median 7). Extensive urological investigations excluded structural
causes for their symptoms. All were dependent upon strong narcotic
analgesia at the time of operation. Patients were followed-up for 14—44
months (median 24). No patient had a deterioration in renal function. One
diabetic patient with extensive vascular disease developed a renal artery
thrombosis requiring transplant nephrectomy. One patient developed a
"urinoma" requiring further surgery. Following surgery, all patients
experienced complete relief of pain for at least two months. Three patients
with four transplants have had no pain since the operation. Eight patients
have had recurrent pain at the transplant site. In spite of this, five of these
considered the operation worthwhile. Of the four patients with the most
severe pain recurrence, three (75%) have a past or current history of
depression, and did not have hematuria (vs. 14% of the remainder, P =
0.09, Fisher's exact test). These results demonstrate that renal autotrans-Control plantation is a nephron-sparing option with low morbidity for manage-N — ment of intractable nephralgia once conservative measures have been
tried. Seventy-two percent of patients developed recurrent pain, usually of
a lesser magnitude. A prior history of depression or absence of hematuria
may he predictive of a poorer post-operative prognosis. A placebo
response to surgery cannot be excluded.
Necrotizing fasciitis: A single center's experience. H.L. Pilmore, Ri.
Walker, iA. Rietveld, PG. Jones, f-C. Theis, D.A. Bowie, and A.G.
Dempster, Departments of Nephrology, Orthopaedics, General Medicine,
Intensive Care, and Pathology, Dunedin Hospital, Dunedin, New Zealand.
Necrotizing fasciitis is a rare but serious soft tissue infection with high
morbidity and mortality. We wished to review our five year experience
with this condition from 1989—1994. Tn addition, in light of recent interest
in the association between necrotizing fasciitis and non-steroidal anti-
inflammatory drugs (NSAID), we wished to determine the incidence of
NSAID use in our necrotizing fasciitis patients. A review of all Dunedin
Hospital eases of necrotizing fasciitis between January 1989 and June 1994
was undertaken. Subsequently, all specialists involved in treating the
patients audited their notes, particularly regarding clinical presentation,
complications, treatment; outcome and Concomitant use of NSAIDs were
also recorded. There has been a total of seven patients (four male) with a
mortality rate of 43%. Survival was associated with early diagnosis, rapid
and intensive medical and surgical intervention, and possibly the early use
of hemofiltration. Five of the seven patients had ingested non-steroidal
anti-inflammatory drugs prior to their presentation which may have
potentiated the severity of the endotoxic shock. Necrotizing fasciitis
remains a potentially lethal disease, but early management and aggressive
treatment improve outcome. A high index of suspicion, avoidance of
NSAIDs, and aggressive multidisciplinary team management of these
patients offer the best chance of survival in necrotizing fasciitis.
Trial of subcutaneous octreotide administration in a patient with the
hepatorenal syndrome (HRS). MA. Lonergan, M.i Field, and B. Jones,
Department of Medicine, University of Sydney, Concord Hospital, New South
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Wales, Australia. Impaired hepatic clearance of vasoactive peptides,
including vasoactive intestinal peptide (VIP), which are released into the
portal circulation, may contribute to the the altered sodium and water
homeostasis in cirrhosis and hepatic failure. A beneficial response to
subcutaneous octreotide, a somatostatin analogue, which blocks the
release and action of a number of peptides including VIP, was reported in
cirrhotic patients with ascites. In view of that report, we examined the
effects of octreotide on renal function, sodium and water excretion and
plasma levels of VIP, insulin and glucagon in a 44 year old female patient
with alcoholic hepatitis who developed the hepatorenal syndrome. Oct-
reotide was administered subcutaneously for 7 days on a reducing dose
regimen. Following the commencement of octreotide a progressive fall in
weight occurred. Plasma creatinine plateaued. Plasma sodium rose from
126 mmol/liter prior to octreotide peaking at 143 mmol/liter. Electrolyte-
free water clearance fell as the dose of octreotide was reduced. Fractional
excretion of sodium did not change, remaining very low (0.02% of filtered
load). Absolute sodium excretion also remained low. Octreotide de-
creased the plasma levels of glucagon and insulin. However, these changes
did not appear to correlate with the onset of renal effects. A small fall in
plasma VIP levels also occurred. In summary, the use of octreotide in a
single patient with the HRS was associated with some beneficial effects,
specifically stabilization of the plasma creatinine, an increase in electro-
lyte-free water clearance and normalization of serum sodium. No increase
in sodium excretion occurred. The alterations in the plasma levels of the
regulatory peptides, insulin and glucagon, did not correlate with the rapid
stabilization of GFR nor the onset of weight loss. These findings suggest
a role for octreotide in the management of HRS, although the mecha-
nisms are unclear.
The kidney in petrol sniffing. M. G. Kinthakaran, Alice Springs Hospital,
Alice Springs, NT, Australia. Petrol sniffing is endemic among some of the
central Australian Aboriginal communities who also have a high incidence
of renal failure of unknown etiology. The toxic effects of sniffing petrol are
usually attributed to the organic lead compound, tetraethyl, which is used
as an anti-knocking agent in leaded petrol. While inorganic lead is
well-known to be highly nephrotoxic, very little is known about the effect
of organic lead on the kidneys. Acute toxicity due to excessive indulgence
in petrol sniffing is usually associated with high blood lead levels, and a
prospective study was undertaken to see if the kidneys were affected in
such patients. A total of 48 patients admitted to Alice Springs Hospital
with acute toxic effects of petrol sniffing were investigated systematically to
determine the nature and extent of renal involvement, if any. The mean
age of the patients studied was 19.8 years with a female:male ratio of 1:3.8.
The duration of sniffing petrol ranged from 4 months to more than 10
years, with a mean of 17.2 months. The mean blood lead level was 3.23
jsmol/liter (range 1.6—4.7; normal < 1.4). None of the patients studied
had hypertension, anemia, hematuria or significant proteinuria, and their
serum creatinine, urea, uric acid and electrolyte levels were all within
normal limits. Fanconi syndrome was not detected in 4 patients tested.
Autopsy was performed on 6 patients and their kidneys showed normal
morphology with no evidence of changes due to lead toxicity. In a separate
survey of 59 central Australian Aboriginal patients with established
chronic renal failure (33 on maintenance hemodialysis, 14 awaiting dialysis
and 12 renal transplant recipients), none gave a history of sniffing petrol in
the past. This study does not show any evidence of acute or chronic renal
damage as a result of sniffing petrol and the organic lead in leaded petrol
does not appear to be nephrotoxic.
Low dose subcutaneous recombinant erythropoietin in children with
chronic renal failure. J.-R. Burke, Y. Mizusawa, M. Falk, P. Roy, P. Knight,
A. Rosenberg, G. Kainer, E. Hoc/son, HR. Powell, C. Jones, and R. Walker,
Australian and New Zealand Paediatric Nephrology Association. In a
multicenter trial low dose subcutaneous (s.c.) recombinant human eiyth-
ropoietin (rHuEPO) was evaluated in 22 children aged 4 months to 16
years, with anemia of chronic renal failure over a 12 month period. A
commencing dosage of 50 j.tg/kg twice weekly was given until a target
hemoglobin of 9—il gldl was achieved. The dosage was increased by 50
es/kg per week, each four weeks, if the hemoglobin did not increase by I
gIdl/month. When the target hemoglobin was achieved, the same weekly
dosage was given as single injection. If the hemoglobin concentration
exceeded 11 g/dl or fell below 9 gldl the dosage was decreased or increased
by 50 p/kg weekly. After treatment the mean hemoglobin increased from
6.75 0.76 to 9.6 1.9 g/dl (P < 0.001), and hematocrit from 19.8 2.4
to 29.3 6.3 (P < 0.001). By four months the target hemoglobin was
achieved in 19 patients on 50 p/kg twice weekly and one patient on 75 j.clkg
twice weekly. Two children with severe renal osteodystrophy failed to
respond to 95 p/kg and 150 p/kg twice weekly. The maintenance weekly
dose of rHuEPO in nine children over 4—12 months ranged between
45—125 p/kg. There were no significant changes in the monthly mean
values of serum iron, transferrin binding capacity, ferritin, parathormone,
calcium, phosphate, alkaline phosphatase and creatinine. Full scale I.Q. in
11 children increased from 92 16.1 to 97 17 over the 12 month period
(P = NS). No adverse effects were recorded. A starting dose of s.c.
rHuEPO 50 pikg twice weekly is recommended as an effective and safe
dosage for the majority of children with anemia of chronic renal failure.
Myeloma and renal failure. A.F. Sharland, L. Snowdon, D.E. Joshua, J.
Gibson, and Di. Tiller, Departments of Nephrology and Haematology, Royal
Prince Alfred Hospital, Camperdown, New South Wales, Australia. Renal
failure at presentation has been reported in up to 56% of myeloma
patients and carries a poor prognosis. Limited data are available on the
prognosis of those who are aggressively treated with dialysis. This study
describes the mycloma population, diagnosed between 1986 and Septem-
ber 1993, and seen at our institution, with particular reference to renal
function and outcome in patients who were dialyzed. Medical records
were examined and evaluated if information was available about renal
function at diagnosis, and there was follow-up for at least 12 months or
until death. One hundred forty patients met the criteria for study. Their
mean age was 62 years (29—87), 77 M and 63 F. Types of myeloma were;
JgGK (56), IgGL (29), IgAL (16), IgAK (12), LLC (11), KLC (9), NS (6),
and IgDL (1). Fifty patients had impaired renal function (serum creatinine
>120 pmol/liter) at diagnosis, 14 were dialyzed, and 82% of patients with
renal failure had stage III disease, compared with 43% of those with
normal function. Median survival in the whole group was 34 months.
Increased age, failure to attain plateau, and impaired renal function at
diagnosis were independently associated with shortened survival. Median
survival in the group with renal impairment was 22 months vs. 47 months
in patients with normal renal function (P < 0.01). Median survival of
dialyzed patients was also 22 months. Hypercalcemia and presence of
Bence-Jones proteinuria were both significantly associated with renal
failure at diagnosis (P < 0.01). Sixty percent of patients with light chain
myeloma had renal impairment compared with 33% with other parapro-
teins and none of the 6 patients with non-secretory myeloma. Patients with
renal failure at diagnosis have more advanced disease and a poorer
prognosis. However, severe azotemia treated with dialysis confers no
worse outcome than mild impairment, and this may continue to improve
with new approaches, such as high dose therapy with stem cell rescue.
Dialysis should be offered to patients with myeloma who require it.
Recovery of gastrointestinal function following renal transplantation in
a patient with scierosing peritonitis secondary to continuous ambulatory
peritoneal dialysis (CAPD). CM. Hawley, R.J. Rigby, D.R. Wall, D. W.
Johnson, SB. Campbel4 AD. Griffin, and J.J.B. Petrie, Departments of
Nephrology and Surgery, Princess Alexandra Hospital, Brisbane, Queensland,
Australia. We report the rapid and dramatic improvement in gastrointes-
tinal function that occurred after a successful renal transplant in a 44 year
old woman with sclerosing peritonitis secondary to CAPD. The patient
had been on CAPD for 9 years and her sclerosing peritonitis was
diagnosed after presenting with recurrent episodes of small bowel obstruc-
tion. CAT Scan had demonstrated severe peritoneal thickening and
calcification, and ultrasound had shown rounded "nubbins" of tissue
attached to the peritoncal surface. Colon transit time had shown markedly
reduced colonic motility. The patient was converted to hemodialysis and
trained for home total parenteral nutrition (TPN). After 9 months she
received a cadaveric renal allograft. Immunosuppression was with cyclo-
sporine, azathioprine and prednisolone. By 2 weeks post-transplant she
was able to tolerate oral fluids, and by 12 weeks TPN was ceased as oral
nutrition was adequate. She has continued to do well with no recurrence
of abdominal symptoms (7 months post-transplant). We support the
hypothesis of Junor et al that immunosuppression may be helpful in
patients with sclerosing peritonitis, and propose that the anti-inflamma-
tory effects of these drugs mediate the improvement in gut function.
Fat free mass (FFM) measurement in CAPD patients. KC. Wong, D.J.
Borovnicar, P. C. Kerr, D.B. Stroud, B.J. G. Strauss, and R. C. Atkins, Monash
Medical Centre, Clayton, Victoria, Australia. As an index of nutritional
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adequacy, FFM is not routinely assessed in dialysis patients because the
tools for direct measurement of FFM are not readily available, and these
techniques have not been validated in this group of patients. This study
compared calculation of FFM by a reference four compartment model
[FFMFCM = TBWD2O (total body water by Deuterium oxide dilution) +
TBPrIVNAA (total body protein by in vivo neutron activation analysis) +
TBBMDexa (total body bone mineral by dual energy x-ray absorptiom-
etry) + glycogen (as 4.4% TBPr)], with values of FFM obtained from
Dexa, BIA (bioelectric impedance), AN (anthropometry), TBK (total
body potassium) and CK (creatinine kinetics), in a cohort of stable CAPD
patients (6 M/12 F, age 33—77 years). FFMFCM showed a strong to
moderate linear correlation with FFMDexa (r = 0.93, P < 0.0001),
FFMBIA (r = 0.89, P < 0.0001), FFMAN (r = 0.86, P < 0.0001),
FFMTBK (r = 0.80, P < 0.0001) and FFMCK (r = 0.71, P < 0.001),
respectively. Intermethod comparison of group mean values of FFM
showed no statistical difference between FFMFCM (46.9 11 kg),
FFMDexa (47.3 12 kg) and FFMCK (44.3 12 kg), respectively. Mean
values of FFMBIA, FFMAN and FFMTBK were significantly different
from that of FFMFCM (P < 0.001,P < 0.05 and P < 0.005, respectively).
Measurement biases of +0.4 kg, +6.1 kg, +2.9 kg, —5.5 kg and —2.6 kg
were observed for FFMDexa, FFMBIA, FFMAN, FFMTBK and
FFMCK, respectively. Limits of agreement were the narrowest (+8.9 to
—8.3 kg) for FFMDexa and greatest for FFMCK (+ 14.8 to —20.1 kg). As
a group, CAPD patients had % hydration of FFM (76.6 2.5%) greater
than normal (published mean value for normal subjects '72%), but there
was no gender difference in % hydration FFM (M 75.2 1.3% vs. F
75.7 3.1%). CAPD males had greater %FFM (of total body weight)
(71.4 6.8%) and %TBPr of FFM (18.4 0.8%) than CAPD females
(62.4 10.8% and 17.4 2.7, respectively) (P < 0.01, P < 0.05,
respectively). Comparison of Z scores for FFM index (FFMI) [FFM
(kg)/height(m) and nitrogen index (NI) showed that FFMDexa was
comparable to TBPr in categorizing nutritional status of individual CAPD
patients. Our data suggest that FFM measurement is a suitable index of
nutrition in CAPD patients and it can be accurately assessed by Dexa
alone.
Predictors of technique failure in New Zealand CAPD patients (1986—
1993). J. Collins, G. Gamble, and J. Leafy, for the NZ CAPD Registry, Renal
Unit, Auckland Hospital, Auckland, New Zealand. The New Zealand (NZ)
CAPD registry collects comprehensive data on all NZ patients on CAPD
after October 1986. Nine hundred thirty-three new patients commenced
CAPD over this period. We performed multivariate stepwise logistic
regression analysis to determine the predictors of technique failure
(including death but excluding successful transplants) at 18 months and 3
years of treatment. Standardized odds ratios were calculated for each
variable after adjustment for all other variables in the model.
Independent predictors of 18 month CAPD failure
Standardized
odds ratio 2P
Male gender 1.2 0.0104
Diabetic 1.3 0.0001
Early school leaver 1.2 0.0147
Treatment for hypertension 1.1 0.027 1
(prior to dialysis)
Years of past cigarette smoking 1.4 0.000 1
Current cigarette smoking 1.2 0.01 65
Previous dialysis experience 1.3 0.0004
Number of episodes of peritonitis 1.6 0.0001
The predictors of 3 year failure were similar to 18 month failure, except
that current cigarette smoking and age when they left school were no
longer significant. Variables included in the model but which failed to
reach statistical significance were age at commencement of CAPD,
tertiary education, race, independence in bag changing, an index of
cardiovascular risk, marital status and visual impairment (all P > 0.05).
We conclude that the number of episodes of peritonitis experienced by an
individual is the strongest predictor of both 18 month and 3 year CAPD
failure. Patients with two or more episodes of peritonitis in their first year
are 60% more likely to fail CAPD within 18 months than those with one
or no episodes of peritonitis. Previously, in univariate models race (Maori,
Pacific Island vs. European) has been an important determinant of CAPD
failure. In these analyses, after multivariate adjustment, race was not
found to be important.
Time-related peritoneal function changes in long-term CAPD: The apex
time. J. Sabto, A. Slingeneyer, and B. Laroche, Clinique du Mas Dc Rocher,
Castelnau le Lez, France. Exposure to long-term CAPD may be accompa-
nied by peritoneal morphological changes. Peritoneal function tests have
not reflected these changes and have not predicted peritoneal membrane
failure when it has occurred. The APEX time corresponds to the point of
intersection of two equilibration curves: urea and glucose. The test was
performed 133 times in 103 CAPD patients. The APEX time measured
within the first month of CAPD was 58.79 14.30 minutes; between 1 and
12 months after the start of CAPD 64.98 20.30 minutes; between 12 and
36 months 65.09 16.53 minutes, while that measured in patients on
CAPD for longer than 36 months was 86.74 31.72 minutes. These
changes were statistically significant (analysis of variance f = 8.61 for
dfl = 3, df2 = 129; P < 0.005). In a subgroup of 14 patients who had a first
test in the first month of CAPD and at least one subsequent measure more
than 3 months later, a rise in the APEX time was demonstrated (paired
t-test P < 0.05). The APEX time combines an index of urea and glucose
transport into one measurement. It does so at a time when transport rates
are greater than those measured at 4 hours as is usual in the simplified
Peritoneal Equilibration Test (PET). It is probably due to these two
reasons that it has been brought to light the time-related peritoneal
functional changes, and it is therefore likely to be useful in detecting and
anticipating deterioration in peritoneal membrane function in long-term
CAPD patients.
The elderly dialysis patient: Quality of life (QOL) and social activity.
H.R. Moody, C. Moody, E. Szabo, and C.M. Kjellstrand, Sir Charles
Gairdner Hospital WA. (Dept. of Renal Medicine); and University ofAlberta
Hospitals, Edmonton, AB, Canada. Elderly patients may be denied the
benefits of dialysis due to perceptions of poor QOL while receiving this
therapy. We have performed an extensive survey of our dialysis and
transplant population to ascertain QOL using the Karnovsky scale,
perceived health, Campbell's and Bradburn's scales. In addition we
assessed parameters of physical function and social activity. The patients
were divided into young (16—39 years, N = 20), middle aged (40—59 years,
N = 23), old (60—69 years, N = 20) and the very old (> 70 years, N = 23).
While physical ability declined with increasing age (95% of those <39
years were capable of all activities of daily living (ADL), only 63% of those
> 70 years were capable of all ADL: young patients appreciated dialysis
least, older patients the most. Seventy percent of those <39 years
perceived their health as worse than their peers while only 35% of those
> 70 years felt this way (P < 0.05). Of the young, 10% perceived life to be
totally miserable on dialysis, while no very old patient held to this belief.
Approximately 20% of the young and very old were happy with their
existence on dialysis and 70% of the very old said that life in general was
quite satisfactory, while only 50% of the of the young said this. Participa-
tion in hobbies, outdoor activities, cleaning, laundry and cooking clearly
changed beyond age 75. Approximately 55—85% of the young, middle-
aged and old were involved in these activities, while only 25% of the very
old participated. Elderly dialysis patients enjoy a satisfactory QOL, often
exceeding that of the younger dialysis patient. While there appears to be
a breakpoint in social activities at age 75 years and there is no doubt that
physical activity declines with age, there is no justification to exclude the
elderly from dialysis on the basis of poor QOL.
Sleep apnea and end-stage renal disease. M. Hallett, S. Burden, D.
Stewart, and P. Farrell, University of New South Wales, ResCare Ltd, New
South Wales, Australia. Previous studies have indicated that there may be
an association between sleep apnea (SA) and end-stage renal disease
(ESRD), regardless of modality of therapy. Full sleep studies were
therefore done on a number of dialysis patients to obtain further
information on prevalence of SA in this group. Fifteen patients were
randomly selected from 4 Sydney metropolitan dialysis centers, [9 on
hemodialysis (HD) and 6 on continuous ambulatory peritoneal dialysis(CAPD)]. All subjects underwent full overnight polysomnography at a
sleep disorders center, with measurement of sleep and breathing variables.
A respiratory disturbance index (RDI) was calculated for both NREM and
REM, and a combined RDI for all subjects. Four out of 6 CAPD patients
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and 8 out of 9 HD patients had evidence of sleep apnea (combined RDI>
5/br). One out of 6 CAPD and 6 Out of 9 HD patients had evidence of
moderate to severe sleep apnea with an RDI > 15/hr. Apneas in all
patients were exclusively obstructive in nature. The other finding of
interest was that there was a high incidence of periodic leg movements
during sleep in this patient group, with 2 out of 6 CAPD and 4 out of 9 HD
patients exhibiting this disorder. This initial study was extended to cover
more patients in both the U.S. (F. Finkelstein, New Haven) and Australia
(J. Mahony/R. Caterson, Sydney). In this case, OSA was assessed by either
Edentrace II (New Haven patients) and ResCare's Clinical System
coupled with pulse oximetry (Sydney patients). In the New Haven sample
of 15 CAPD patients, 7 patients (47%) had an RDI > 5 while 4 had more
severe OSA with an RDI > 15 (27%). However, in the Sydney sample of
21 dialysis patients, 9/11 (82%) HD patients and 7/10 (70%) CAPD
patients had an RDI > 15. The combined data show that for all patients
at the 3 centers, 72.5% had an RDI > 5 and 53% had an RDI> 15. These
results confirm the high incidence of sleep disordered breathing in
patients with ESRD on dialysis therapy. The link between OSA and
cardiovascular and cerebrovascular disorders is now recognized. As these
are the most common causes of death in the dialysis population, treatment
of sleep apnea by nasal CPAP should be of considerable benefit to these
patients.
Varying concentration and delivery of dialysate bicarbonate: Effect on
phosphate removal. E. Yuill, D. Cheshe,; and D.C.H. Harris, Departments
of Renal Medicine and Clinical Chemistry, Westmead Hospital, New South
Wales, Australia. High bicarbonate (HB) dialysis may be used to reduce
osteodystrophy and other complications of acidosis, but may impair
phosphate (P,) clearance by increasing cell uptake of P,. It has been
proposed that P, clearance may be improved by bicarbonate modelling
(BM), with early low dialysate HCO3 (to increase clearance) and late high
HCO3 (to correct acidosis). To test the utility of BM and HB in low-flux
dialysis, 12 stable chronic haemodialysis patients received standard bicar-
bonate (SB, dialysate HCO3: 28—30 mmol/liter), HB (dialysate HCO3: 40
mmol/liter) or BM (dialysate HCO3: increasing exponentially from 28 to
40; 35 mmol/liter at 3 hrs) for 4 weeks each in a randomized double-
crossover design. Oral bicarbonate supplements were used during HB and
BM. Nine patients completed the trial. During week 4 of each treatment
dialysis kinetics of P,, urea, HCO1, K and Ca2', plasma lipids (triglyc-
erides, cholesterol, HDL cholesterol) and patient tolerance were assessed
during both of the second and third dialysis sessions. Pre- and post-dialysis
serum HCOI was significantly (all P < 0.003) lower in SB (20.2 1.0,
23.8 0.7 mmol/liter, respectively, j.r SE) than HB (26.1 1.1, 29.7
1.4) and BM (25.4 0.6, 27.3 0.6). There was no difference among SB,
HB and BM in plasma P at any time point, in 2 hours post-dialysis P
rebound (0.33 0.04, 0.34 0.06, 0.29 0.03) or in clearance of P, from
blood (such as at one hour, 87.9 3.0, 91.3 1.7, 92.7 2.4 mI/mm). P
clearance tended to rise during SB, but fall with HB and BM. There were
no changes in plasma lipids. Other biochemical data, including dialysate P
appearance, are yet to be analyzed. Patient tolerance was equal with each
treatment. In summary, acidosis can be controlled well by low-flux dialysis
using HB, without any measurable reduction in phosphate clearance. BM
has no demonstrable advantage over HB.
Kinetic modelling in assessment of adequacy of hemodialysis (HD).
f/A. Pollock, F.Y-P. Zhu, W Ayass, R.J. f/aterson, iF. Mahony, D.A.
Waugh, S.D. Roger, and L.S. Ibels, Department of Renal Medicine, Royal
North Shore Hospital, New Soot/i Wales, Australia. In order to assess the
value of urea kinetic modelling and nutritional markers in I-ID, 76 patients
(32 M, 44 F; aged 55 3.1 vs. 63.1 2.1 years, respectively; P < 0.01)
underwent dialytic and urinary measurements of urea generation rate,
from which Kt/V and protein catabolic rate (PCR) were determined.
Hospital admission rates, infectious episodes and access complications
were recorded. At the commencement of the study, these patients had
been on dialysis for 41.9 5.7 (mean suM) months, with 19 patients
undergoing assessment within 1 month of the commencement of dialysis.
During the 12 month study period, 47 patients (61.8%) required admis-
sion, spending 7.9 1.4 days in the hospital (range 2—146 days): 29
patients (38.1%) had at least one infectious complication requiring
antibiotic therapy; 18 patients (23.6%) developed access problems need-
ing intervention; and 27 patients (35.5%) had symptomatic peripheral
vascular or isehemic heart disease. Multivariant analyses demonstrated
that female patients had more frequent (P < 0.01) and longer (P < 0.05)
hospital admissions, but no difference was observed in Kt/V or PCR when
compared to males. PCR correlated inversely with hospital admission
rates (P < 0.01), total days spent in hospital (P < 0.05) and infectious
complications (P < 0.05). Infectious complications further correlated with
time on dialysis (P < 0.005) and the presence of diabetes (P < 0.005), and
inversely with total body nitrogen (P < 0.05). Diabetes was associated with
increased (P < 0.05) and longer (P < 0.001) hospitalization, increased
access problems (P < 0.001), but no difference in Kt/V, PCR, TBN or
vascular pathology was observed. Vascular pathology was associated with
more frequent hospitalization (P < 0.05), a lower PCR (P < 0.01) and
increased access complications (P < 0.05), but not with Kt/V. In conclu-
sion, urea kinetic modelling provides predictive value with respect to
dialysis related morbidity. Measurement of PCR is of more prognostic
value than Kt/V in the HD population.
Factors determining Kt/V and protein catabolic rate (PCR) in hemo-
dialysis (HD). CA. Pollock, F.Y-P. Zhu, W Ayass, Ri. Caterson, J.F.
Mahony, D.A. Waugh, S.D. Roger, and L.S. Ihel,c, Department of Renal
Medicine, Royal North Shore Hospital, New South Wales, Australia. The
stability of markers of measurements derived from urea kinetic modelling
in HD is unknown, and factors which modify them are generally assumed
rather than measured. The stability of measurement of Kt/V and PCR was
therefore assessed in 12 hemodialysis patients by repeated determinations
one week apart. This demonstrated excellent reproducibilty with coeffi-
cients of variation of 6.8% and 9.1%, respectively. In 45 patients (15 M, 30
F) Kt/V and PCR were assessed on 2 occasions, 6 months apart. Time on
dialysis, blood flow rate and dialyzer type were recorded. Kt/V at the
commencement of the study was 1.23 0.04 and at the conclusion of the
study 1.41 0.06 (P < 0.005). PCR was 1.06 0.04 and 1.31 0.05
g/kg/day, respectively (P < 0.001). During the study 30 patients had an
increase in Kt/V of 0.33 0.04 associated with an increase in PCR of
0.24 0.06 g/kg/day, 7 patients had a decrease in Kt/V of 0.33 0.01 with
a decrease in PCR of (1.002 0.1, and 8 patients had stable Kt/V
measurements. Of the 30 patients who increased their Kt/V, 11 increased
their hours of dialysis alone, 2 increased the dialyzer size alone, 1
increased the blood flow rate alone, 6 patients increased all three
parameters, 5 altered 2 of the three parameters, while 5 had no discernible
change in their dialysis regimen. An increase in Kt/V correlated with an
increase in time on dialysis (P < 0.02), but not with a change in either
blood flow rate, which in these patients averaged 58 12 mI/mm (P =
0.49), or type of dialyzer (P = 0.56). A close correlation existed between
Kt/V and PCR (P < 0.001). An increased PCR was observed with
increased time on dialysis (P < 0.05) and increased dialyzer size (P <
0.05), but not with an increased blood flow rate. In the 7 patients whose
Kt/V decreased, PCR decreased in 3 and was unchanged in 3. Of these 7
patients, access problems were identified in 4 patients, suggesting this
should he suspected if unexplained decreases in Kt/V occur. In the I
patient with a disproportionate increase in PCR sepsis was recognized. We
conclude that both Kt/V and PCR are reproducible measures. Both Kt/V
and PCR may he increased by more time on dialysis, whereas PCR may he
further increased by an increased dialyzer size.
Specific detection of membrane inserted C5b-9(m) complexes in human
renal biopsies. B.1 Murphy, M. Polihronis, 1). Power, and D. Machet,
Departments of Nephrolo, and Clinical Immunolo, St. Vincent '1 Hospital,
Fitzroy, Victona, Australia. We have recently characterized a murine
monoclonal antibody (254 Mab) which identifies a neoepitope on com-
plement C9 which is revealed only when C9 is in the membrane bound
(that is: lytic) terminal C5b-9(m) complex. This Mab is distinguished from
all other anti-C5b-9 neoepitope antibodies in that it does not react with
the soluble, non-lytic, SC5b-9 terminal complex. Both SC5b-9 and CSb-
9(m) are present in glomerular immune deposits and at other sites in
pathological kidneys, and it has not been previously possible to distinguish
immunohistologically between the pathogenic C5b-9(m) complex and the
"inactive" SC5b-9 complex. The 254 Mab has now enabled, for the first
time, a distinction between these 2 complexes to that made in human
tissue. We have performed a prospective immunofluorescence study of
200 percutaneous renal biopsies comparing the distribution of C5b-9(m)
with that of other complement components and immunoglobulmns. The
following antibodies were used: 254 MAb to detect C5h-9(m), conven-
tional anti-C9 neoepitope Mab to detect total C5b-9, anti-clusterin and
anti-vitronectin Mabs to detect SC5b-9, and the routine polyclonal
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antisera to detect immunoglobulin and early complement components
(Clq, C3, IgG, IgA, 1gM). Polyclonal antisera were FITC-eonjugated and
used directly, Mabs were used in indirect immunofluorescence with a
secondary antibody [FITC-conjugated anti-mouse Ig (DAKO)I. C5b-9(m)
was invariably detected as part of total C5b-9 in glomerular immune
deposits and in most extraglomerular sites (vessels and tubular basement
membrane). There was no C5b-9 detected with either antibody in histo-
logically normal glomeruli. C5b-9(m) was also found together with
immunoglobulin in a number of immune glomerular lesions where early
complement components (C3, Clq) and SC5b-9 components were not
detected. In particular, in IgA nephropathy, 5/19 biopsies showed this
pattern. This suggests that in these biopsies only C5b-9(m) and not SC5b-9
was present. Finally, three cases of non-IgA diffuse mesangial proliferative
GN showed C5b-9(m) deposition in the absence of antibody and other
complement components, suggesting that direct activation of C5b-9(m)
without antibody may occur in mesangial cells. These data confirm that
membrane insertion of C5b-9 is an invariable feature of glomerular
complement deposition and that the 254 Mab is a highly sensitive reagent
for the detection of glomerular complement.
Tamm-Horsfall protein (THP) in rat anti-gbm glomerulonephritis
(GN). I. Potential nephritogenic autoantigen. H.Y. Lan, S. Qing, D.J.
Nikolic-Paterson, and R.C. Atkins, Department of Nephrology, Monash
Medical Centre, Clayton, Victoria, Australia. Tubulointerstitial leukocytic
infiltration is a common feature of most forms of human and experimental
GN and correlates better with the degree of renal function impairment
than glomerular lesions. We hypothesize that this tubulointerstitial inflam-
mation is, at least partially, an autoimmune response to intrinsic kidney
antigens which are released as neo-antigens following initial renal damage.
The nephritogenic potential of THP, a glycoprotein produced exclusively
by tubular epithelial cells, was investigated in a study of rat accelerated
anti-GBM GN. Disease was induced by injection of rabbit anti-GBM
serum into rats primed with rabbit IgG and killed at various times over a
28 day time course. In normal rats, no circulating anti-THP was detectable
by ELISA and no skin DTH response to purified THP was evident. In rat
anti-GBM disease, significant levels of serum anti-THP antibodies were
detected on day 7 which increased further to day 28. A marked skin DTH
response to THP antigen was seen on day 7 which increased in severity up
to day 28—indeed the reaction was similar in intensity to the DTH
response to rabbit IgG (immunizing antigen). Double immunohistochem-
istry staining to localize THP and leukocyte subsets found that from day 14
onwards there was a 3—4-fold greater number of T cells and macrophages
in contact with THP positive tubules compared to that around THP
negative tubules. This was also the time of onset of severe tubulointersti-
tial damage and renal function impairment. In conclusion, an autoimmune
response to THP was generated during rat anti-GBM disease as demon-
strated by specific antibody production and skin DTH reaction. Further-
more, the association of leukocyte infiltration with THP positive tubules
suggests an active role for the THP immune response in mediating renal
injury in this model.
Infiltration of TH1 subsets into kidneys in Heymann's nephritis. M.J.
Penny, R. Boyd, A. Spinelli, and B.M. Ha14 Department of Medicine,
Liverpool Hospital, Liverpool, New South Wales, Australia. Thi cells arc
principally involved with delayed-type hypersensitivity (DTH) and cyto-
toxicity, and are characterized by expression of IL-2, IFN-y, and TNF-J3.
Th2 cells are required for B cell maturation and Ig isotype switching and
produce IL-4, IL-5, IL-6, IL-b, and IL-13. We examined the cytokine
profiles in active Heymann's nephritis (HN), a disease model of membra-
nous GN in which antibody and complement are thought to be mediators
of injury. HN was induced in 5 male Lewis rats by subcutaneous injection
of renal tubular antigen (FxlA) in CFA, and boosted at two weeks with
Fx1A in IFA. The control group (Controls) comprised 5 male Lewis rats
which received the same induction protocol, without Fx1A. Disease in the
HN group was demonstrated at 8 weeks. Proteinuria in the HN group was
206 16 mgIlOO g body weight/day (X SD) compared to 6 3 mg/100
g body weight/day in Controls, P < 0.001. Mean auto-Ig titers (compared
to normal serum titer corrected to 1.0) were 37.6 14.0 in the HN group,
and 1.6 0.3 in Controls, P = 0.002. In renal biopsies glomerular Ig
deposition was present in the HN group but absent in Controls, and
immunoperoxidase cytochemistry of lymphocyte subsets in renal cortex
(cells/HPF, X SD of 10 HPF) demonstrated:
Target Control HN P
TCR 6.0 1.7 24.6 9.7 = 0.011
CD4 48.3 8.0 97.6 20.6 = 0.006
CD8 7.9 1.3 11.3 0.2 = 0.007
NK 1.5 0.3 2.3 1.5 = 0.003
mRMA extracted from renal cortex was assayed by a semiquantitative RT
PCR:
TH cell Cytokine Control HN
TH1 IFN-y
IL-2
TNF-p/LT
TH2 IL-4
IL-b —
+
+
This study identified increased numbers of T cells (CD4+ and CD8+) in
Heymann's nephritis, with evidence of activation of TH1 subsets. This
suggests DTH or cytolytic T cell activation may play a role in the
mediation of this disease.
Mycophenolate mofetil prevents the induction of active Heymann's
nephritis. M.J. Penny, R. Boyd, A. Spinelli, and B.M. Hall, Department of
Medicine, Liverpool Hospital, Liverpool, New South Wales, Australia. This
study examined the effectiveness of Myeophenolate mofetil (Mm) in
suppression of active Heymann's Nephritis (HN) in rats. MN was induced
in male Lewis rats by immunization with Fx1A in CFA, and boosted at 2
weeks with Fx1A in IFA. A control MN group was compared to a group
given Mm for 4 weeks from the time of induction of I-IN (30 mg/kg/day,
p.o.) and a normal group immunized only with adjuvant. MN activity was
monitored by urine protein excretion and autoantibodies at 4, 6, 8 and 12
weeks, and renal biopsies at 4, 8, and 12 weeks. Biopsies were examined
for Ig and C deposition. Renal cortical leukocyte infiltrates were examined
using indirect immunoperoxidase staining with mAbs to cell markers, and
the expression of cytokines by infiltrating cells was examined using RT
PCR. In the Mm group proteinuria was not significantly increased when
compared to the normal group (<10 mg/100 g body weight/day) at 6,8 and
12 weeks but significantly less than the untreated HN group (>200 mg/100
g body weight/day, P < 0.001). Auto-Ig titers were suppressed to baseline
levels during the four weeks of Mm therapy, but at 6, 8 and 12 weeks were
significantly elevated compared to normals, P < 0.011, and not signifi-
cantly different to the untreated HN group. There was marked glomerular
Ig deposition in the Mm group which was only slightly less than the
untreated MN group at 8 weeks and absent in the normal group.
Significantly increased CD4+, CD8+, NK and monoeyte/maerophage
numbers were identified in HN controls compared to the Mm treated and
normal control groups, P < 0.016 (there being no significant difference
between Mm treated and normal control groups). RT PCR of cytokine
mRNA in renal cortex demonstrated activation of antigen presenting
cells/macrophages (TNF-a) and Thi cells (IFN-y, IL-2, TNF-p) in HN
controls compared to the Mm treated and normal control groups. No
increase in Th2 activity (IL-4, IL-b) was demonstrated. In conclusion,
Mm prevented proteinuria and leukoeyte infiltrates to 12 weeks, with
suppression of Thi and APC cytokine mRNA. Mm did inhibit auto-Ab
titers and glomerular Ig and C deposits during the four weeks of therapy,
but these appeared following cessation of Mm. This study suggests
Mycophenolate mofetil may have a role in the treatment of glomerulone-
phritis.
Biased TCR Vy gene usage by infiltrating T cells in IgAN. J.F.
Knight, G. Ng, G. Zhang, H-L. Wu, AR. Clarkson, A.J. Woodroffe, L.P. Roy,
and M. C. Falk, Renal Research Laboratories, The Children's Hospital,
Camperdown, New South Wales, and Renal Unit, Royal Adelaide Hospital,
Adelaide, SA, Australia. Infiltration of the kidney by yb T cells is associated
with progression to renal failure in IgA nephropathy (IgAN). It is yet to be
determined whether these cells are recruited from peripheral blood as
part of a non-specific inflammatory response, or whether they represent a
selective subset of circulating yb T cells, infiltrating and proliferating in
response to a particular antigen or antigens. To address this question, a T
cell receptor (TCR) repertoire analysis was performed on blood and renal
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tissue. mRNA was extracted from renal biopsies from 7 adults with IgAN
who had been shown to have a significant yb T cell infiltrate. rtPCR was
performed with primers specific for the four TCR Vy and six TCR Vb
gene subfamilies, as described. A kidney with pyelonephritis served as a
positive control and the unaffected pole of a kidney removed for Wilms'
tumor as a negative control. Because a biased repertoire in the kidney
might simply reflect changes in peripheral blood, ybTCR repertoire was
also assessed in blood from 12 IgAN patients (including four of the seven
patients whose biopsies were examined) and from 12 healthy adults. PCR
product was dot-blotted, hybridized with P32-lahelled oligonucleotide
probes specific for TCR Cy and Cb, respectively and densitometry
performed on an autoradiograph. TCR Vy and Vb repertoire in peripheral
blood did not differ between IgAN patients and controls. TCR Vb repertoire
in the IgAN biopsies also did not vary from that seen in peripheral blood in
patients and in healthy controls—all six families were represented in typical
proportions. TCR Vy repertoire was characterized by the marked absence of
Vyl, which was undetectable in five of the seven IgAN biopsies, although it
was expressed by at least 20% of peripheral blood ybT cells in all controls and
IgAN patients, and 30% of y cells in the pyelonephritic kidney. In the four
IgAN patients on whom both blood and tissue were available, TCR Vyl was
24—61% of blood ybTCR repertoire but only 0—1% of the renal infiltrate.
These data suggest that the y T cells seen in IgAN biopsies are a selective
subset of those circulating in peripheral blood, yet they do not appear to be
a clonal population. The striking absence of Vyl requires further examination
in a larger, prospective series, with a detailed sequence analysis of TCR gene
usage.
P-selectin directs autologous antibody induced injury in the skin
(passive Arthus reaction) but not in the glomerulus. L. Santas, PG.
Tipping, XR. Huang, M. C. Berndt, and S.R. Holdsworth, Centre fbr Inflam-
matory Disease, Monash University Department of Medicine, Monash Mcd-
ical Centre, Clayton, and Baker Medical Research Institute, Prahran, Victo-
ria, Australia. Binding of autologous antibody to antigen presented in the
skin and the glomerulus initiates local tissue injury. In the skin, this is
known as the Arthus reaction and is characterized by complement
dependent neutrophil accumulation. Rats given autologous rat anti-sheep
globulin i.v. (10 mg/150 g body weight) develop skin swelling (2.85 0.20
mm) and neutrophil accumulation 4 hours after intradermal challenge
with sheep globulin (170 jig; passive Arthus reaction). This response was
associated with local up-regulation of P-selectin on endothelial cells in
intradermal vessels. Pretreatment with a functionally inhibitory rabbit
anti-P-selectin antibody, 1 hour prior to induction of passive Arthus,
prevented up-regulation of endothelial P-selectin, neutrophil accummula-
tion and skin swelling (2.20 0.04 mm, normal 1.94 0.04 mm). These
parameters were unaffected by pretreatment with non-immune rabbit 1g.
Glomerular binding of passively administered autologous antibody to the
same planted antigen (a subnephritogenic dose of sheep anti-rat GBM
globulin) results in proteinuria (49 9.5 mg/24 hr, normal 1.9 0.5 mg/24
hr) and proliferative glomeruloncphritis in rats and is also associated with
up-regulation of P-sclectin on glomerular endothelial cells. This form of
glomerular injury is the theorectical equivalent of the dermal passive
Arthus reaction but was associated with a predominant macrophage rather
than neutrophil influx. The role of P-selectin in this passive autologous
antibody initiated glomerular injury was assessed by in viva inhibition
using an identical dose of anti-P-selectin antibody to that employed to
inhibit passive dermal Arthus. However, unlike dermal Arthus, glomerular
injury was unaffected by inhibition of P-selectin (proteinuria 51 9.5
mg124 hr), suggesting that glomerular macrophage infiltration is P-selectin
independent. Thus autologous antibody binding to antigen presented in
the skin and glomerulus results in recruitment of a different profile of
inflammatory cells dependent on different cell adhesion molecules.
